WO1992007852A1

WO1992007852A1 - Biphenylalkyl xanthine compounds for treatment of cardiovascular disorders

Info

Publication number: WO1992007852A1
Application number: PCT/US1991/007426
Authority: WO
Inventors: Philippe R. Bovy; Joe T. Collins; Timothy S. Chamberlain; Brian K. Gheng
Original assignee: G.D. Searle & Co.
Priority date: 1990-10-25
Filing date: 1991-10-16
Publication date: 1992-05-14
Also published as: AU9024591A; CA2055129A1

Abstract

A class of non-peptidic biphenylalkyl xanthine compounds is described for use in treatment of cardiovascular disorders. Compounds of particular interest are angiotensin II antagonists of formula (I) wherein each of X?1 and X2¿ is independently selected from oxygen atom and sulfur atom; wherein m is one; wherein each of R?0 and R1¿ is independently selected from hydrido, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, 4-methylbutyl, n-pentyl, neopentyl, methoxycarbonylmethyl, methoxycarbonylethyl, cyclopropylmethyl, cyclopropylethyl, propenyl, phenyl, benzyl, phenethyl, cyclohexyl, cyclohexylmethyl, 4-hydroxybutyl, 2-hydroxyethyl and 3-hydroxypropyl; wherein R2 is selected from ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, 4-methylbutyl, tert-butyl, n-pentyl, neopentyl, 2-cyclohexylethyl, benzyl, 2-phenylethyl, 3-phenylpropyl, cyclohexylmethyl, cyclohexyl, propoxy, butoxy, 1-butenyl, buten-2-yl, 3-butenyl, butyn-1-yl, butyn-2-yl, butyn-3-yl, propylthio and butylthio; wherein each of R3 through R11 is hydrido with the proviso that at lest one of R?5, R6, R8 and R9¿ is an acidic group selected from CO¿2?H, SH, PO3H2, SO3H, CONHNH2, CONHNHSO2CF3, OH, NHSO2CH3, NHSO2CF3, NHCOCF3, CONHSO2C6H5, CONHOH, CONHOCH3, CONHSO2CH3 and tetrazole; or a tautomer thereof or a pharmaceutically-acceptable salt thereof. These compounds are particularly useful in treatment or control of hypertension and congestive heart failure.

Description

BIPHENYLALKYL XANTHINE COMPOUNDS FOR TREATMENT OF CARDIOVASCULAR DISORDERS

Field of the Invention

Non-peptidic biphenylalkyl xanthine compounds are described for use in treatment of cardiovascular disorders such as hypertension and congestive heart failure. Of particular interest are angiotensin II antagonist compounds having a biphenylmethyl moiety attached to the N-7 or N-9 position of the xanthine ring.

Background of the Invention The renin-angiotensin system is one of the hormonal mechanisms involved in regulation of

pressure/volume homeostasis and in expression of

hypertension. Activation of the renin-angiotensin cascade begins with renin secretion from the juxtaglomerular apparatus of the kidney and culminates in the formation of angiotensin II, an octapeptide which is the primary active species of this system. Angiotensin II is a potent vasoconstrictor agent and also produces other physiological effects such as promoting aldosterone secretion, promoting sodium and fluid retention, inhibiting renin secretion, increasing sympathetic nervous system activity, increasing vasopressin secretion, causing positive cardiac inotropic effect and modulating other hormonal systems. Previous studies have shown that antagonizing angiotensin II at its receptors is a viable approach to inhibit the renin-angiotensin system, given the pivotal role of this octapeptide which mediates the actions of the renin-angiotensin system through interaction with various tissue receptors. There are several known angiotensin II antagonists, most of which are peptidic in nature . Such peptidic compounds are of limited use due to their lack of oral bioavailability or their short duration of action. Also, commercially-available peptidic angiotensin II antagonists (e.g., Saralasin) have a significant residual agonist activity which further limit their therapeutic application.

Non-peptidic compounds with angiotensin II antagonist properties are known. For example, the sodium salt of 2-n-butyl-4-chloro-1-(2-chlorobenzyl)imidazole-5- acetic acid has specific competitive angiotensin II antagonist activity as shown in a series of binding experiments, functional assays and in vivo tests [P. C. Wong et al, J. Pharmacol. Exp. Ther., 247 (1), 1-7 (1988)]. Also, the sodium salt of 2-sbutyl-4-choloro-1-(2- nitrobenzyl)imidazole-5-acetic acid has specific

competitive angiotensin II antagonist activity as shown in a series of binding experiments, functional assays and in vivo tests [A. T. Chiu et al, European J. Pharmacol., 157, 3121 (1988)]. A family of 1-benzylimidazole-5-acetate derivatives has been shown to have competitive angiotensin II antagonist properties [A. T. Chiu et al, J. Pharmacol. Exp. Ther., 250 (3) , 867-874 (1989)]. U.S. Patent No.

4,816,463 to Blankey et al describes a family of 4,5,6,7- tetrahydro-1H-imidazo(4,5-c)-tetrahydro-pyridine

derivatives useful as antihypertensives, some of which are reported to antagonize the binding of labelled angiotensin II to rat adrenal receptor preparation and thus cause a significant decrease in mean arterial blood pressure in conscious hypertensive rats. EP No. 253,310, published 20 January 1988, describes a series of aralkyl imidazole compounds, including in particular a family of

biphenylmethyl substituted imidazoles, as antagonists to the angiotensin II receptor. EP No. 323,841, published 12 July 1989, describes four classes of angiotensin II antagonists, namely, biphenylmethylpyrroles,

biphenylmethylpyrazoles, biphenylmethyl-1,2,3-triazoles and biphenylmethyl 4-substituted-4H-1,2,4-triazoles, including the compound 3,5-dibutyl-4-[(2'-carboxybiphenyl-4- yl)methyl]-4H-1,2,4-triazole. U.S. Patent No. 4,880,804 to Carini et al describes a family of

biphenylmethylbenzimidazole compounds as angiotensin II receptor blockers for use in treatment of hypertension and congestive heart failure.

Several families of imidazo-pyridazine derivatives have been synthesized. For example, alkaline hydrolysis of 1,2,5-thiadiazole-3,4-dicarboxylic acid bishydrazide followed by a cyclization step in the presence of formic acid produced 4,7-dihydroxy- and 4,7- dichloro[4,5-d]pyridazine derivatives [I. Sekikawa,

J. Heterocyclic Chem., 6, 129-130 (1969)]. Also synthesis of imidazo-pyridazine nucleoside analogues has been described. For example, ring closure of an imidazole nucleoside produced the compound 1- (β-D- ribofuranosyl)imidazo[4,5-d]pyridazine-4,7-dione [C.

Tapiero et al, J. of Carbohydrates Nucleoside s Nncleotides,3(3), 191-195 (1976)]. In a study of chemical modification of antibiotic nucleosides, the compound 1-(2,3,5-tri-O- benzoyl-β-D-ribofuranosyl)imidazo-[4,5-d]pyridazine- 4,7(5H,7H)dione was synthesized [P.D. Cook et al, J.

Heterocyclic Chem., 15, 1 (1978)]. A series of substituted imidazo(4,5-d)pyridazines has been studied for

pharmacological properties [G. G. Ferguson et al, J. Pharm. Sci., 59(11), 1584-1586 (1970)]. A family of 4-substituted imidazo[4,5-d]pyridazines, including several 4-amino- and 4-alkylamino-1-benzyl-7-chloroimidazo[4,5-d]pyridazines, has been prepared for antitumor evaluation [J.A. Carbon, J. Am. Chem. Soc., 80, 6083-6088 (1958)]. In view of the antitumor activity of 5-amino-7-hydroxy-v- triazolo[d]pyrimidine, several 4,7-disubstituted

imidazo[4,5-d]pyridazines were synthesized including the compound 4,7-bisethylmercapto-1-ethylimidazo[4,5- d]pyridazine [R. N. Castle et al, J . Org. Chem., 23, 1534- 1538 (1958)]. Based on the antimalarial activity of certain quinoline derivatives, a family of ω- dialkylaminoalkylaminoimidazo[4,5-d]pyridazines was synthesized including, typically, the compound 4- (3- dimethylaminopropylamino)-7-chloro-1-(tetrahydro-2'- pyranyl)imidazo[4,5-d]pyridazine [N. R. Patel et al,

J. Heterocyclic Chem., 5, 13-24 (1968)].

Certain imidazo-pyridazine compounds have been described for treatment of cardiovascular disorders. For example, EP #184,738, published 18 June 1986, describes a family of 2-naphthyl-substituted imidazo [4, 5-d]pyridazin-4- on compounds having antithrombotic, cardiotonic and hypotensive properties. Japanese Patent #065,202,

published 18 March 1987, describes a family of imidazo heterocyclic carbostyril derivatives useful as cardiotonic, hypotensive and antiinflammatory agents. U.S. Patent No. 4,656,171 describes certain 2-phenyl-imidazo-pyridazines for use as cardiotonics, including a benzyloxy-substituted 2-phenyl-imidazole[4,5-c]pyridazine. U.S. Patent No.

4,722,929 describes 2-aryl-imidazo-pyridazine compounds for use as cardiotonics, including a benzyloxy-substituted 2- phenyl-4-chloro-imidazo[4,5-d] pyridazine.

Alkylated xanthine compounds are known for example, 1,3, 7, 8-alkyl-substituted xanthine compounds have been prepared by crotyl bromide alkylation of theophylline at the C₈ position of the theophylline nucleus to provide, specifically, 1,3,7-trimethyl-8-crotyl-xanthine [J. Donat et al, Chim . Ber., 92, 1500-1503 (1959)]. Also, xanthines have been selectively alkylated by various benzylic halides. Specifically, a xanthine compound having a biphenylmethyl substitutent at the N⁷ position, namely 7- [[(1,1'-biphenyl)-4-ylJmethyl]-3,7-dihydro-1H-purine-2,6- dione, has been prepared. This compound was made to show regioselective alkylation of the xanthine nucleus [L.G. Marzilli et al, J. Am. Chem. Soc., 97(12), 3351- 3358 (1975)]. Theophylline, theobromine and other alkylated xanthines derivatives have been used for many years in various pharmaceutical applications, including the

treatment of certain cardiac conditions and as diuretics. For example. East German Patent No. 39,142 published 25 May 1965 describes certain alkylated or alkoxylated xanthines for use as heart and circulatory activators. French Patent Document No. 3586M published 8 November 1965 describes 7- (paradimethylaminobenzyl)-1,3-dimethylxanthine for use in treatment of dyspnea and asthma, and for use as a

cardiotonic and as a coronary vasodilator. U.S. Patent No. 4,061,753 describes certain alkylated xanthines, such as 7- α-ethoxybenzyl)theophylline, for use in treatment of dermal inflammation, such as psoriasis.

DESCRIPTION OF THE INVENTION A class of biphenylalkyl xanthine compounds useful in treating circulatory disorders, particularly cardiovascular disorders, is defined by Formula I:

(I)

wherein m is a number selected from one to four, inclusive; wherein the dotted line between seven- and eight-positions and the eight- and nine-positions represents optionally a double bond; wherein each of X¹ and X² is independently selected from oxygen atom and sulfur atom; wherein each of R⁰ and R¹ is independently selected from hydrido, alkyl, hydroxyalkyl, haloalkyl, cycloalkyl, cycloalkylalkyl, aralkyl, aryl, aroylalkyl,

alkylalkoxyalkyl, alkylcarbonyl, alkylcarbonylalkyl, alkylcarbonyloxyalkyl, alkoxycarbonylalkyl, alkenyl, cycloalkenyl, aralkoxycarbonyl, alkynyl, cyanoalkyl, aminoalkyl, monoalkylaminoalkyl, dialkylaminoalkyl, mercaptoalkyl, mercaptocarbonylalkyl,

mercaptothiocarbonylalkyl, alkylthiocarbonylalkyl, alkylthiothiocarbonylalkyl, arylthiocarbonylalkyl, arylthiothiocarbonylalkyl, aralkylthiocarbonylalkyl, alkylthiocarbonyl, alkylsulfinyl, alkylsulfonyl,

aralkylsulfinyl, aralkylsulfonyl, arylsulfinyl,

arylsulfonyl, heteroaryl having one or more ring atoms selected from oxygen, sulfur and nitrogen atoms, and radicals of the formula

wherein X is oxygen atom or sulfur atom with z being a number selected from one to four, inclusive; wherein each of R¹² and R¹³ is independently selected from hydrido, alkyl, cycloalkyl, cyano, amino, monoalkylamino, dialkylamino, hydroxyalkyl, cycloalkylalkyl, alkoxyalkyl, aralkyl and aryl, and wherein R¹² and R¹³ taken together may form a heterocyclic group having five to seven ring members including the nitrogen atom of said amido radical and which heterocyclic group may further contain one or more hetero atoms as ring members selected from oxygen, nitrogen and sulfur atoms and which heterocyclic group may be saturated or partially unsaturated; wherein each of R² through R¹¹ is independently selected from hydrido, alkyl, hydroxyalkyl, halo, haloalkyl. cycloalkyl, cycloalkylalkyl, cycloalkylhaloalkyl,

cycloalkylcarbonyl, formyl, alkoxy, aralkyl,

aralkylhaloalkyl, aryl, aroyl, aryloxy, aryloxyalkyl, aralkoxy, alkoxyalkyl, alkylcarbonyl, alkylcarbonylalkyl, alkoxycarbonyl, alkenyl, cycloalkenyl, alkynyl, cyano, nitro, carboxyl, carboxyalkyl, alkylcarbonyloxy,

alkylcarbonyloxyalkyl, alkoxycarbonylalkyl,

aralkoxycarbonylalkyl, aralkylcarbonyloxyalkyl,

mercaptocarbonyl, mercaptothiocarbonyl, mercaptoalkyl, alkoxycarbonyloxy, alkylthio, cycloalkylthio,

cycloalkylalkylthio, alkylthiocarbonyl, alkylcarbonylthio, alkylthiocarbonyloxy, alkylthiocarbonylthio,

alkylthiothiocarbonyl, alkylthiothiocarbonylthio, arylthio, arylthiocarbonyl, arylcarbonylthio, arylthiocarbonyloxy, arylthiocarbonylthio, arylthiothiocarbonyl,

arylthiothiocarbonylthio, aralkylthio, aralkylthiocarbonyl, aralkylcarbonylthio, aralkylthiocarbonyloxy,

aralkylthiocarbonylthio, alkylthiocarbonyl,

aralkylthiocarbonylthio, mercapto, alkylsulfinyl,

alkylsulfonyl, aralkylsulfinyl, aralkylsulfonyl,

arylsulfinyl, arylsulfonyl, phthalimido, phthalimidoalkyl, heteroaryl, heteroarylalkyl, cycloheteroalkyl,

cycloheteroalkylalkyl and cycloheteroalkylcarbonylalkyl wherein each of said heteroaryl- and cyclohetero-containing groups has one or more ring atoms selected from oxygen, sulfur and nitrogen atoms, and wherein each of R² through R¹¹ may be further independently selected from amino and amido radicals of the formula

wherein X is oxygen atom or sulfur atom; wherein each r is a number independently selected from zero to six, inclusive; wherein each of R¹⁴ through R²⁶ is independently selected from hydrido, alkyl, cycloalkyl, cyano, amino,

monoalkylamino, dialkylamino, hydroxyalkyl,

cycloalkylalkyl, alkoxyalkyl, aralkyl and aryl, and wherein R¹⁴ and R¹⁵ taken together, R¹⁶ and R¹⁷ taken together, R¹⁸ and R¹⁹ taken together, R²¹ and R²² taken together and R²³ and R²⁴ taken together may each form a heterocyclic group having five to seven ring members including the nitrogen atom of said amino or amido radical and which heterocyclic group may further contain one or more hetero atoms as ring members selected from oxygen, nitrogen and sulfur atoms and which heterocyclic group may be saturated or partially unsaturated; and wherein each of R³ through R¹¹ may be further

independently selected from hydroxy and acidic moieties of the formula -Y_nA wherein n is a number selected from zero through three, inclusive, and wherein A is an acidic group selected to contain at least one acidic hydrogen atom, and the amide, ester and salt derivatives of said acidic moieties;

wherein Y is a spacer group independently selected from one or more of alkyl, cycloalkyl, cycloalkylalkyl, alkenyl, alkynyl, aryl, aralkyl and heteroaryl having one or more ring atoms selected from oxygen, sulfur and nitrogen atoms; and wherein any of the foregoing R¹ through R²⁶, Y and A groups having a substitutable position may be substituted by one or more groups independently selected from hydroxy, alkyl, alkenyl, alkynyl, aralkyl, hydroxyalkyl, haloalkyl, halo, oxo, alkoxy, aryloxy, aralkoxy, aralkylthio, alkoxyalkyl, cycloalkyl, cycloalkylalkyl, aryl, aroyl, cycloalkenyl, cyano, cyanoamino, nitro, alkylcarbonyloxy, alkoxycarbonyloxy, alkylcarbonyl, alkoxycarbonyl,

aralkoxycarbonyl, carboxyl, mercapto, mercaptocarbonyl, alkylthio, arylthio, alkylthiocarbonyl, alkylsulfinyl, alkylsulfonyl, haloalkylsulfonyl, aralkylsulfinyl,

aralkylsulfonyl, arylsulfinyl, arylsulfonyl, heteroaryl having one or more ring atoms selected from oxygen, sulfur and nitrogen atoms, and amino and amido radicals of the formula

wherein X is oxygen atom or sulfur atom; wherein each of R²⁷ through R³¹ is independently selected from hydrido, alkyl, cycloalkyl, cycloalkylalkyl, aralkyl, aryl, DR³² and

wherein D is selected from oxygen atom and sulfur atom and R³² is selected from hydrido, alkyl, cycloalkyl,

cycloalkylalkyl, aralkyl and aryl; wherein each of R²⁷, R²⁸, R²⁹, R³⁰, R³¹, R³³ and R³⁴ is independently selected from hydrido, alkyl, cycloalkyl, cyano, hydroxyalkyl, haloalkyl, cycloalkylalkyl, alkoxyalkyl, alkylcarbonyl, alkoxycarbonyl, carboxyl, alkylsulfinyl, alkylsulfonyl, arylsulfinyl, arylsulfonyl, haloalkylsulfinyl,

haloalkylsulfonyl, aralkyl and aryl, and wherein each of R²⁷, R²⁸, R²⁹, R³⁰, R³¹, R³³ and R³⁴ is further independently selected from amino and amido radicals of the formula

wherein X is oxygen atom or sulfur atom;

wherein each of R³⁵, R³⁶, R³⁷, R³⁸, R³⁹ and R⁴⁰ is

independently selected from hydrido, alkyl, cycloalkyl, cyano, hydroxyalkyl, cycloalkylalkyl, alkoxyalkyl,

haloalkylsulfinyl, haloalkylsulfonyl, aralkyl and aryl, and wherein each of R²⁸ and R²⁹ taken together and each of R³⁰ and R³¹ taken together may form a heterocyclic group having five to seven ring members including the nitrogen atom of said amino or amido radical, which heterocyclic group may further contain one or more hetero atoms as ring members selected from oxygen, nitrogen and sulfur atoms and which heterocyclic group may be saturated or partially

unsaturated; with the proviso that R⁰, R¹, and R² cannot all

simultaneously be hydrido; or a tautomer thereof or a pharmaceutically-acceptable salt thereof.

With regard to the optionally-present double bond at the N⁷ or N⁸ positions within the five-membered ring-portion of the xanthine ring of Formula I, it is intended that no more than one such double bond may be present. That is, only one of the N⁷ or N⁸ atoms may have a double bond at one time. It is also intended that when the N⁷ atom has a double bond in the rings the depicted biphenylalkyl portion of Formula I must be attached at the other N⁹ atom. When the N⁹ atom has a double bond within the ring, the biphenylalkyl portion of Formula I is attached at the N⁷ atom such as depicted in Formula II, below.

A preferred class of compounds consists of those compounds of Formula I within a sub-set of compounds of Formula II:

wherein m is one; wherein each of X¹ and X² is

independently selected from oxygen atom and sulfur atom; wherein each of R⁰ and R¹ is independently selected from hydrido, alkyl, hydroxyalkyl, haloalkyl, cycloalkyl, cycloalkylalkyl, aralkyl, aryl, alkoxyalkyl, mercaptoalkyl, alkoxycarbonylalkyl, alkylcarbonyloxyalkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkynyl, alkylsulfonyl, aralkylsulfonyl, arylsulfonyl, heteroaryl having one or more ring atoms selected from oxygen, sulfur and nitrogen atoms, and amido radicals of the formula

wherein X is oxygen atom or sulfur atom with r being a number selected from one or two; wherein each of R¹² and R¹³ is independently selected from hydrido, alkyl, cycloalkyl, cyano, amino, monoalkylamino, dialkylamino, hydroxyalkyl, cycloalkylalkyl, alkoxyalkyl, aralkyl and aryl; with the proviso that R⁰ and R¹ cannot simultaneously be hydrido; wherein R² is selected from hydrido, alkyl, hydroxyalkyl, halo, haloalkyl, cycloalkyl, cycloalkylalkyl,

cycloalkylhaloalkyl, cycloalkylcarbonyl, alkoxy, aralkyl, aralkylhaloalkyl, aryl, aroyl, aryloxy, aryloxyalkyl, aralkoxy, alkoxyalkyl, alkylcarbonyl, alkoxycarbonyl, alkenyl, cycloalkenyl, alkynyl, cycloalkynyl, cyano, nitro, carboxyl, carboxyalkyl, alkylcarbonyloxy,

alkylcarbonyloxyalkyl, alkoxycarbonylalkyl,

aralkoxycarbonylalkyl, aralkylcarbonyloxyalkyl,

aralkylthiocarbonylthio, aralkylthiocarbonyl,

aralkylthiocarbonylthio, mercapto, alkylsulfinyl,

alkylsulfonyl, aralkylsulfinyl, aralkylsulfonyl,

cycloheteroalkylalkyl and cycloheteroalkylcarbonylalkyl wherein each of said heteroaryl- and cycloheteroalkyl- containing groups has one or more hetero ring atoms selected from oxygen, sulfur and nitrogen atoms, and wherein each of R² through R¹¹ may be further independently selected from amino and amido radicals of the formula

wherein X is selected from oxygen atom or sulfur atom; wherein each r is a number independently selected from zero to six, inclusive; wherein each of R¹⁴ through R²⁶ is independently selected from hydrido, alkyl, cycloalkyl, cyano, amino,

monoalkylamino, dialkylamino, hydroxyalkyl,

cycloalkylalkyl, alkoxyalkyl, aralkyl and aryl; wherein each of R³ through R¹¹ is independently selected from hydrido, hydroxy, alkyl, hydroxyalkyl, halo,

haloalkyl, cycloalkyl, cycloalkylalkyl, alkoxy, aralkyl, aryl, aroyl, aryloxy, aralkoxy, alkoxyalkyl, alkylcarbonyl, alkoxycarbonyl, alkenyl, cycloalkenyl, alkynyl,

cycloalkynyl, cyano, nitro, carboxyl, alkylcarbonyloxy, mercaptocarbonyl, mercaptothiocarbonyl, alkoxycarbonyloxy, alkylthio, alkylthiocarbonyl, alkylcarbonylthio,

alkylthiocarbonyloxy, alkylthiocarbonylthio,

alkylthiothiocarbonyl, arylthio, arylthiocarbonyl,

arylcarbonylthio, arylthiocarbonyloxy,

arylthiothiocarbonyl, aralkylthio, aralkylthiocarbonyl, aralkylcarbonylthio, aralkylthiocarbonyloxy,

aralkylthiocarbonylthio, aralkylthiocarbonyl,

aralkylthiocarbonylthio, mercapto, alkylsulfonyl,

aralkylsulfonyl and arylsulfonyl, and amino and amido radicals of the formula 14

wherein X is oxygen atom or sulfur atom;

wherein each of R¹⁴, R¹⁵, R¹⁶, R¹⁷, R¹⁸ and R¹⁹ is

independently selected from hydrido, alkyl, cycloalkyl, cyano, hydroxyalkyl, cycloalkylalkyl, alkoxyalkyl, aralkyl and aryl; and wherein each of R³ through R¹¹ may be further

independently selected from acidic moieties of the formula

-Y_nA wherein n is a number selected from zero through three, inclusive; wherein A is an acidic group selected from acids containing one or more atoms selected from oxygen, sulfur, phosphorus and nitrogen atoms, and wherein said acidic group is selected to contain at least one acidic hydrogen atom, and the amide, ester and salt derivatives of said acidic moieties; wherein Y is a spacer group independently selected from one or more of alkyl, cycloalkyl,

cycloalkylalkyl, alkenyl, alkynyl, aryl, aralkyl and heteroaryl having one or more ring atoms selected from oxygen, sulfur and nitrogen atoms; and wherein any of the foregoing R¹ through R²⁶, Y and A groups having a substitutable position may be substituted by one or more groups independently selected from hydroxy, alkyl, alkenyl, aralkyl, hydroxyalkyl, halo, haloalkyl, oxo, alkoxy, aryloxy, aralkoxy, alkoxyalkyl, alkylcarbonyl, alkoxycarbonyl, carboxyl, cyano, nitro, alkylsulfonyl, haloalkylsulfonyl, aryl, aralkyl, mercaptocarbonyl, alkylthio and alkylthiocarbonyl, and amino and amido radicals of the formula

wherein X is oxygen atom or sulfur atom; wherein each of R²⁷ through R³¹ is independently selected from hydrido, alkyl, cycloalkyl, cycloalkylalkyl, aralkyl, aryl, and DR³² and

wherein D is selected from oxygen atom and sulfur atom, and R³² is selected from hydrido, alkyl, cycloalkyl, cycloalkylalkyl, aralkyl and aryl; wherein each of R²⁷, R²⁸, R²⁹, R³⁰, R³¹, R³³ and R³⁴ is independently selected from hydrido, alkyl, cycloalkyl, cyano, hydroxyalkyl, haloalkyl, cycloalkylalkyl, alkoxyalkyl, alkanoyl,

alkoxycarbonyl, carboxyl, haloalkylsulfinyl,

haloalkylsulfonyl, aralkyl and aryl; or a tautomer thereof or a pharmaceutically-acceptable salt thereof.

Compounds within the foregoing classes of

Formula I and II are believed to be structurally novel when the definitions of compounds within each class are

qualified by the proviso language which excludes known compounds. All of the compounds of Formula I and II without the proviso language are believed novel for use in pharmaceutical applications, more particularly, for use in treatment of circulatory disorders.

Compounds of Formula I and Formula II would be useful in treating a variety of circulatory disorders. including cardiovascular disorders, such as hypertension, congestive heart failure and arteriosclerosis, and to treat other disorders such as glaucoma. Treatment subjects would include mammalian subjects, particularly human subjects, afflicted by or susceptible to circulatory disorders.

These compounds would also be useful as adjunctive

therapies. For example, compounds of Formula I and Formula II may be used in combination with other drugs, such as a diuretic, to treat hypertension. Also, compounds of

Formula I and Formula II could be used in conjunction with certain surgical procedures. For example, these compounds could be used to prevent post-angioplasty re-stenosis.

Compounds of Formula I and Formula II are therapeutically effective in treatment of cardiovascular disorders by acting as antagonists to, or blockers of, the angiotensin II (All) receptor. Compounds of Formula I and Formula II would be therapeutically effective in treatment of the above-mentioned circulatory and cardiovascular disorders or would be precursors to, or prodrugs of, therapeutically- effective compounds.

The phrase "acidic group selected to contain at least one acidic hydrogen atom", as used to define the -Y_nA moiety, is intended to embrace chemical groups which, when attached to any of the R³ through R¹¹ positions of Formula I and Formula II, confers acidic character to the compounds of Formula I and Formula II. "Acidic character" means proton-donor capability, that is, the capacity of the compounds of Formula I and Formula II to be a proton donor in the presence of a proton-receiving substance such as water. Typically, the acidic group should be selected to have proton-donor capability such that the product

compounds of Formula I and Formula II has a pK_a in a range from about one to about twelve. More typically, the

Formula I and Formula II compounds would have a pK_a in a range from about two to about seven. An example of an acidic group containing at least one acidic hydrogen atom is carboxyl group (-COOH). Where n is zero and A is -COOH, in the -Y_nA moiety, such carboxyl group would be attached directly to one of the R³ through R¹¹ positions. The Formula I and Formula II compounds may have one -Y_nA moiety attached at one of the R³ through R¹¹ positions, or may have a plurality of such -Y_nA moieties attached at more than one of the R³ through R¹¹ positions, up to a maximum of nine such -Y_nA moieties. There are many examples of acidic groups other than carboxyl group, selectable to contain at least one acidic hydrogen atom. Such other acidic groups may be collectively referred to as

"bioisosteres of carboxylie acid" or referred to as "acidic bioisosteres". Specific examples of such acidic

bioisosteres are described hereinafter. Compounds of

Formula I and Formula II having the -Y_nA moiety attached at one of positions R⁵, R⁶, R⁸ and R⁹ would be expected to have preferred properties, while attachment at R⁵ or R⁹ would be more preferred. A more preferred class of compounds consists of those compounds of Formula II wherein m is one; wherein each of X¹ and X² is independently selected from oxygen atom and sulfur atom; wherein each of R⁰ and R¹ is

independently selected from hydrido, alkyl, hydroxyalkyl, mercaptoalkyl, haloalkyl, cycloalkyl, cycloalkylalkyl, aralkyl, aryl, alkoxyalkyl, alkoxycarbonylalkyl,

alkylcarbonyloxyalkyl, alkenyl, cycloalkenyl, alkynyl and cycloalkynyl; wherein R² is selected from alkyl, hydroxyalkyl, halo, haloalkyl, cycloalkyl, cycloalkylalkyl,

cycloalkylhaloalkyl, cycloalkylcarbonyl, alkoxy, aralkyl, aralkylhaloalkyl, aryl, aroyl, aryloxy, aryloxyalkyl, aralkoxy, alkoxyalkyl, alkylcarbonyl, alkoxycarbonyl, alkenyl, cycloalkenyl, alkynyl, cycloalkynyl, cyano, nitro, carboxyl, carboxyalkyl, alkylcarbonyloxy, mercaptocarbonyl, alkoxycarbonyloxy, alkylcarbonyloxyalkyl, alkoxycarbonylalkyl, araxkoxycarbonylalkyl,

aralkylcarbonyloxyalkyl, alkylthio, cycloalkylthio, cycloalkylalkylthio, arylthio, aralkylthio,

aralkylthiocarbonylthio, mercapto, alkylsulfinyl,

alkylsulfonyl, aralkylsulfinyl, aralkylsulfonyl,

cycloheteroalkylalkyl and cycloheteroalklylcarbonylalkyl wherein each of said heteroaryl- and cycloheteroalkyl- containing groups has one or more hetero ring atoms selected from oxygen, sulfur and nitrogen atoms, and wherein R² may be further selected from amino and amido radicals of the formula

monoalkylamino, dialkylamino, hydroxyalkyl,

haloalkyl, cycloalkyl, alkoxy, aralkyl, aryl, aroyl, aryloxy, aralkoxy, alkoxyalkyl, alkylcarbonyl,

alkoxycarbonyl, alkenyl, cycloalkenyl, alkynyl, cyano. nitro, carboxyl, alkylcarbonyloxy, mercaptocarbonyl, alkoxycarbonyloxy, alkylthio, arylthio, aralkylthio, mercapto, alkylsulfonyl, aralkylsulfonyl and arylsulfonyl, and amino and amido radicals of the formula

wherein each of R¹⁴, R¹⁵, R¹⁶, R¹⁷, R¹⁸ and R¹⁹ is

independently selected from hydrido, alkyl, cycloalkyl, cyano, amino, monoalkylamino, dialkylamino, hydroxyalkyl, cycloalkylalkyl, alkoxyalkyl, aralkyl and aryl; and wherein each of R³ through R¹¹ may be further

independently selected from acidic moieties of the formula

-Y_nA wherein n is a number selected from zero through three, inclusive; wherein A is selected from carboxylic acid and bioisosteres of carboxylic acid selected from

wherein each W is independently selected from oxygen atom, sulfur atom and NR³⁹; wherein each of R³⁵, R³⁶, R³⁷, R³⁸ and R³⁹ is independently selected from hydrido, alkyl, haloalkyl, haloalkylsulfonyl, haloalkylcarbonyl,

cycloalkyl, cycloalkylalkyl, aryl and aralkyl; wherein each of R³⁵, R³⁶, R³⁷ and R³⁹ may be further independently selected from amino radical of the formula

wherein each of R⁴⁰ and R⁴¹ is independently selected from hydrido, alkyl, cycloalkyl, hydroxyalkyl, haloalkyl, cycloalkylalkyl, alkoxyalkyl, aralkyl and aryl, and wherein R⁴⁰ and R⁴¹ taken together may form a heterocyclic group having five to seven ring members including the nitrogen atom of said amino radical, which heterocyclic group may further contain one or more hetero atoms as ring members selected from oxygen, nitrogen and sulfur atoms and which heterocyclic group may be saturated or partially

unsaturated; wherein R⁴⁰ and R⁴¹ taken together may form an aromatic heterocyclic group having five ring members including the nitrogen atom of said amino radical and which aromatic heterocyclic group may further contain one or more hetero atoms as ring atoms selected from oxygen, nitrogen and sulfur atoms; wherein each of R³⁶ and R³⁷ may be further independently selected from hydroxy, alkoxy, alkylthio, aryloxy, arylthio, aralkylthio and aralkoxy; and the amide, ester and salt derivatives of said acidic groups; wherein said bioisostere of carboxylic acid may be further selected from heterocyclic acidic groups consisting of heterocyclic rings of four to about nine ring members, which heterocyclic ring contains at least one hetero atom selected from oxygen, sulfur and nitrogen atoms, which heterocyclic ring may be saturated, fully unsaturated or partially unsaturated, and which heterocyclic ring may be attached at a single position selected from R³ through R¹¹ or may be attached at any two adjacent positions selected from R³ through R¹¹ so as to form a fused-ring system with one of the phenyl rings of Formula II; and the amide, ester and salt derivatives of said heterocyclic acidic groups; wherein Y is a spacer group independently selected from one or more of alkyl, cycloalkyl, cycloalkylalkyl, alkenyl, aryl and aralkyl; and wherein any of the foregoing R¹ through R²⁶ and R³⁵ through R⁴¹, Y and A groups having a substitutable position may be substituted by one or more groups independently selected from hydroxy, alkyl, alkenyl, aralkyl,

hydroxyalkyl, halo, oxo, haloalkyl, alkoxy, aryloxy, aralkoxy, alkoxyalkyl, alkylcarbonyl, alkoxycarbonyl, carboxyl, cyano, nitro, alkylsulfonyl, haloalkylsulfonyl, aryl, aralkyl, mercaptocarbonyl, alkylthio and

alkylthiocarbonyl, and amino and amido radicals of the formula

wherein X is selected from oxygen atom and sulfur atom; wherein R²⁷ is selected from hydrido, alkyl, cycloalkyl, cycloalkylalkyl, aralkyl, aryl and DR³² and

wherein D is selected from oxygen atom and sulfur atom;

wherein R³² is selected from hydrido, alkyl, cycloalkyl, cycloalkylalkyl, aralkyl and aryl; wherein each of R²⁷, R²⁸, R²⁹, R³⁰, R³¹, R³³ and R³⁴ is independently selected from hydrido, alkyl, cycloalkyl, cyano, hydroxyalkyl, haloalkyl, cycloalkylalkyl,

alkoxyalkyl, alkanoyl, alkoxycarbonyl, carboxyl,

haloalkylsulfinyl, haloalkylsulfonyl, aralkyl and aryl; or a tautomer thereof or a pharmaceutically-acceptable salt thereof. An even more preferred class of compounds consists of those compounds of Formula II wherein m is one; wherein each of X¹ and X² is selected from oxygen atom and sulfur atom; wherein each of R⁰ and R¹ is independently selected from hydrido, alkyl, hydroxyalkyl, mercaptoalkyl, haloalkyl, cycloalkyl, cycloalkylalkyl, aralkyl, aryl, alkoxyalkyl, alkoxycarbonylalkyl, alkylcarbonyloxyalkyl, alkenyl, cycloalkenyl and alkynyl with the proviso that R⁰ and R¹ cannot simultaneously be hydrido; wherein R² is selected from alkyl, hydroxyalkyl, halo, haloalkyl, cycloalkyl, cycloalkylalkyl,

alkylcarbonyloxyalkyl, alkoxycarbonylalkyl,

aralkoxycarbonylalkyl, aralkylcarbonyloxyalkyl,

mercaptocarbonyl, mercaptoalkyl, alkoxycarbonyloxy, alkylthio, cycloalkylthio, cycloalkylalkylthio, arylthio, aralkylthio, mercapto, alkylsulfinyl, alkylsulfonyl, aralkylsulfinyl, aralkylsulfonyl, arylsulfinyl,

arylsulfonyl, phthalimido, phthalimidoalkyl, heteroaryl, heteroarylalkyl, cycloheteroalkyl, cycloheteroalkylalkyl and cycloheteroalkylcarbonylalkyl wherein each of said heteroaryl- and cycloheteroalkyl-containing groups has one or more hetero ring atoms selected from oxygen, sulfur and nitrogen atoms, and wherein each of R² through R¹¹ may be further independently selected from amino and amido radicals of the formula

wherein X is selected from oxygen atom and sulfur atom; wherein each r is a number independently selected from zero to six, inclusive; wherein each of R¹⁴ through R²⁶ is independently selected from hydrido, alkyl, cycloalkyl, cyano, amino,

monoalkylamino, dialkylamino, hydroxyalkyl,

alkoxycarbonyl, alkenyl, cycloalkenyl, alkynyl, cyano, nitro, carboxyl, alkylthio, aralkylthio and mercapto; and wherein each of R³ through R¹¹ may be further

independently selected from acidic moieties of the formula

wherein each W is independently selected from oxygen atom, sulfur atom and NR³⁹; wherein each of R³⁵, R³⁸ and R³⁹ is independently selected from hydrido, alkyl, haloalkyl, haloalkylsulfonyl, haloalkylcarbonyl, cycloalkyl,

cycloalkylalkyl, aryl and aralkyl; wherein each of R³⁵ and R³⁹ may be further independently selected from amino radical of the formula

wherein each of R⁴⁰ and R⁴¹ is independently selected from hydrido, alkyl, cycloalkyl, hydroxyalkyl, haloalkyl, cycloalkylalkyl, alkoxyalkyl, aralkyl and aryl, and wherein R⁴⁰ and R⁴¹ taken together may form a heterocyclic group having five to seven ring members including the nitrogen atom of said amino radical, which heterocyclic group may further contain one or more hetero atoms as ring members selected from oxygen, nitrogen and sulfur atoms, and which heterocyclic group may be saturated or partially

unsaturated; wherein R⁴⁰ and R⁴¹ taken together may form an aromatic heterocyclic group having five ring members including the nitrogen atom of said amino radical and which aromatic heterocyclic group may further contain one or more hetero atoms as ring atoms selected from oxygen, nitrogen and sulfur atoms; and the amide, ester and salt derivatives of said acidic groups; wherein said bioisostere of

carboxylic acid may be further selected from heterocyclic acidic groups consisting of heterocyclic rings of four to about nine ring members, which ring contains at least one hetero atom, selected from oxygen, sulfur and nitrogen atoms, which heterocyclic ring may be saturated, fully unsaturated or partially unsaturated, and which

heterocyclic ring may be attached at a single position selected from R³ through R¹¹ or may be attached at any two adjacent positions selected from R³ through R¹¹ so as to form a fused-ring system with one of the phenyl rings of Formula II; and the amide, ester and salt derivatives of said heterocyclic acidic groups; wherein Y is a spacer group independently selected from one or more of alkyl, cycloalkyl, cycloalkylalkyl, alkenyl, aryl and aralkyl; wherein each of R¹ through R²⁶, R³⁵ and R³⁸ through R⁴¹, Y and A independently may be substituted at any substitutable position with one or more groups selected from alkyl, hydroxy, halo, oxo, haloalkyl, alkoxycarbonyl, cyano, nitro, alkylsulfonyl, haloalkylsulfonyl, aryl, aralkyl, alkoxy, aryloxy and aralkoxy; or a tautomer thereof or a pharmaceutically-acceptable salt thereof. A highly preferred class of compounds within

Formula II consists of those compounds wherein m is one; wherein each of X¹ and X² is independently selected from oxygen atom and sulfur atom; wherein each of R⁰ and R¹ is independently selected from hydrido, alkyl, hydroxyalkyl, mercaptoalkyl, haloalkyl, cycloalkyl, cycloalkylalkyl, aralkyl, aryl, alkoxyalkyl, alkoxycarbonylalkyl,

alkylcarbonyloxyalkyl, alkenyl and alkynyl; wherein R² is selected from alkyl, hydroxyalkyl, halo, haloalkyl, cycloalkyl, cycloalkylalkyl,

cycloalkylhaloalkyl, cycloalkylcarbonyl, alkoxy, aralkyl, aralkylhaloalkyl, aryl, benzoyl, phenoxy, phenoxyalkyl, phenalkyloxy, phenylthio, phenalkylthio, aralkoxy,

alkoxyalkyl, alkylcarbonyl, alkoxycarbonyl, alkenyl, cycloalkenyl, alkynyl, cyano, nitro, carboxyl,

carboxyalkyl, alkylcarbonyloxy, alkylcarbonyloxyalkyl, alkoxycarbonylalkyl, aralkoxycarbonylalkyl, aralkylcarbonyloxyalkyl, mercaptocarbonyl, mercaptoalkyl, alkoxycarbonyloxy, alkylthio, cycloalkylthio,

cycloalkylalkylthio, phthalimido, phthalimidoalkyl, heteroaryl, heteroarylalkyl, cycloheteroalkyl,

hydroxyalkyl, alkoxyalkyl, phenalkyl and phenyl; wherein each of R³ through R¹¹ is independently selected from hydrido, hydroxy, alkyl, hydroxyalkyl, halo,

haloalkyl, cycloalkyl, alkoxy, phenalkyl, phenyl, benzoyl, phenoxy, phenalkyloxy, alkoxyalkyl, alkylcarbonyl,

alkoxycarbonyl, alkenyl, cyano, nitro, carboxyl, alkylthio and mercapto; and wherein each of R³ through R¹¹ may be further

independently selected from acidic moieties of the formula

-Y_nA wherein n is a number selected from zero through two, inclusive; wherein A is selected from carboxylic acid and bioisosteres of carboxylic acid selected from

wherein each W is independently selected from oxygen atom, sulfur atom and NR³⁹; wherein each of R³⁵, R³⁸ and R³⁹ is independently selected from hydrido, alkyl, haloalkyl, haloalkylsulfonyl, haloalkylcarbonyl, cycloalkyl, phenyl and benzyl; wherein each of R³⁵ and R³⁹ may be further independently selected from amino radical of the formula

wherein each of R⁴⁰ and R⁴¹ is independently selected from hydrido, alkyl, cycloalkyl, hydroxyalkyl, haloalkyl, alkoxyalkyl, benzyl and phenyl; and the amide, ester and salt derivatives of said acidic groups; wherein said bioisostere of carboxylic acid may be further selected from heterocyclic acidic groups consisting of heterocyclic rings of four to about nine ring members, which ring contains at least one hetero atom, selected from oxygen, sulfur and nitrogen atoms, which heterocyclic ring may be saturated, fully unsaturated or partially

unsaturated, and which heterocyclic ring may be attached at a single position selected from R³ through R¹¹ or may be attached at any two adjacent positions selected from R³ through R¹¹ so as to form a fused-ring system with one of the phenyl rings of Formula II; and the amide, ester and salt derivatives of said heterocyclic acidic groups; wherein Y is a spacer group independently selected from one or more of alkyl, cycloalkyl, cycloalkylalkyl, alkenyl, phenyl, phenalkyl and aralkyl; wherein each of R¹ through R²⁶, R³⁵ and R³⁸ through R⁴¹, Y and A and independently may be substituted at any

substitutable position with one or more groups selected from alkyl, cycloalkyl, cycloalkylalkyl, hydroxy, halo, oxo, haloalkyl, alkoxycarbonyl, cyano, nitro,

alkylsulfonyl, haloalkylsulfonyl, aryl, aralkyl, alkoxy, aryloxy and aralkoxy; or a tautomer thereof or a pharmaceutically-acceptable salt thereof. An even more highly preferred class of compounds consists of those compounds of Formula II wherein m is one; wherein each of X¹ and X² is independently selected from oxygen atom and sulfur atom; wherein R⁰ and R¹ is

alkylcarbonyloxyalkyl, alkenyl and alkynyl; where R² is selected from alkyl, aminoalkyl, hydroxyalkyl, halo, haloalkyl, cycloalkyl, cycloalkylalkyl,

alkoxyalkyl, acetyl, alkoxycarbonyl, alkenyl, cycloalkenyl, alkynyl, cyano, nitro, carboxyl, carboxyalkyl,

alkylcarbonyloxy, mercaptoalkyl, mercaptocarbonyl,

alkoxycarbonyloxy, alkylcarbonyloxyalkyl, alkoxycarbonylalkyl, aralkoxycarbonylalkyl,

aralkylcarbonyloxyalkyl, phthalimido, phthalimidoalkyl, imidazoalkyl, tetrazole, tetrazolealkyl, alkylthio, cycloalkylthio, cycloalkylalkylthio, and amino and amido radicals of the formula

haloalkyl, alkoxy, phenyl, benzoyl, phenoxy, alkoxyalkyl, acetyl, alkoxycarbonyl, alkenyl, cyano, nitro, carboxyl, alkylthio and mercapto; and wherein each of R³ through R¹¹ may be further

independently selected from acidic moieties consisting of CO₂H, CO₂CH₃, SH, CH₂SH, C₂H₄SH, PO₃H₂, NHSO₂CF₃,

NHSO₂C₆F₅, SO₃H, CONHNH₂, CONHNHSO₂CF₃, CONHOCH₃,

CONHOC₂H₅, CONHCF₃, OH, CH₂OH, C₂H₄OH, OPO₃H₂, OSO₃H ,

wherein each of R⁴², R⁴³ and R⁴⁴ is independently selected from H, Cl, CN, NO₂, CF_3, C₂F₅, C₃F₇, CHF₂, CH₂F, CO₂CH₃, CO₂C₂H₅, SO₂CH₃ SO₂CF₃ and SO₂C₅F₅; wherein Z is selected from O, S, NR⁴⁵ and CH₂; wherein R⁴⁵ is selected from hydrido, CH₃ and CH₂C₆H_5; and wherein said acidic moiety may be a heterocyclic acidic group attached at any two adjacent positions of R³ through R¹¹ so as to form a fused ring system with one of the phenyl rings of the biphenyl moiety of Formula II, said biphenyl fused ring system selected from

and the esters, amides and salts of said acidic moieties; or a tautomer thereof or a pharmaceutically-acceptable salt thereof.

A class of compounds of particular interest consists of those compounds of Formula II wherein m is one; wherein each of X¹ and X² is independently selected from oxygen atom and sulfur atom; wherein each of R⁰ and R¹ is independently selected from hydrido, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert- butyl, n-pentyl, isopentyl, neopentyl, phenyl, benzyl, phenethyl, cyclohexyl, cyclopropylmethyl, cyclopropylethyl, cyclohexylmethyl, alkoxycarbonylalkyl,

alkylcarbonyloxyalkyl, buten-2-yl, 3-butenyl, butyn-2-yl, butyn-3-yl, haloloweralkyl and hydroxyloweralkyl; wherein R² is selected from methyl, ethyl, n-propyl, isopropyl, n- butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, n-hexyl, isopentyl, neopentyl, phenyl, cyclohexyl, cyclohexylmethyl, CH₃CH=CH-CH₂, SC₃H₇, cyclohex-3-en-1-yl, SC₄H₉,

CH₂S , CH₃CH=CH, CH₂=CH-CH₂, CH₃CH₂CH₂CH=CH-, amino,

alkoxy, aminomethyl, aminoethyl, aminopropyl, CH₂OCOCH₃, CH₂CI, CH₂OCH₃, CH₂OCH(CH₃)₂, CH₂CO₂H, CH(CH₃)CO₂H,

-CH₂OCOCH₂CH₂ -CH₂CH₂CH₂CO₂H, -CH₂CH₂F, -CH₂CH₂CH₂F,

-CH₂ONO₂, -CH₂SH, -CH₂O > CF₃, CH₂OH, hydroxyalkyl,

halo, 1-oxo-2-phenylethyl, 2-cyclohexylethyl,

3-cyclohexylpropyl, benzyl, 2-phenylethyl, 3-phenylpropyl, cyclohexylmethyl, cyclohexanoyl, 1-butenyl, buten-2-yl, 3-butenyl, butyn-1-yl, butyn-2-yl, butyn-3-yl and

difluoromethyl; wherein each of R³ through R¹¹ is hydrido with the proviso that at least one of R⁵, R⁶, R⁸ and R⁹ is an acidic group selected from CO₂H, SH, PO₃H₂, SO₃H,

CONHNH₂, CONHNHSO₂CF₃, OH,

wherein each of R⁴² and R⁴³ is independently selected from chloro, cyano, nitro, trifluoromethyl, methoxycarbonyl and trifluoromethylsulfonyl; or a tautomer thereof or a pharmaceutically-acceptable salt thereof.

A class of compounds of more particular interest consists of those compounds of Formula II wherein m is one; wherein each of X¹ and X² is independently selected from oxygen atom and sulfur atom; wherein R⁰ and R¹ is

independently selected from hydrido, methyl, ethyl. n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert- butyl, 4-methylbutyl, n-pentyl, neopentyl,

cyclopropylmethyl, cyclopropylethyl, propenyl, phenyl, benzyl, phenethyl, cyclohexyl, cyclohexylmethyl,

methoxycarbonylmethyl, methoxycarbonylethyl, 4- hydroxybutyl, 2-hydroxyethyl and 3-hydroxypropyl; wherein

R² is selected from ethyl, n-propyl, isopropyl,

n-butyl, sec-butyl, isobutyl, 4-methylbutyl, tert-butyl, n-pentyl, neopentyl, 2-phenylethyl, 2-cyclohexylethyl, benzyl, 2-phenylethyl, 3-phenylpropyl, cyclohexylmethyl, cyclohexyl, propoxy, butoxy, 1-butenyl, buten-2-yl, 3- butenyl, butyn-1-yl, butyn-2-yl, butyn-3-yl, propylthio and butylthio; wherein each of R³ through R¹¹ is hydrido with the proviso that at least one of R⁵, R⁶, R⁸ and R⁹ is an acidic group selected from CO₂H, SH, PO₃H₂, SO₃H, CONHNH₂, CONHNHSO₂CF₃, OH,

A class of compounds of more particular interest consists of those compounds of Formula II wherein m is one; wherein each of X¹ and X² is independently selected from oxygen atom and sulfur atom; wherein each of R⁰ and R¹ is independently selected from hydrido, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tertbutyl, 4-methylbutyl, n-pentyl, neopentyl, cyclopropylmethyl, cyclopropylethyl, propenyl, phenyl, benzyl, phenethyl, cyclohexl, cyclohexylmethyl, methoxycarbonyl- methyl, methoxycarbonylethyl, 4-hydroxy-butyl, 2- hydroxyethyl and 3-hydroxypropyl; wherein R² is selected from ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, 4-methylbutyl, tert-butyl, n-pentyl, neopentyl, benzyl, 2-phenylethyl, 3-phenylpropyl, cyclohexylmethyl, cyclohexyl, propoxy, butoxy, 1-butenyl, buten-2-yl, 3- butenyl, butyn-1-yl, butyn-2-yl, butyn-3-yl, propylthio; wherein each of R³, R⁴, R⁶, R⁷, R⁸, R¹⁰ and R¹¹ is hydrido; wherein one of R⁵ and R⁹ is hydrido and the other of R⁵ and R⁹ is an acidic group selected from CO₂H and

N or a tautomer thereof or a pharmaceutically-acceptable salt thereof.

A class of compounds of more particular interest consists of those compounds of Formula II wherein m is one; wherein X¹ is an oxygen atom and X² is a sulfur atom;

wherein each of R⁰ and R¹ is independently selected from hydrido, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec- butyl, isobutyl, tert-butyl, 4-methylbutyl, n-pentyl, neopentyl, cyclopropylmethyl, cyclopropylethyl, propenyl, phenyl, benzyl, phenethyl, cyclohexl, cyclohexylmethyl, methoxycarbonylmethyl, methoxycarbonylethyl, 4-hydroxy- butyl, 2-hydroxyethyl and 3-hydroxypropyl; wherein R² is selected from ethyl, n-propyl, isopropyl, n-butyl, sec- butyl, isobutyl, 4-methylbutyl, tert-butyl, n-pentyl, neopentyl, benzyl, 2-phenylethyl, 3-phenylpropyl,

cyclohexylmethyl, cyclohexyl, propoxy, butoxy, 1-butenyl, buten-2-yl, 3-butenyl, butyn-1-yl, butyn-2-yl, butyn-3-yl, propylthio and butylthio; wherein each of R³, R⁴, R⁶, R⁷, R⁸, R¹⁰ and R¹¹ is hydrido; wherein one of R⁵ and R⁹ is hydrido and the other of R⁵ and R⁹ is an acidic group selected from CO₂H and

or a tautomer thereof or a pharmaceutically-acceptable salt thereof.

A class of compounds of more particular interest consists of those compounds of Formula II wherein m is one; wherein X¹ is an oxygen atom and X² is an oxygen atom;

or a tautomer thereof or a pharmaceutically-acceptable salt thereof. The term "hydrido" denotes a single hydrogen atom (H). This hydrido group may be attached, for example, to a oxygen atom to form a hydroxyl group; or, as another example, two hydrido groups may be attached to a carbon atom to form a -CH₂- group. Where the term "alkyl" is used, either alone or within other terms such as

"haloalkyl" and "hydroxyalkyl", the term "alkyl" embraces linear or branched radicals having one to about twenty carbon atoms or, preferably, one to about twelve carbon atoms. More preferred alkyl radicals are "lower alkyl" radicals having one to about ten carbon atoms. Most preferred are lower alkyl radicals having one to about five carbon atoms. The term "cycloalkyl" embraces cyclic radicals having three to about ten ring carbon atoms, preferably three to about six carbon atoms, such as cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl. The term "haloalkyl" embraces radicals wherein any one or more of the alkyl carbon atoms is substituted with one or more halo groups, preferably selected from bromo, chloro and fluoro. Specifically embraced by the term "haloalkyl" are monohaloalkyl, dihaloalkyl and polyhaloalkyl groups. A monohaloalkyl group, for example, may have either a bromo, a chloro, or a fluoro atom within the group. Dihaloalkyl and polyhaloalkyl groups may be substituted with two or more of the same halo groups, or may have a combination of different halo groups. A dihaloalkyl group, for example, may have two fluoro atoms, such as difluoromethyl and difluorobutyl groups, or two chloro atoms, such as a dichloromethyl group, or one fluoro atom and one chloro atom, such as a fluoro-chloromethyl group. Examples of a polyhaloalkyl are trifluoromethyl, 1,1-difluoroethyl, 2,2,2-trifluoroethyl, perfluoroethyl and 2,2,3,3- tetrafluoropropyl groups. The term "difluoroalkyl" embraces alkyl groups having two fluoro atoms substituted on any one or two of the alkyl group carbon atoms. The terms "alkylol" and "hydroxyalkyl" embrace linear or branched alkyl groups having one to about ten carbon atoms any one of which may be substituted with one or more hydroxyl groups. The term "alkenyl" embraces linear or branched radicals having two to about twenty carbon atoms, preferably three to about ten carbon atoms, and containing at least one carbon-carbon double bond, which carbon-carbon double bond may have either cis or trans geometry within the alkenyl moiety. The term "alkynyl" embraces linear or branched radicals having two to about twenty carbon atoms, preferably two to about ten carbon atoms, and containing at least one carbon-carbon triple bond. The term

"cycloalkenyl" embraces cyclic radicals having three to about ten ring carbon atoms including one or more double bonds involving adjacent ring carbons. The terms "alkoxy" and "alkoxyalkyl" embrace linear or branched oxy-containing radicals each having alkyl portions of one to about ten carbon atoms, such as methoxy group. The term

"alkoxyalkyl" also embraces alkyl radicals having two or more alkoxy groups attached to the alkyl radical, that is, to form monoalkoxyalkyl and dialkoxyalkyl groups. The

"alkoxy" or "alkoxyalkyl" radicals may be further substituted with one or more halo atoms, such as fluoro, chloro or bromo, to provide haloalkoxy or haloalkoxyalkyl groups. The term "alkylthio" embraces radicals containing a linear or branched alkyl group, of one to about ten carbon atoms attached to a divalent sulfur atom, such as a methythio group. Preferred aryl groups are those consisting of one, two, or three benzene rings. The term "aryl" embraces aromatic radicals such as phenyl, naphthyl and biphenyl. The term "aralkyl" embraces aryl-substituted alkyl radicals such as benzyl, diphenylmethyl, triphenylmethyl, phenyl- ethyl, phenylbutyl and diphenylethyl. The terms "benzyl" and "phenylmethyl" are interchangeable. The terms

"aryloxy" and "arylthio" denote radical respectively, aryl groups having an oxygen or sulfur atom through which the radical is attached to a nucleus, examples of which are phenoxy and phenylthio. The terms "sulfinyl" and "sulfonyl", whether used alone or linked to other terms, denotes respectively divalent radicals SO and SO₂ . The term "aralkoxy", alone or within another term, embraces an aryl group attached to an alkoxy group to form, for example, benzyloxy. The term "acyl" whether used alone, or within a term such as acyloxy, denotes a radical provided by the residue after removal of hydroxyl from an organic acid, examples of such radical being acetyl and benzoyl. "Lower alkanoyl" is an example of a more prefered sub-class of acyl. The term "amido" denotes a radical consisting of nitrogen atom attached to a carbonyl group, which radical may be further substituted in the manner described herein. The amido radical can be attached to the nucleus of a compound of the invention through the carbonyl moiety or through the nitrogen atom of the amido radical. The term "alkenylalkyl" denotes a radical having a double-bond unsaturation site between two carbons, and which radical may consist of only two carbons or may be further substituted with alkyl groups which may optionally contain additional double-bond unsaturation. The term "heteroaryl" embraces aromatic ring systems containing one or two hetero atoms selected from oxygen, nitrogen and sulfur in a ring system having five or six ring members, examples of which are thienyl, furanyl, pyridinyl, thiazolyl, pyrimidyl and isoxazolyl. Such heteroaryl may be attached as a

substituent through a carbon atom of the heteroaryl ring system, or may be attached through a carbon atom of a moiety substituted on a heteroaryl ring-member carbon atom, for example, through the methylene substituent of

imidazolemethyl moiety. Also, such heteroaryl may be attached through a ring nitrogen atom as long as

aromaticity of the heteroaryl moiety is preserved after attachment. For any of the foregoing defined radicals, preferred radicals are those containing from one to about ten carbon atoms. Specific examples of alkyl groups are methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl, methylbutyl, dimethylbutyl and neopentyl. Typical alkenyl and alkynyl groups may have one unsaturated bond, such as an allyl group, or may have a plurality of unsaturated bonds, with such plurality of bonds either adjacent, such as allene-type structures, or in conjugation, or separated by several saturated carbons. For the R⁰ and R¹ substituents which are each attached to a nitrogen atom of the xanthine ring, it is preferred that certain selections of radicals for R⁰ and R¹ be avoided. Radicals which should preferably be avoided are alkyl, alkenyl and alkynyl moieties having a halo, hydroxy, alkoxy or double bond or triple bond attached to the alpha carbon of the moiety, that is, the carbon attached to a nitrogen atom of the xanthine ring.

Compounds of Formulas I and II have been found to inhibit the action of angiotensin II in mammals.

Angiotensin II is a potent vasoconstrictor and participates in the formation of aldosterone which regulates sodium and water balance in mammals. Thus, compounds of Formulas I and II are therapeutically useful in methods for treating hypertension by administering to a hypertensive patient a therapeutically-effective amount of a compound of Formula I or II. The phrase "hypertensive patient" means, in this context, a mammalian subject suffering from or afflicted by the effects of hypertension or susceptible to a hyperten- sive condition if not treated to prevent or control such hypertension.

Also included in the family of compounds of Formulas I and II are isomeric forms including

diastereoisomers, regioisomers and the pharmaceutically- acceptable salts thereof. The term "pharmaceutically- acceptable salts" embraces salts commonly used to form alkali metal salts and to form addition salts of free acids or free bases. The nature of the salt is not critical, provided that it is pharmaceutically-acceptable. Suitable pharmaceutically-acceptable acid addition salts of

compounds of Formulas I and II may be prepared from an inorganic acid or from an organic acid. Examples of such inorganic acids are hydrochloric, hydrobromic, hydroiodic, nitric, carbonic, sulfuric and phosphoric acid.

Appropriate organic acids may be selected from aliphatic, cycloaliphatic, aromatic, araliphatic, heterocyclic, carboxylic and sulfonic classes of organic acids, example of which are formic, acetic, propionic, succinic, glycolic, gluconic, lactic, malic, tartaric, citric, ascorbic, glucuronic, maleic, fumaric, pyruvic, aspartic, glutamic, benzoic, anthranilic, p-hydroxybenzoic, salicyclic, phenylacetic, mandelic, embonic (pamoic), methansulfonic, ethanesulfonic, 2-hydroxyethanesulfonic, pantothenic, benzenesulfonic, toluenesulfonic, sulfanilic, mesylic, cyclohexylaminosulfonic, stearic, algenic,

β-hydroxybutyric, malonic, galactaric and galacturonic acid. Suitable pharmaceutically-acceptable base addition salts of compounds of Formulas I and II include metallic salts made from aluminium, calcium, lithium, magnesium, potassium, sodium and zinc or organic salts made from N,N'- dibenzylethylenediamine, chloroprocaine, choline,

diethanolamine, ethylenediamine, meglumine (N-methylglucamine) and procaine. All of these salts may be prepared by conventional means from the corresponding compound of Formula I or II by reacting, for example, the appropriate acid or base with the compound of Formula I or II. A family of specific compounds of particular interest within Formula I and Formula II consists of the following compounds:

8-butyl-3,7-dihydro-7-[[2'-(1H-tetrazol-5-yl)(1,1'- biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-butyl-3,7-dihydro-3-methyl-7-[[2'-(1H-tetrazol-5- yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-butyl-3,7-dihydro-3-ethyl-7-[[2'-(1H-tetrazol-5-yl)(1,1'- biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-butyl-3,7-dihydro-3-ρropyl-7-[[2'-(1H-tetrazol-5- yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-butyl-3,7-dihydro-3-isobutyl-7-[[2'-(1H-tetrazol-5- yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-butyl-3,7-dihydro-3-phenyl-7-[[2'-(1H-tetrazol-5- yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-butyl-3,7-dihydro-3-cycloρroρylmethyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-butyl-3,7-dihydro-3-phenylethyl-7-[[2'-(1H-tetrazol-5- yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-butyl-3,7-dihydro-3-methoxyethyl-7-[[2'-(1H-tetrazol-5- yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-butyl-3,7-dihydro-3-carbomethoxymethyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-propyl-3,7-dihydro-7-[[2'-(1H-tetrazol-5-yl)(1,1'- biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-propyl-3,7-dihydro-3-methyl-7-[[2'-(1H-tetrazol-5- yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-propyl-3,7-dihydro-3-ethyl-7-[[2'-(1H-tetrazol-5- yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-propyl-3,7-dihydro-3-propyl-7-[[2'-(1H-tetrazol-5- yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-propyl-3,7-dihydro-3-isobutyl-7-[[2'-(1H-tetrazol-5- yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione; 8-propyl-3,7-dihydro-3-phenyl-7-[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-propyl-3,7-dihydro-3-cyclopropylmethyl-7-[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-propyl-3,7-dihydro-3-phenylethyl-7-[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-propyl-3,7-dihydro-3-methoxyethyl-7-[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-propyl-3,7-dihydro-3-carbomethoxymethyl-7-[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-pentyl-3,7-dihydro-7-[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-pentyl-3,7-dihydro-3-methyl-7-[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-pentyl-3,7-dihydro-3-ethyl-7-[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-pentyl-3,7-dihydro-3-propyl-7-[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-pentyl-3,7-dihydro-3-isobutyl-7-[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-pentyl-3,7-dihydro-3-phenyl-7-[[2'-(1H-tetrazol-5- yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-pentyl-3,7-dihydro-3-cyclopropylmethyl-7-[[2'-(1H- tetrazol-5-yl) (1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-pentyl-3,7-dihydro-3-phenylethyl-7-[[2'-(1H-tetrazol-5- yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-pentyl-3,7-dihydro-3-methoxyethyl-7-[[2'-(1H-tetrazol-5- yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-pentyl-3,7-dihydro-3-carbomethoxymethyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-ethyl-3,7-dihydro-7-[[2'-(1H-tetrazol-5-yl)(1,1'- biphenyl)-4-yl]methyl]-1H-purine-2,6-dione; 8-ethyl-3,7-dihydro-3-methyl-7-[[2'-(1H-tetrazol-5- yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-ethyl-3,7-dihydro-3-ethyl-7-[[2'-(1H-tetrazol-5-yl)(1,1'- biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-ethyl-3,7-dihydro-3-propyl-7-[[2'-(1H-tetrazol-5- yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-ethyl-3,7-dihydro-3-isobutyl-7-[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-ethyl-3,7-dihydro-3-phenyl-7-[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-ethyl-3,7-dihydro-3-cyclopropylmethyl-7-[[2'-(1H-tetrazol-5-yl)(1,1'-biρhenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-ethyl-3,7-dihydro-3-phenylethyl-7-[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-ethyl-3,7-dihydro-3-methoxyethyl-7-[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-ethyl-3,7-dihydro-3-carbomethoxymethyl-7-[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-methyl-3,7-dihydro-7-[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-methyl-3,7-dihydro-3-methyl-7-[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-methyl-3,7-dihydro-3-ethyl-7-[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-methyl-3,7-dihydro-3-propyl-7-[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-methyl-3,7-dihydro-3-isobutyl-7-[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-methyl-3,7-dihydro-3-phenyl-7-[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-methyl-3,7-dihydro-3-cyclopropylmethyl-7-[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione; 8-methyl-3,7-dihydro-3-phenylethyl-7-[[2'-(1H-tetrazol-5- yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-methyl-3,7-dihydro-3-methoxyethyl-7-[[2'-(1H-tetrazol-5- yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-methyl-3,7-dihydro-3-carbomethoxymethyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-cyclohexyl-3,7-dihydro-7-[[2'-(1H-tetrazol-5-yl)(1,1'- biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-cyclohexyl-3,7-dihydro-3-methyl-7-[[2'-(1H-tetrazol-5- yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-cyclohexyl-3,7-dihydro-3-ethyl-7-[[2'-(1H-tetrazol-5- yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-cyclohexyl-3,7-dihydro-3-propyl-7-[[2'-(1H-tetrazol-5- yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-cyclohexyl-3,7-dihydro-3-isobutyl-7-[[2'-(1H-tetrazol-5- yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-cyclohexyl-3,7-dihydro-3-phenyl-7-[[2'-(1H-tetrazol-5- yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-cyclohexyl-3,7-dihydro-3-cyclopropylmethyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-cyclohexyl-3,7-dihydro-3-phenylethyl-7-[[2'-(1H-tetrazol-

5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-cyclohexyl-3,7-dihydro-3-methoxyethyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-cyclohexyl-3,7-dihydro-3-carbomethoxymethyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-isopropyl-3,7-dihydro-7-[[2'-(1H-tetrazol-5-yl)(1,1'- biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-isopropyl-3,7-dihydro-3-methyl-7-[[2'-(1H-tetrazol-5- yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-isopropyl-3,7-dihydro-3-ethyl-7-[[2'-(1H-tetrazol-5- yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione; 8-isopropyl-3,7-dihydro-3-propyl-7-[[2'-(1H-tetrazol-5- yl) (1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-isopropyl-3,7-dihydro-3-isobutyl-7-[[2'-(1H-tetrazol-5- yl) (1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-isopropyl-3,7-dihydro-3-phenyl-7-[[2'-(1H-tetrazol-5- yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-isopropyl-3,7-dihydro-3-cyclopropylmethyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-isoρropyl-3,7-dihydro-3-phenylethyl-7-[[2'-(1H-tetrazol-

5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-isopropyl-3,7-dihydro-3-methoxyethyl-7-[[2'-(1H-tetrazol-

5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-isopropyl-3,7-dihydro-3-carbomethoxymethyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-neopentyl-3,7-dihydro-7-[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-neopentyl-3,7-dihydro-3-methyl-7-[[2'-(1H-tetrazol-5- yl) (1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8 -neopentyl-3,7-dihydro-3-ethyl-7-[[2'-(1H-tetrazol-5- yl) (1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-neopentyl-3,7-dihydro-3-proρyl-7-[[2'-(1H-tetrazol-5- yl) (1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8 -neopentyl-3,7-dihydro-3-isobutyl-7-[[2'-(1H-tetrazol-5- yl) (1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-neopentyl-3,7-dihydro-3-phenyl-7-[[2'-(1H-tetrazol-5- yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-neopentyl-3,7-dihydro-3-cyclopropylmethyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-neopentyl-3,7-dihydro-3-phenylethyl-7-[[2'-(1H-tetrazol-

5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-neopentyl-3,7-dihydro-3-methoxyethyl-7-[[2'-(1H-tetrazol- 5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione; 8-neopentyl-3,7-dihydro-3-carbomethoxymethyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-butyl-3,7-dihydro-1-methyl-7-[[2'-(1H-tetrazol-5- yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-butyl-3,7-dihydro-1,3-dimethyl-7-[[2'-(1H-tetrazol-5- yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-butyl-3,7-dihydro-1-methyl-3-ethyl-7-[[2'-(1H-tetrazol-5- yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-butyl-3,7-dihydro-1-methyl-3-propyl-7-[[2'-(1H-tetrazol- 5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-butyl-3,7-dihydro-1-methyl-3-isobutyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl] -1H-purine-2, 6- dione;

8-butyl-3,7-dihydro-1-methyl-3-phenyl-7-[[2'-(1H-tetrazol- 5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-butyl-3,7-dihydro-1-methyl-3-cyclopropylmethyl-7-[[2'-

(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine- 2,6-dione;

8-butyl-3,7-dihydro-1-methyl-3-phenylethyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-butyl-3,7-dihydro-1-methyl-3-methoxyethyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-butyl-3,7-dihydro-1-methyl-3-carbomethoxymethyl-7-[[2'-

(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-

2,6-dione;

8-propyl-3, 7-dihydro-1-methyl-7- [ [2'- (1H-tetrazol-5- yl) (1, 1 '-biphenyl) -4-yl]methyl]-1H-purine-2, 6-dione;

8-propyl-3, 7-dihydro-1, 3-dimethyl-7- [ [2 '- (1H-tetrazol-5- yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-propyl-3,7-dihydro-1-methyl-3-ethyl-7-[[2'-(1H-tetrazol-

5-yl) (1, 1 ' -biphenyl) -4-yl]methyl] -1H-purine-2, 6-dione;

8-propyl-3, 7-dihydro-1-methyl-3-propyl-7- [ [2 '- (1H-tetrazol-

5-yl) (1, 1 ' -biphenyl) -4-yl]methyl] -1H-purine-2, 6-dione; 8-propyl-3, 7-dihydro-1-methyl-3-isobutyl-7- [ [2 '- (1H- tetrazol-5-yl) (1, 1 '-biphenyl) -4-yl]methyl] -1H-purine-2, 6 - dione;

8-propyl-3, 7-dihydro-1-methyl-3-phenyl-7- [ [2 '- (1H-tetrazol- 5-yl) (1, 1 '-biphenyl) -4-yl]methyl] -1H-purine-2, 6-dione;

8-propyl-3, 7-dihydro-1-methyl-3-cyclopropylmethyl-7- [ [2 ' -

(1H-tetrazol-5-yl) (1, 1 ' -biphenyl) -4-yl]methyl] -1H-purine-

2, 6-dione;

8-propyl-3,7-dihydro-1-methyl-3-phenylethyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-propyl-3,7-dihydro-1-methyl-3-methoxyethyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-propyl-3,7-dihydro-1-methyl-3-carbomethoxymethyl-7-[[2'-

(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-

2,6-dione;

8-pentyl-3,7-dihydro-1-methyl-7-[[2'-(1H-tetrazol-5- yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-pentyl-3,7-dihydro-1,3-dimethyl-7-[[2'-(1H-tetrazol-5- yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-pentyl-3,7-dihydro-1-methyl-3-ethyl-7-[[2'-(1H-tetrazol-

5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-pentyl-3,7-dihydro-1-methyl-3-propyl-7-[[2'-(1H-tetrazol- 5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-pentyl-3,7-dihydro-1-methyl-3-isobutyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-pentyl-3,7-dihydro-1-methyl-3-phenyl-7-[[2'-(1H-tetrazol- 5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-pentyl-3,7-dihydro-1-methyl-3-cyclopropylmethyl-7-[[2'-

(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-

2,6-dione;

8-pentyl-3,7-dihydro-1-methyl-3-phenylethyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione; 8-pentyl-3,7-dihydro-1-methyl-3-methoxyethyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-pentyl-3,7-dihydro-1-methyl-3-carbomethoxymethyl-7-[[2'- (1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-

2, 6-dione;

8-ethyl-3,7-dihydro-1-methyl-7-[[2'-(1H-tetrazol-5- yl) (1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-ethyl-3,7-dihydro-1,3-dimethyl-7-[[2'-(1H-tetrazol-5- yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-ethyl-3,7-dihydro-1-methyl-3-ethyl-7-[[2'-(1H-tetrazol-5- yl)(1,1'-(iphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-ethyl-3,7-dihydro-1-methyl-3-propyl-7-[[2'-(1H-tetrazol-

5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-ethyl-3,7-dihydro-1-methyl-3-isobutyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-ethyl-3,7-dihydro-1-methyl-3-phenyl-7-[[2'-(1H-tetrazol-

5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-ethyl-3,7-dihydro-1-methyl-3-cyclopropylmethyl-7-[[2'-

(1H-tetrazol-5-yl) (1,1'-biphenyl)-4-yl]methyl]-1H-purine-

2, 6-dione;

8-ethyl-3,7-dihydro-1-methyl-3-phenylethyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-ethyl-3,7-dihydro-1-methyl-3-methoxyethyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-ethyl-3,7-dihydro-1-methyl-3-carbomethoxymethyl-7-[[2'- (1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-

2,6-dione;

8-methyl-3,7-dihydro-1-methyl-7-[[2'-(1H-tetrazol-5- yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-methyl-3,7-dihydro-1,3-dimethyl-7-[[2'-(1H-tetrazol-5- yl)(1,1'-biphenyl)-4-yl]methyl]-1H-p-urine-2,6-dione; 8-methyl-3,7-dihydro-1-methyl-3-ethyl-7-[[2'-(1H-tetrazol-

5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-methyl-3,7-dihydro-1-methyl-3-propyl-7-[[2'-(1H-tetrazol-

5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-methyl-3,7-dihydro-1-methyl-3-isobutyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-methyl-3,7-dihydro-1-methyl-3-phenyl-7-[[2'-(1H-tetrazol-

5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-methyl-3,7-dihydro-1-methyl-3-cyclopropylmethyl-7-[[2'-

(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-

2,6-dione;

8-methyl-3,7-dihydro-1-methyl-3-phenylethyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-methyl-3,7-dihydro-1-methyl-3-methoxyethyl-7-[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-methyl-3,7-dihydro-1-methyl-3-carbomethoxymethyl-7-[[2'- (1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine- 2,6-dione;

8-cyclohexyl-3,7-dihydro-1-methyl-7-[[2'-(1H-tetrazol-5- yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-cyclohexyl-3,7-dihydro-1,3-dimethyl-7-[[2'-(1H-tetrazol- 5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-cyclohexyl-3,7-dihydro-1-methyl-3-ethyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-cyclohexyl-3,7-dihydro-1-methyl-3-propyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-cyclohexyl-3,7-dihydro-1-methyl-3-isobutyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione; 8-cyclohexyl-3,7-dihydro-1-methyl-3-phenyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-cyclohexyl-3,7-dihydro-1-methyl-3-cyclopropylmethyl-7- [[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione;

8-cyclohexyl-3,7-dihydro-1-methyl-3-phenylethyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-cyclohexyl-3,7-dihydro-1-methyl-3-methoxyethyl-7-[[2'-

(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-

2,6-dione;

8-cyclohexyl-3,7-dihydro-1-methyl-3-carbomethoxymethyl-7-

[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione;

8-isopropyl-3,7-dihydro-1-methyl-7-[[2'-(1H-tetrazol-5- yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-isopropyl-3,7-dihydro-1,3-dimethyl-7-[[2'-(1H-tetrazol-5- yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-isopropyl-3,7-dihydro-1-methyl-3-ethyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-isopropyl-3,7-dihydro-1-methyl-3-propyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-isopropyl-3,7-dihydro-1-methyl-3-isobutyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-isopropyl-3,7-dihydro-1-methyl-3-phenyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-isopropyl-3,7-dihydro-1-methyl-3-cyclopropylmethyl-7-

[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione; 8-isopropyl-3,7-dihydro-1-methyl-3-phenylethyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-isoproρyl-3,7-dihydro-1-methyl-3-methoxyethyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-isopropyl-3,7-dihydro-1-methyl-3-carbomethoxymethyl-7-

[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]met4yl]-1H- purine-2,6-dione;

8-neopentyl-3,7-dihydro-1-methyl-7-[[2'-(1H-tetrazol-5- yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-neopentyl-3,7-dihydro-1,3-dimethyl-7-[[2'-(1H-tetrazol-5- yl) (1, 1 '-biphenyl) -4-yl]methyl] -1H-purine-2, 6-dione;

8-neopentyl-3, 7-dihydro-1-methyl-3-ethyl-7- [ [2 '- (1H- tetrazol-5-yl) (1, 1 '-biphenyl) -4-yl]methyl] -1H-purine-2, 6- dione;

8-neopentyl-3, 7-dihydro-1-methyl-3-propyl-7- [ [2 '- (1H- tetrazol-5-yl) (1, 1 '-biphenyl) -4-yl]methyl] -1H-purine-2, 6- dione;

8-neopentyl-3, 7-dihydro-1-methyl-3-isobutyl-7- [ [2 ' - (1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-neopentyl-3,7-dihydro-1-methyl-3-phenyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-neopentyl-3,7-dihydro-1-methyl-3)cyclopropylmethyl-7-

[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione;

8-neopentyl-3,7-dihydro-1-methyl-3-phenylethyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-neopentyl-3,7-dihydro-1-methyl-3-methoxyethyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione; 8-neopentyl-3,7-dihydro-1-methyl-3-carbomethoxymethyl-7-

[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione;

8-butyl-3,7-dihydro-1-ethyl-7-[[2'-(1H-tetrazol-5-yl)(1,1'- biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-butyl-3,7-dihydro-1-ethyl-3-methyl-7-[[2'-(1H-tetrazol-5- yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-butyl-3,7-dihydro-1,3-diethyl-7-[[2'-(1H-tetrazol-5- yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-butyl-3,7-dihydro-1-ethyl-3-propyl-7-[[2'-(1H-tetrazol-5- yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-butyl-3,7-dihydro-1-ethyl-3-isobutyl-7-[[2'-(1H-tetrazol-

5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-butyl-3,7-dihydro-1-ethyl-3-phenyl-7-[[2'-(1H-tetrazol-5- yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-butyl-3,7-dihydro-1-ethyl-3-cyclopropylmethyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-butyl-3,7-dihydro-1-ethyl-3-phenylethyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-butyl-3,7-dihydro-1-ethyl-3-methoxyethyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-butyl-3,7-dihydro-1-ethyl-3-carbomethoxymethyl-7-[[2'-

(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-

2,6-dione;

8-propyl-3,7-dihydro-1-ethyl-7-[[2'-(1H-tetrazol-5- yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-propyl-3,7-dihydro-1-ethyl-3-methyl-7-[[2'-(1H-tetrazol-

5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-propyl-3,7-dihydro-1,3-diethyl-7-[[2'-(1H-tetrazol-5- yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-propyl-3,7-dihydro-1-ethyl-3-propyl-7-[[2'-(1H-tetrazol- 5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione; 8-propyl-3,7-dihydro-1-ethyl-3-isobutyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-propyl-3,7-dihydro-1-ethyl-3-phenyl-7-[[2'-(1H-tetrazol- 5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purinee2,6-dione;

8-propyl-3,7-dihydro-1-ethyl-3-cyclopropylmethyl-7-[[2'- (1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-

2,6-dione;

8-propyl-3,7-dihydro-1-ethyl-3-ρhenylethyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-propyl-3,7-dihydro-1-ethyl-3-methoxyethyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-propyl-3,7-dihydro-1-ethyl-3-carbomethoxymethyl-7-[[2'-

(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-

2,6-dione;

8-pentyl-3,7-dihydro-1-ethyl-7-[[2'-(1H-tetrazol-5- yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-pentyl-3,7-dihydro-1-ethyl-3-methyl-7-[[2'-(1H-tetrazol-

5-yl) (1, 1 ' -biphenyl) -4-yl]methyl] -1H-purine-2, 6-dione;

8-pentyl-3, 7-dihydro-1, 3-diethyl-7- [ [2 ' - (1H-tetrazol-5- yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-pentyl-3,7-dihydro-1-ethyl-3-propyl-7-[[2'-(1H-tetrazol- 5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-pentyl-3,7-dihydro-1-ethyl-3-isobutyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-pentyl-3,7-dihydro-1-ethyl-3-phenyl-7-[[2'-(1H-tetrazol- 5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-pentyl-3,7-dihydro-1-ethyl-3-cyclopropylmethyl-7-[[2'- (1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-

2,6-dione;

8-pentyl-3,7-dihydro-1-ethyl-3-phenylethyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione; 8-pentyl-3,7-dihydro-1-ethyl-3-methoxyethyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-pentyl-3,7-dihydro-1-ethyl-3-carbomethoxymethyl-7-[[2'- (1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-

2,6-dione;

8-ethyl-3,7-dihydro-1-ethyl-7-[[2'-(1H-tetrazol-5-yl)(1,1'- biphenyl) -4-yl]methyl] -1H-purine-2, 6-dione;

8-ethyl-3, 7-dihydro 1-ethyl-3-methyl-7- [ [2'- (1H-tetrazol-5- yl) (1, 1 '-biphenyl) -4-yl]methyl]-1H-purine-2, 6-dione;

8-ethyl-3, 7-dihydro-1, 3-diethyl-7- [ [2 '- (1H-tetrazol-5- yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-ethyl-3,7-dihydro-1-ethyl-3-propyl-7-[[2'-(1H-tetrazol-5- yl) (1, 1 '-biphenyl) -4-yl]methyl]-1H-purine-2, 6-dione;

8-ethyl-3, 7-dihydro-1-ethyl-3-isobutyl-7- [ [2 '- (1H-tetrazol-

5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-ethy1-3,7-dihydro-1-ethyl-3-phenyl-7-[[2'-(1H-tetrazol-5- yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-ethyl-3,7-dihydro-1-ethyl-3-cyclopropylmethyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-ethyl-3,7-dihydro-1-ethyl-3-phenylethyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-ethyl-3,7-dihydro-1-ethyl-3-methoxyethyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-ethyl-3,7-dihydro-1-ethyl-3-carbomethoxymethyl-7-[[2'- (1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine- 2,6-dione;

8-methyl-3,7-dihydro-1-ethyl-7-[[2'-(1H-tetrazol-5- yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-methyl-3,7-dihydro-1-ethyl-3-methyl-7-[[2'-(1H-tetrazol-

5-yl) (1, 1'-biphenyl) -4-yl]methyl] -1H-purine-2, 6-dione;

8-methyl-3, 7-dihydro-1, 3-diethyl-7- [ [2'- (1H-tetrazol-5- yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-ddone; 8-methyl-3, 7-dihydro-1-ethyl-3-propyl-7- [ [2 ' - (1H-tetrazol-

5-yl) (1, 1 ' -biphenyl) -4-yl]methyl] -1H-purine-2, 6-dione;

8-methyl-3, 7-dihydro-1-ethyl-3-isobutyl-7- [ [2 ' - (1H- tetrazdl-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-methyl-3,7-dihydro-1-ethyl-3-phenyl-7-[[2'-(1H-tetrazol-

5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-methyl-3,7-dihydro-1-ethyl-3-cyclopropylmethyl-7-[[2'- (1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine- 2,6-dione;

8-methyl-3,7-dihydro-1-ethyl-3-phenylethyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-methyl-3,7-dihydro-1-ethyl-3-methoxyethyl-7-[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-methyl-3,7-dihydro-1-ethyl-3-carbomethoxymethyl-7-[[2'-

(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-

2,6-dione;

8-cyclohexyl-3,7-dihydro-1-ethyl-7-[[2'-(1H-tetrazol-5- yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-cyclohexyl-3,7-dihydro-1-ethyl-3-methyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-cyclohexyl-3,7-dihydro-1,3-diethyl-7-[[2'-(1H-tetrazol-5- yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-cyclohexyl-3,7-dihydro-1-ethyl-3-propyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-cyclohexyl-3,7-dihydro-1-ethyl-3-isobutyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-cyclohexyl-3,7-dihydro-1-ethyl-3-phenyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione; 8-cyclohexyl-3,7-dihydro-1-ethyl-3-cyclopropylmethyl-7- [[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione;

8-cyclohexyl-3,7-dihydro-1-ethyl-3-phenylethyl-7-[[2'-(1H- tetrazol-5-ylt(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-cyclohexyl-3,7-dihydro-1-ethyl-3-methoxyethyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-cyclohexyl-3,7-dihydro-1-ethyl-3-carbomethoxymethyl-7-

[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione;

8-isopropyl-3,7-dihydro-1-ethyl-7-[[2'-(1H-tetrazol-5- yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-isopropyl-3,7-dihydro-1-ethyl-3-methyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-isopropyl-3,7-dihydro-1,3-diethyl-7-[[2'-(1H-tetrazol-5- yl) (1, 1 '-biphenyl) -4-yl]methyl] -1H-purine-2, 6-dione;

8-isopropyl-3,7-dihydro-1-ethyl-3-propyl-7- [ [2 '- (1H- tetrazol-5-yl) (1, 1 '-biphenyl) -4-yl]methyl] -1H-purine-2, 6- dione;

8-isoρropyl-3, 7-dihydro-1-ethyl-3-isobutyl-7- [ [2 '- (1H- tetrazol-5-yl)(1,1'-biphenyl) -4-yl]methyl] -1H-purine-2, 6- dione;

8-isopropyl-3,7-dihydro-1-ethyl-3-phenyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-isopropyl-3,7-dihydro-1-ethyl-3-cyclopropylmethyl-7-[[2'- (1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine- 2,6-dione;

8-isopropyl-3,7-dihydro-1-ethyl-3-phenylethyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione; 8-isopropyl-3, 7-dihydro-1-ethyl-3-methoxyethyl-7- [ [2 ' - (1H- tetrazol-5-yl) (1, 1 '-biphenyl) -4-yl]methyl] -1H-purine-2, 6- dione;

8-isopropyl-3,7-dihydro-1-ethyl-3-carbomethoxymethyl-7- [[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione;

8-neopyntyl-3,7-dihydro-1-ethyl-7-[[2'-(1H-tetrazol-5- yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-neopentyl-3, 7-dihydro-1-ethyl-3-methyl-7- [ [2 '- (1H- tetrazol-5-yl) (1, 1 '-biphenyl) -4-yl]methyl] -1H-purine-2, 6 - dione;

8-neopentyl-3,7-dihydro-1,3-diethyl-7-[[2'-(1H-tetrazol-5- yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-neopentyl-3,7-dihydro-1-ethyl-3-propyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-neopentyl-3,7-dihydro-1-ethyl-3-isobutyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-neopentyl-3,7-dihydro-1-ethyl-3-phenyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-neopentyl-3,7-dihydro-1-ethyl-3-cyclopropylmethyl-7-[[2'-

(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-neopentyl-3,7-dihydro-1-ethyl-3-phenylethyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-neopentyl-3,7-dihydro-1-ethyl-3-methoxyethyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-neopentyl-3,7-dihydro-1-ethyl-3-carbomethoxymethyl-7-

[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione;

8-butyl-3,7-dihydro-1-propyl-7-[[2'-(1H-tetrazol-5- yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione; 8-butyl-3,7-dihydro-1-propyl-3-methyl-7-[[2'-(1H-tetrazol- 5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-butyl-3,7-dihydro-1,3-dipropyl-7-[[2'-(1H-tetrazol-5- yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-butyl-3,7-dihydro-1-propyl-3-isobutyl-7-[[2'-(1H- tetr-zol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-butyl-3,7-dihydro-1-propyl-3-phenyl-7-[[2'-(1H-tetrazol- 5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-butyl-3,7-dihydro-1-propyl-3-cycloρropylmethyl-7-[[2'- (1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine- 2,6-dione;

8-butyl-3,7-dihydro-1-propyl-3-phenylethyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-butyl-3,7-dihydro-1-propyl-3-methoxyethyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-butyl-3,7-dihydro-1-propyl-3-carbomethoxymethyl-7-[[2'- (1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine- 2,6-dione;

8-propyl-3,7-dihydro-1-propyl-7-[[2'-(1H-tetrazol-5- yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-propyl-3,7-dihydro-1-propyl-3-methyl-7-[[2'-(1H-tetrazol- 5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-propyl-3,7-dihydro-1,3-diρropyl-7-[[2'-(1H-tetrazol-5- yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-propyl-3,7-dihydro-1-propyl-3-isobutyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-propyl-3,7-dihydro-1-propyl-3-phenyl-7-[[2'-(1H-tetrazol- 5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-propyl-3,7-dihydro-1-propyl-3-cyclopropylmethyl-7-[[2'- (1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine- 2,6-dione; 8-propyl-3,7-dihydro-1-propyl-3-phenylethyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-propyl-3,7-dihydro-1-proρyl-3-methoxyethyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-propyl-3,7-dihydro-1-propyl-3-carbomethoxymethyl-7-[[2'-

(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-

2,6-dione;

8-pentyl-3,7-dihydro-1-propyl-7-[[2'-(1H-tetrazol-5- yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-pentyl-3,7-dihydro-1-propyl-3-methyl-7-[[2'-(1H-tetrazol-

5-yl)(1,1'-biphenyl)-4-yllmethyl]-1H-purine-2,6-dione;

8-pentyl-3,7-dihydro-1,3-dipropyl-7-[[2'-(1H-tetrazol-5- yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-pentyl-3,7-dihydro-1-propyl-3-isobutyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-pentyl-3,7-dihydro-1-propyl-3-phenyl-7-[[2'-(1H-tetrazol- 5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-pentyl-3,7-dihydro-1-propyl-3-cyclopropylmethyl-7-[[2'-

(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-

2,6-dione;

8-pentyl-3,7-dihydro-1-propyl-3-phenylethyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-pentyl-3,7-dihydro-1-propyl-3-methoxyethyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-pentyl-3,7-dihydro-1-propyl-3-carbomethoxymethyl-7-[[2'-

(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-

2,6-dione;

8-ethyl-3,7-dihydro-1-propyl-7-[[2'-(1H-tetrazol-5- yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-ethyl-3,7-dihydro-1-propyl-3-methyl-7-[[2'-(1H-tetrazol-

5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-diine; 8-ethyl-3,7-dihydro-1,3-dipropyl-7-[[2'-(1H-tetrazol-5- yl) (1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-ethyl-3,7-dihydro-1-propyl-3-isobutyl-7-[[2'-(1H- tetrazol-5-yl) (1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-ethyl-3,7-dihydro-1-propyl-3-phenyl-7-[[2'-(1Hhtetrazol-

5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-ethyl-3,7-dihydro-1-propyl-3-cyclopropylmethyl-7-[[2'-

(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine- 2,6-dione;

8-ethy1-3,7-dihydro-1-propyl-3-phenylethyl-7-[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-ethyl-3,7-dihydro-1-propyl-3-methoxyethyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-ethyl-3,7-dihydro-1-propyl-3-carbomethoxymethyl-7-[[2'-

(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-

2,6-dione;

8-methyl-3,7-dihydro-1-propyl-7-[[2'-(1H-tetrazol-5- yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-methyl-3,7-dihydro-1-propyl-3-methyl-7-[[2'-(1H-tetrazol-

5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-methyl-3,7-dihydro-1,3-dipropyl-7-[[2'-(1H-tetrazol-5- yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-methyl-3,7-dihydro-1-propyl-3-isobutyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-methyl-3,7-dihydro-1-propyl-3-phenyl-7-[[2'-(1H-tetrazol- 5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-methyl-3,7-dihydro-1-propyl-3-cyclopropylmethyl-7-[[2'- (1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-

2,6-dione;

8-methyl-3,7-dihydro-1-propyl-3-phenylethyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione; 8-methyl-3,7-dihydro-1-propyl-3-methoxyethyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-methyl-3,7-dihydro-1-propyl-3-carbomethoxymethyl-7-[[2'- (1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-

2,6-dione;

8-cyclohexyl-3,7-dihydro-1-propyl-7-[[2'-(1H-tetrazol-5- yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-cyclohexyl-3,7-dihydro-1-propyl-3-methyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-cyclohexyl-3,7-dihydrop1,3-dipropyl-7-[[2'-(1H-tetrazol-

5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-cyclohexyl-3,7-dihydro-1-propyl-3-isobutyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-cyclohexyl-3,7-dihydro-1-propyl-3-phenyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-cyclohexyl-3,7-dihydro-1-propyl-3-cyclopropylmethyl-7-

[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione;

8-cyclohexyl-3,7-dihydro-1-propyl-3-phenylethyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-cyclohexyl-3,7-dihydro-1-propyl-3-methoxyethyl-7-[[2'-

(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-

2,6-dione;

8-cyclohexyl-3,7-dihydro-1-propyl-3-carbomethoxymethyl-7- [[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione;

8-isopropyl-3,7-dihydro-1-propyl-7-[[2'-(1H-tetrazol-5- yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-isopropyl-3,7-dihydro-1-propyl-3-methyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione; 8-isopropyl-3, 7-dihydro-1, 3-dipropyl-7- [ [2' - (1H-tetrazol-5- yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-isopropyl-3,7-dihydro-1-propyl-3-isobutyl-7-[[2'-(1H- tetrazol-5-yl) (1, 1 '-biphenyl) -4-yl]methyl] -1H-purine-2, 6- dione;

8-isopropyl-3, 7-dihydro-1-propyl-3-phenyl-7-[ [2 ' - (1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-iso ropyl-3,7-dihydro-1-propyl-3-cyclopropylmethyl-7- [[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione;

8-isopropyl-3,7-dihydro-1-propyl-3-phenylethyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-isopropyl-3,7-dihydro-1-propyl-3-methoxyethyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-isopropyl-3,7-dihydro-1-propyl-3-carbomethoxymethyl-7- [[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione;

8-neopentyl-3,7-dihydro-l-propyl-7-[[2'-(1H-tetrazol-5- yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-neopentyl-3,7-dihydro-1-propyl-3-methyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-neopentyl-3,7-dihydro-1,3-dipropyl-7-[[2'-(1H-tetrazol-5- yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-neopentyl-3,7-dihydro-1-propyl-3-isobutyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-neopentyl-3,7-dihydro-1-propyl-3-phenyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-neopentyl-3,7-dihydro-1-propyl-3-cyclopropylmethyl-7- [[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione; 8-neopentyl-3,7-dihydro-1-propyl-3-phenylethyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-neopentyl-3,7-dihydro-1-propyl-3-methoxyethyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-neopentyl-3,7-dihydro-1-propyl-3-carbomlthoxymethyl-7-

[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione;

8-butyl-3,7-dihydro-1-isobutyl-7-[[2'-(1H-tetrazol-5- yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-butyl-3,7-dihydro-1-isobutyl-3-methyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-butyl-3,7-dihydro-1-isobutyl-3-propyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-butyl-3,7-dihydro-1,3-diisobutyl-7-[[2'-(1H-tetrazol-5- yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-butyl-3,7-dihydro-1-isobutyl-3-phenyl-7-[[2'-(1H- tetrazol-5-yl) (1, 1 '-biphenyl) -4-yl]methyl] -1H-purine-2, 6- dione;

8-butyl-3,7-dihydro-1-isobutyl-3-cyclopropylmethyl-7-[[2'-

(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine- 2,6-dione;

8-butyl-3,7-dihydro-1-isobutyl-3-phenylethyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-butyl-3,7-dihydro-1-isobutyl-3-methoxyethyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-butyl-3,7-dihydro-1-isobutyl-3-carbomethoxymethyl-7-[ [2'-

(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine- 2,6-dione;

8-propyl-3,7-dihydro-1-isobutyl-7-[[2'-(1H-tetrazol-5- yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione; 8-propyl-3,7-dihydro-1-isobutyl-3-methyl-7-[[2'-(1H- tetrazol-5-yl) (1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-propyl-3,7-dihydro-1-isobutyl-3-propyl-7-[[2'-(1H- tetrazol-5-yl) (1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-propyl-3,7-dihydro-1,3-diisobutyl-7-[[2'-(1H-tetrazol-5- yl) (1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-propyl-3,7-dihydr3-1-isobutyl-3-phenyl-7-[[2'-(1H- tetrazol-5-yl) (1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-propyl-3,7-dihydro-1-isobutyl-3-cyclopropylmethyl-7-[[2'-

(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-

2,6-dione;

8-propyl-3,7-dihydro-1-isobutyl-3-phenylethyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-propyl-3,7-dihydro-1-isobutyl-3-methoxyethyl-7-[(2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-propyl-3,7-dihydro-1-isobutyl-3-carbomethoxymethyl-7-

[[2'-(1H-tetrazol-5-y1)(1,1'-biphenyl)-4-y1]methyl]-1H- purine-2,6-dione;

8-pentyl-3,7-dihydro-1-isobutyl-7-[[2'-(1H-tetrazol-5- yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-pentyl-3,7-dihydro-1-isobutyl-3-methyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-pentyl-3,7-dihydro-1-isobutyl-3-propyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-pentyl-3,7-dihydro-1,3-diisobutyl-7-[[2'-(1H-tetrazol-5- yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-pentyl-3,7-dihydro-1-isobutyl-3-phenyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione; 8-pentyl-3,7-dihydro-1-isobutyl-3-cyclopropylmethyl-7-[[2'- (1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-

2,6-dione;

8-pentyl-3,7-dihydro-1-isobutyl-3-phenylethyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-pentyl-3,7-dihydro-1-isobutyl-3-methoxyethyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-pentyl 3,7-dihydro-1-isobutyl-3-carbomethoxymethyl-7-

[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione;

8-ethyl-3,7-dihydro-1-isobutyl-7-[[2'-(1H-tetrazol-5- yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-ethyl-3,7-dihydro-1-isobutyl-3-methyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-ethyl-3,7-dihydro-1-isobutyl-3-propyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-ethyl-3,7-dihydro-1,3-diisobutyl-7-[[2'-(1H-tetrazol-5- yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-ethy1-3,7-dihydro-1-isobutyl-3-phenyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-ethyl-3,7-dihydro-1-isobutyl-3-cyclopropylmethyl-7-[[2'-

(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-

2,6-dione;

8-ethyl-3,7-dihydro-1-isobutyl-3-phenylethyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-ethyl-3,7-dihydro-1-isobutyl-3-methoxyethyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione; 8-ethyl-3,7-dihydro-1-isobutyl-3-carbomethoxymethyl-7-[[2'-

(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-

2,6-dione;

8-methyl-3,7-dihydro-1-isobutyl-7-[[2'-(1H-tetrazol-5- yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-methyl-3,7-dihydro-1-isobutyl-3-methyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-methyl-3,7-dihydro-1-isobutyl-3-propyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-methyl-3, 7-dihydro-1, 3-diisobutyl-7- [ [2 '- (1H-tetrazol-5- yl) (1, 1 '-biphenyl) -4-yl]methyl]-1H-purine-2, 6-dione;

8-methyl-3, 7-dihydro-1-isobutyl-3-phenyl-7- [ [2 '- (1H- tetrazol-5-yl) (1, 1 '-biphenyl) -4-yl]methyl] -1H- urine-2, 6- dione;

8-methyl-3,7-dihydro-1-isobutyl-3-cyclopropylmethyl-7-[[2'-

(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-

2,6-dione;

8-methyl-3,7-dihydro-1-isobutyl-3-phenylethyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-methyl-3,7-dihydro-1-isobutyl-3-methoxyethyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-methyl-3,7-dihydro-1-isobutyl-3-carbomethoxymethyl-7-

[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione;

8-cyclohexyl-3,7-dihydro-1-isobutyl-7-[[2'-(1H-tetrazol-5- yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-cyclohexyl-3,7-dihydro-1-isobutyl-3-methyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-cyclohexyl-3,7-dihydro-1-isobutyl-3-propyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione; 8-cyclohexyl-3,7-dihydro-1,3-diisobutyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-cyclohexyl-3,7-dihydro-1-isobutyl-3-phenyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-cyclohexyl-3,7-dihydro-1-isobutyl-3-cyclopropylmethyl-7-

[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione;

8-cyclohexyl-3,7-dihydro-1-isobutyl-3-phenylethyl-7-[[2'-

(1H-tetraz-l-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-

2,6-dione;

8-cyclohexyl-3,7-dihydro-1-isobutyl-3-methoxyethyl-7-[[2'-

(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine- 2,6-dione;

8-cyclohexyl-3,7-dihydro-1-isobutyl-3-carbomethoxymethyl-7-

[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione;

8-isopropyl-3, 7-dihydro-1-isobutyl-7- [ [2 '- (1H-tetrazol-5- yl) (1, 1 '-biphenyl) -4-yl]methyl] -1H-purine-2, 6-dione;

8-isopropyl-3, 7-dihydro-1-isobutyl-3-methyl-7- [ [2 '- (1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-isopropyl-3,7-dihydro-1-isobutyl-3-propyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-isopropyl-3,7-dihydro-1,3-diisobutyl-7-[[2'-(1H-tetrazol-

5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-isopropyl-3,7-dihydro-1-isobutyl-3-phenyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-isopropyl-3,7-dihydro-1-isobutyl-3-cyclopropylmethyl-7-

[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione; 8-isopropyl-3,7-dihydro-1-isobutyl-3-phenylethyl-7-[[2'-

(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-

2,6-dione;

8-isopropyl-3,7-dihydro-1-isobutyl-3-methoxyethyl-7-[[2'- (1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-

2,6-dione;

8-isopropyl-3,7-dihydro-1-isobutyl-3-carbomethoxymethyl-7-

[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione;

8-neopentyl-3,7-dihydro-1-isobutyl-7-[[2'-(1H-tetrazol-5- yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-neoρentyl-3,7-dihydro-1-isobutyl-3-methyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-neopentyl-3,7-dihydro-1-isobutyl-3-propyl-7-[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-neopentyl-3,7-dihydro-1,3-diisobutyl-7-[[2'-(1H-tetrazol-

5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-neopentyl-3,7-dihydro-1-isobutyl-3-phenyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-neopentyl-3,7-dihydro-1-isobutyl-3-cyclopropylmethyl-7-

[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione;

8-neopentyl-3,7-dihydro-1-isobutyl-3-phenylethyl-7-[[2'-

(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine- 2,6-dione;

8-neopentyl-3,7-dihydro-1-isobutyl-3-methoxyethyl-7-[[2 ' - (1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-

2,6-dione;

8-neopentyl-3,7-dihydro-1-isobutyl-3-carbomethoxymethyl-7- [[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione;

8-butyl-3,7-dihydro-1-phenyl-7-[[2'-(1H-tetrazol-5- yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione; 8-butyl-3, 7-dihydro-1-phenyl-3-methyl-7- [ [2 '- (1H-tetrazol-

5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-butyl-3,7-dihydro-1-phenyl-3-propyl-7-[[2'-(1H-tetrazol-

5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-butyl-3,7-dihydro-1,3-diphenyl-7-[[2'-(1H-tetrazol-5- yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-butyl-3,7-dihydro-1-phenyl-3-phenyl-7-[[2 ' -(1H-tetrazol-

5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-butyl-3,7-dihydro-1-phenyl-3-cyclopropylmethyl-7-[[2'- (1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-

2,6-dione;

8-butyl-3,7-dihydro-1-phenyl-3-phenylethyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-butyl-3,7-dihydro-1-phenyl-3-methoxyethyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-butyl-3,7-dihydro-1-phenyl-3-carbomethoxymethyl-7-[[2'-

(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine- 2,6-dione;

8-propyl-3,7-dihydro-1-phenyl-7-[[2'-(1H-tetrazol-5- yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-propyl-3,7-dihydro-1-phenyl-3-methyl-7-[[2'-(1H-tetrazol-

5-yl) (1, 1 ' -biphenyl) -4-yl]methyl] -1H-purine-2, 6-dione;

8-propyl-3, 7-dihydro-1-phenyl-3-propyl-7- [ [2 ' - (1H-tetrazol-

5-yl) (1, 1 '-biphenyl) -4-yl]methyl] -1H-purine-2, 6-dione;

8-propyl-3, 7-dihydro-1, 3-diphenyl-7- [ [2 '- (1H-tetrazol-5- yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-propyl-3,7-dihydro-1-phenyl-3-phenyl-7-[[2'-(1H-tetrazol- 5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-propyl-3,7-dihydro-1-phenyl-3-cyclopropylmethyl-7-[[2'-

(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-

2,6-dione;

8-propyl-3,7-dihydro-1-phenyl-3-phenylethyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione; 8-propyl-3,7-dihydro-1-phenyl-3-methoxyethyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-propyl-3,7-dihydro-1-phenyl-3-carbomethoxymethyl-7-[[2'- (1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine- 2,6-dione;

8-pentyl-3,7-dihydro-1-phenyl-7-[[2'-(1H-tetrazol-5- yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-pentyl-3,7-dihydro-1-phenyl-3-methyl-7-[[2'-(1H-tetrazol- 5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-pentyl-3,7-dihydro-1-phenyl-3-propyl-7-[[2'-(1H-tetrazol- 5-yl)(1,1'-biphenyl)-4-y1]methyl]-1H-purine-2,6-dione;

8-pentyl-3,7-dihydro-1,3-diphenyl-7-[[2'-(1H-tetrazol-5- yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-pentyl-3,7-dihydro-1-phenyl-3-ρhenyl-7-[[2'-(1H-tetrazol- 5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-pentyl-3,7-dihydro-1-phenyl-3-cyclopropylmethyl-7-[[2'-

(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine- 2,6-dione;

8-pentyl-3,7-dihydro-1-phenyl-3-phenylethyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-pentyl-3,7-dihydro-1-phenyl-3-methoxyethyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-pentyl-3,7-dihydro-1-phenyl-3-carbomethoxymethyl-7-[[2'-

(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-

2,6-dione;

8-ethyl-3, 7-dihydro-1-phenyl-7- [ [2'- (1H-tetrazol-5- yl) (1, 1 '-biphenyl) -4-yl]methyl] -1H-purine-2, 6-dione;

8-ethyl-3,7-dihydro-1-phenyl-3-methyl-7- [ [2 '- (1H-tetrazol-

5-yl) (1, 1 '-biphenyl) -4-yl]methyl] -1H-purine-2, 6-dione;

8-ethyl-3,7-dihydro-1-phenyl-3-propyl-7- [ [2 ' - (1H-tetrazol-

5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-ethyl-3,7-dihydro-1,3-diphenyl-7-[[2'-(1H-tetrazol-5- yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione; 8-ethyl-3,7-dihydro-1-phenyl-3-phenyl-7-[[2'-(1H-tetrazol-

5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-ethyl-3,7-dihydro-1-phenyl-3-cyclopropylmethyl-7-[[2'-

(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine- 2,6-dione;

8-ethyl-3,7-dihydro-1-phenyl-3-phenylethyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-ethyl-3, 7-dihydro-1-phenyl-3-methoxyethyl-7- [ [2 ' - (1H- tetrazol-5-yl) (1, 1 '-biphenyl) -4-yl]methyl] -1H-purine-2, 6- dione;

8-ethyl-3,7-dihydro-1-phenyl-3-carbomethoxymethyl-7-[[2'-

(1H-tetrazol-5-yl)(-,1'-biphenyl)-4-yl]methyl]-1H-purine-

2,6-dione;

8-methyl-3,7-dihydro-1-phenyl-7-[[2'-(1H-tetrazol-5- yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-methyl-3,7-dihydro-1-phenyl-3-methyl-7-[[2'-(1H-tetrazol-

5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-methyl-3,7-dihydro-1-phenyl-3-propyl-7-[[2'-(1H-tetrazol- 5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-methyl-3,7-dihydro-1,3-diphenyl-7-[[2'-(1H-tetrazol-5- yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-methyl-3,7-dihydro-1-phenyl-3-phenyl-7-[[2'-(1H-tetrazol-

5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-methyl-3,7-dihydro-1-phenyl-3-cyclopropylmethyl-7-[[2'-

(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-

2,6-dione;

8-methyl-3,7-dihydro-1-phenyl-3-phenylethyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-methyl-3,7-dihydro-1-phenyl-3-methoxyethyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-methyl-3,7-dihydro-1-phenyl-3-carbomethoxymethyl-7-[[2'- (1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-

2,6-dione; 8-cyclohexyl-3,7-dihydro-1-phenyl-7-[[2'-(1H-tetrazol-5- yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-cyclohexyl-3,7-dihydro-1-phenyl-3-methyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-cyclohexyl-3,7-dihydro-1-phenyl-3-propyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-cyclohexyl-3,7-dihydro-1,3-diphenyl-7-[[2'-(1H-tetrazol- 5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-cyclohexyl-3,7-dihydro-1-phenyl-3-phenyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-cyclohexyl-3,7-dihydro-1-phenyl-3-cyclopropylmethyl-7- [[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione;

8-cyclohexyl-3,7-dihydro-1-phenyl-3-phenylethyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-cyclohexyl-3,7-dihydro-1-phenyl-3-methoxyethyl-7-[[2'-

(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-

2,6-dione;

8-cyclohexyl-3,7-dihydro-1-phenyl-3-carbomethoxymethyl-7-

[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione;

8-isopropyl-3,7-dihydro-1-phenyl-7-[[2'-(1H-tetrazol-5- yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-isopropyl-3,7-dihydro-1-phenyl-3-methyl-7-[[2'-(1H- tetrazol-5-yl) (1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-isopropyl-3,7-dihydro-1-phenyl-3-propyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-isopropyl-3,7-dihydro-1,3-diphenyl-7-[[2'-(1H-tetrazol-5- yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione; 8-isopropyl-3, 7-dihydro-1-phenyl-3-phenyl-7- [ [2 ' - (1H- tetrazol-5-yl) (1, 1 '-biphenyl) -4-yl]methyl] -1H-purine-2, 6 - dione;

8-isopropyl-3,7-dihydro-1-phenyl-3-cyclopropylmethyl-7- [[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione;

8-isopropyl-3,7-dihydro-1-phenyl-3-phenylethyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dion ;

8-isopropyl-3,7-dihydro-1-phenyl-3-methoxyethyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-isopropyl-3, 7-dihydro-1-phenyl-3-carbomethoxymethyl-7-

[ [2 '- (1H-tetrazol-5-yl) (1, 1 '-biphenyl) -4-yl]methyl] -1H- purine-2, 6-dione;

8-neopentyl-3, 7-dihydro-1-phenyl-7- [ [2'- (1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-neopentyl-3,7-dihydro-1-phenyl-3-methyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-neopentyl-3,7-dihydro-1-phenyl-3-propyl-7-[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-neopentyl-3,7-dihydro-1,3-diphenyl-7-[[2'-(1H-tetrazol-5- yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-neopentyl-3,7-dihydro-1-phenyl-3-phenyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-neopentyl-3,7-dihydro-1-phenyl-3-cyclopropylmethyl-7- [[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione;

8-neopentyl-3,7-dihydro-1-phenyl-3-phenylethyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2, - dione; 8-neopentyl-3,7-dihydro-1-phenyl-3-methoxyethyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-neopentyl-3,7-dihydro-1-phenyl-3-carbomethoxymethyl-7- [[2'-(1H-petrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione;

8-butyl-3,7-dihydro-1-cyclopropylmethyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-butyl-3,7-dihydro-1-cyclopropylmethyl-3-methyl-7-[[2'-

(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-

2,6-dione;

8-butyl-3,7-dihydro-1-cyclopropylmethyl-3-propyl-7-[[2'-

(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine- 2,6-dione;

8-butyl-3,7-dihydro-1-cyclopropylmethyl-3- cyclopropylmethyl-7-[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-

4-yl]methyl]-1H-purine-2,6-dione;

8-butyl-3,7-dihydro-1-cyclopropylmethyl-3-phenyl-7-[[2'- (1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-

2,6-dione;

8-butyl-3,7-dihydro-1,3-dicyclopropylmethyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-butyl-3,7-dihydro-1-cyclopropylmethyl-3-phenylethyl-7- [[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione;

8-butyl-3,7-dihydro-1-cyclopropylmethyl-3-methoxyethyl-7- [[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione;

8-butyl-3,7-dihydro-1-cyclopropylmethyl-3- carbomethoxymethyl-7-[[2'-(1H-tetrazol-5-yl)(1,1'- biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-propyl-3,7-dihydro-1-cyclopropylmethyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione; 8-propyl-3,7-dihydro-1-cyclopropylmethyl-3-methyl-7-[[2'-

(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-

2,6-dione;

8-propyl-3,7-dihydro-1-cyclopropylmethyl-3-propyl-7-[[2'- (1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-

2,6-dione;

8-propyl-3,7-dihydro-1-cyclopropylmethyl-3- cyclopropylmethyl-7-[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)

4-yl]methyl]-1H-purine-2,6-dione;

8-propyl-3,7-dihydro-1-cyclopropylmethyl-3-phenyl-7-[[2'-

(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-

2,6-dione;

8-propyl-3,7-dihydro-1,3-dicyclopropylmethyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-propyl-3,7-dihydro-1-cyclopropylmethyl-3-phenylethyl-7-

[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione;

8-propyl-3,7-dihydro-1-cyclopropylmethyl-3-methoxyethyl-7- [[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione;

8-propyl-3,7-dihydro-1-cyclopropylmethyl-3- carbomethoxymethyl-7-[[2'-(1H-tetrazol-5-yl)(1,1'- biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-pentyl-3,7-dihydro-1-cyclopropylmethyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-pentyl-3,7-dihydro-1-cyclopropylmethyl-3-methyl-7-[[2'-

(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine- 2,6-dione;

8-pentyl-3,7-dihydro-1-cyclopropylmethyl-3-propyl-7-[[2'-

(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine- 2,6-dione;

8-pentyl-3,7-dihydro-1-cyclopropylmethyl-3- cyclopropylmethyl-7-[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-

4-yl]methyl]-1H-purine-2,6-dione; 8-pentyl-3,7-dihydro-1-cyclopropylmethyl-3-phenyl-7-[[2'-

(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-

2,6-dione;

8-pentyl-3,7-dihydro-1,3-dicyclopropylmethyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-pentyl-3,7-dihydro-1-cyclopropylmethyl-3-phenylethyl-7-

[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione;

8-pentyl-3,7-dihydro-1-cyclopropylmethyl-3-methoxyethyl-7-

[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione;

8-pentyl-3,7-dihydro-1-cyclopropylmethyl-3- carbomethoxymethyl-7-[[2'-(1H-tetrazol-5-yl)(1,1'- biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-ethyl-3,7-dihydro-1-cyclopropylmethyl-7-[[2'-(1H- tetrazol-5 yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-ethyl-3,7-dihydro-1-cyclopropylmethyl-3-methyl-7-[[2'- (1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-

2,6-dione;

8-ethyl-3,7-dihydro-1-cyclopropylmethyl-3-propyl-7-[[2'-

(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-

2,6-dione;

8-ethyl-3,7-dihydro-1-cyclopropylmethyl-3- cyclopropylmethyl-7-[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)- 4-yl]methyl]-1H-purine-2,6-dione;

8-ethyl-3,7-dihydro-1-cyclopropylmethyl-3-phenyl-7-[[2'-

(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine- 2,6-dione;

8-ethyl-3,7-dihydro-1,3-dicyclopropylmethyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-ethyl-3,7-dihydro-1-cyclopropylmethyl-3-phenylethyl-7- [[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione; 8-ethyl-3,7-dihydro-1-cyclopropylmethyl-3-methoxyethyl-7-

[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione;

8-ethyl-3,7-dihydro-1-cyclopropylmethyl-3- carbomethoxymethyl-7-[[2'-(1H-tetrazol-5-yl)(1,1'- biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-methyl-3,7-dihydro-1-cycloρropylmethyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-methyl-3, 7-dihydro-1-cyclopropylmethyl-3-methyl-7- [ [2 ' -

(1H-tetrazol-5-yl) (1, 1 ' -biphenyl) -4-yl]methyl] -1H-purine-

2, 6-dione;

8-methyl-3,7-dihydro-1-cyclopropylmethyl-3-propyl-7-[[2'-

(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine- 2,6-dione;

8-methyl-3,7-dihydro-1-cyclopropylmethyl-3- cyclopropylmethyl-7-[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-

4-yl]methyl]-1H-purine-2,6-dione;

8-methyl-3,7-dihydro-1-cyclopropylmethyl-3-phenyl-71[[2'- (1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-

2,6-dione;

8-methyl-3,7-dihydro-1,3-dicyclopropylmethyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-methyl-3,7-dihydro-1-cyclopropylmethyl-3-phenylethyl-7-

[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione;

8-methyl-3,7-dihydro-1-cyclopropylmethyl-3-methoxyethyl-7-

[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-methyl-3,7-dihydro-1-cyclopropylmethyl-3- carbomethoxymethyl-7-[[2'-(1H-tetrazol-5-yl)(1,1'- biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-cyclohexyl-3,7-dihydro-1-cyclopropylmethyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione; 8-cyclohexyl-3,7-dihydro-1-cyclopropylmethyl-3-methyl-7-

[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione;

8-cyclohexyl-3,7-dihydro-1-cyclopropylmethyl-3-propyl-7- [[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-cyclohexyl-3,7-dihydro-1-cyclopropylmethyl-3- cyclopropylmethyl-7-[[2'-(1H-tetrazol-5-yl)(1,1'-bichenyl)-

4-yl]methyl]-1H-purine-2,6-dione;

8-cyclohexyl-3,7-dihydro-1-cyclopropylmethyl-3-phenyl-7-

[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione;

8-cyclohexyl-3,7-dihydro-1,3-dicyclopropylmethyl-7-[[2'-

(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine- 2,6-dione;

8-cyclohexyl-3,7-dihydro-1-cyclopropylmethyl-3-phenylethyl-

7-[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione;

8-cyclohexyl-3,7-dihydro-1-cyclopropylmethyl-3- methoxyethyl-7-[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4- yl]methyl]-1H-purine-2,6-dione;

8-cyclohexyl-3,7-dihydro-1-cyclopropylmethyl-3- carbomethoxymethyl-7-[[2'-(1H-tetrazol-5-yl)(1,1'- biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-isopropyl-3,7-dihydro-1-cyclopropylmethyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-isopropyl-3,7-dihydro-1-cyclopropylmethyl-3-methyl-7-

[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione;

8-isopropyl-3,7-dihydro-1-cyclopropylmethyl-3-propyl-7-

[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione;

8-isopropyl-3,7-dihydro-1-cyclopropylmethyl-3- cyclopropylmethyl-7-[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-

4-yl]methyl] -1H-purine-2, 6-dione; 8-isopropyl-3,7-dihydro-1-cyclopropylmethyl-3-phenyl-7- [[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione;

8-isopropyl-3,7-dihydro-1,3-dicyclopropylmethyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-isopropyl-3,7-dihydro-1-cyclopropylmethyl-3-phenylethyl-

7-[[2'-(1H-tetrazol-5-yl)(1,1'-yiphenyl)-4-yl]methyl]-1H- purine-2,6-dione;

8-isopropyl-3,7-dihydro-1-cyclopropylmethyl-3-methoxyethyl-

7-[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione;

8-isopropyl-3,7-dihydro-1-cyclopropylmethyl-3- carbomethoxymethyl-7-[[2'-(1H-tetrazol-5-yl)(1,1'- biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-neopentyl-3,7-dihydro-1-cyclopropylmethyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-neopentyl-3,7-dihydro-1-cyclopropylmethyl-3-methyl-7- [[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione;

8-neopentyl-3,7-dihydro-1-cyclopropylmethyl-3-propyl-7-

[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione;

8-neopentyl-3,7-dihydro-1-cyclopropylmethyl-3- cyclopropylmethyl-7-[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-

4-yl]methyl]-1H-purine-2,6-dione;

8-neopentyl-3,7-dihydro-1-cyclopropylmethyl-3-phenyl-7-

[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione;

8-neopentyl-3,7-dihydro-1,3-dicyclopropylmethyl-7-[[2 ' -(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-neopentyl-3,7-dihydro-1-cyclopropylmethyl-3-phenylethyl- 7-[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione; 8-neopentyl-3,7-dihydro-1-cyclopropylmethyl-3-methoxyethyl-

7-[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione;

8-neopentyl-3,7-dihydro-1-cyclopropylmethyl-3- carbomethoxymethyl-7-[[2'-(1H-tetrazol-5-yl)(1,1'- biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-butyl-3,7-dihydro-1-phenylethyl-7-[[2'-(1H-tetrazol-5- yl)(1,1'-biphenyl)-4-yl]methyl]-1H-p-rine-2,6-dione;

8-butyl-3,7-dihydro-1-phenylethyl-3-methyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-butyl-3,7-dihydro-1-phenylethyl-3-propyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-butyl-3,7-dihydro-1-phenylethyl-3-phenylethyl-7-[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-butyl-3,7-dihydro-1-phenylethyl-3-phenyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-butyl-3,7-dihydro-1-phenylethyl-3-cyclopropylmethyl-7-

[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione;

8-butyl-3,7-dihydro-1-phenylethyl-3-phenylethyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-butyl-3,7-dihydro-1-phenylethyl-3-methoxyethyl-7-[[2'- (1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-

2,6-dione;

8-butyl-3,7-dihydro-1-phenylethyl-3-carbomethoxymethyl-7- [[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione;

8-propyl-3,7-dihydro-1-phenylethyl-7-[[2'-(1H-tetrazol-5- yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione; 8-propyl-3,7-dihydro-1-phenylethyl-3-methyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-propyl-3,7-dihydro-1-phenylethyl-3-propyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-propyl-3,7-dihydro-1-phenylethyl-3-phenylethyl-7-[[2'-

(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purin -

2,6-dione;

8-propyl-3,7-dihydro-1-phenylethyl-3-phenyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-propyl-3,7-dihydro-1-phenylethyl-3-cyclopropylmethyl-7-

[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione;

8-propyl-3,7-dihydro-1-phenylethyl-3-phenylethyl-7-[[2'-

(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-

2,6-dione;

8-propyl-3,7-dihydro-1-phenylethyl-3-methoxyethyl-7-[[2'- (1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-

2,6-dione;

8-propyl-3,7-dihydro-1-phenylethyl-3-carbomethoxymethyl-7-

[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione;

8-pentyl-3,7-dihydro-1-phenylethyl-7-[[2'-(1H-tetrazol-5- yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-pentyl-3,7-dihydro-1-phenylethyl-3-methyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-pentyl-3,7-dihydro-1-phenylethyl-3-propyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-pentyl-3,7-dihydro-1-phenylethyl-3-phenylethyl-7-[[2'-

(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine- 2,6-dione; 8-pentyl-3,7-dihydro-1-phenylethyl-3-phenyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-pentyl-3,7-dihydro-1-phenylethyl-3-cyclopropylmethyl-7- [[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione;

8-pentyl-3,7-dihydro-1-phenylethyl-3-phenylethyl-7-[[2'- (1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine- 2,6-dione;

8-pentyl-3,7-dihydro-1-phenylethyl-3-methoxyethy1-7-[[2'- (1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine- 2,6-dione;

8- entyl-3,7-dihydro-1-phenylethyl-3-carbomethoxymethyl-7- [[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione;

8-ethyl-3,7-dihydro-1-phenylethyl-7-[[2'-(1H-tetrazol-5- yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-ethyl-3,7-dihydro-1-phenylethyl-3-methyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-ethyl-3,7-dihydro-1-phenylethyl-3-propyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-ethyl-3,7-dihydro-1-phenylethyl-3-phenylethyl-7-[[2 '-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-ethyl-3,7-dihydro-1-phenylethyl-3-phenyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-ethyl-3,7-dihydro-1-phenylethyl-3-cyclopropylmethyl-7- [[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione;

8-ethyl-3,7-dihydro-1-phenylethyl-3-phenylethyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione; 8-ethyl-3,7-dihydro-1-phenylethyl-3-methoxyethyl-7-[[2'-

(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-

2,6-dione;

8-ethyl-3,7-dihydro-1-phenylethyl-3-carbomethoxymethyl-7- [[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione;

8-methyl-3,7-dihydro-1-phenylethyl-7-[[2'-(1H-tetrazol-5- yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-methyl-3,7-dihydro-1-phenylethyl-3-methyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-methyl-3,7-dihydro-1-phenylethyl-3-propyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-methyl-3,7-dihydro-1-phenylethyl-3-phenylethyl-7-[[2'-

(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-

2,6-dione;

8-methyl-3,7-dihydro-1-phenylethyl-3-phenyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-methyl-3,7-dihydro-1-phenylethyl-3-cyclopropylmethyl-7-

[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione;

8-methyl-3,7-dihydro-1-phenylethyl-3-phenylethyl-7-[[2'- (1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-

2,6-dione;

8-methyl-3,7-dihydro-1-phenylethyl-3-methoxyethyl-7-[[2'-

(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-

2,6-dione;

8-methyl-3,7-dihydro-1-phenylethyl-3-carbomethoxymethyl-7-

[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione;

8-cyclohexyl-3,7-dihydro-1-phenylethyl-7-[[2'-(1H-tetrazol-

5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione; 8-cyclohexyl-3,7-dihydro-1-phenylethyl-3-methyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-cyclohexyl-3,7-dihydro-1-phenylethyl-3-propyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-cyclohexyl-3,7-dihydro-1-phenylethyl-3-phenylethyl-7-

[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione;

8-cyclohexyl-3,7-dihydro-1-phenylethyl-3-phenyl-7-[[2'-(1H- tetrazol-n-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-cyclohexyl-3,7-dihydro-1-phenylethyl-3-cyclopropylmethyl-

7-[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione;

8-cyclohexyl-3,7-dihydro-1-phenylethyl-3-phenylethyl-7-

[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione;

8-cyclohexyl-3,7-dihydro-1-phenylethyl-3-methoxyethyl-7- [[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione;

8-cyclohexyl-3,7-dihydro-1-phenylethyl-3- carbomethoxymethyl-7-[[2'-(1H-tetrazol-5-yl)(1,1'- biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-isopropyl-3,7-dihydro-1-phenylethyl-7-[[2'-(1H-tetrazol-

5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-isopropyl-3,7-dihydro-1-phenylethyl-3-methyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-isopropyl-3,7-dihydro-1-phenylethyl-3-propyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-isopropyl-3,7-dihydro-1-phenylethyl-3-phenylethyl-7-[[2'- (1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine- 2,6-dione; 8-isopropyl-3,7-dihydro-1-phenylethyl-3-phenyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-isopropyl-3,7-dihydro-1-phenylethyl-3-cyclopropylmethyl- 7-[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione;

8-isopropyl-3,7-dihydro-1-phenylethyl-3-phenylethyl-7-[[2'- (1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-

2,6-dione;

8-isopropyl-3,7-dihydro-1-phenylethy--3-methoxyethyl-7-

[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione;

8-isopropyl-3,7-dihydro-1-phenylethyl-3-carbomethoxymethyl-

7-[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione;

8-neopentyl-3,7-dihydro-1-phenylethyl-7-[[2'-(1H-tetrazol-

5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-neopentyl-3,7-dihydro-1-phenylethyl-3-methyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-neopentyl-3,7-dihydro-1-phenylethyl-3-propyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-neopentyl-3,7-dihydro-1-phenylethyl-3-phenylethyl-7-[[2'- (1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-

2,6-dione;

8-neopentyl-3,7-dihydro-1-phenylethyl-3-phenyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-neopentyl-3,7-dihydro-1-phenylethyl-3-cyclopropylmethyl-

7-[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-neopentyl-3,7-dihydro-1-phenylethyl-3-phenylethyl-7-[[2'-

(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine- 2,6-dione; 8-neopentyl-3,7-dihydro-1-phenylethyl-3-methoxyethyl-7- [[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione;

8-neopentyl-3,7-dihydro-1-phenylethyl-3-carbomethoxymethyl- 7-[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione;

8-butyl-3,7-dihydro-1-methoxyethyl-7-[[2'-(1H-tetrazol-5- yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-butyl-3,7-dihydro-1-methoxyethyl-3-methyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-butyl-3,7-dihydro-1-methoxyethyl-3-propyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-butyl-3,7-dihydro-1,3-dimethoxyethyl-7-[[2'-(1H-tetrazol- 5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-butyl-3,7-dihydro-1-methoxyethyl-3-phenyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl] 1H-purine-2,6- dione;

8-butyl-3,7-dihydro-1-methoxyethyl-3-cyclopropylmethyl-7-

[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione;

8-butyl-3,7-dihydro-1-methoxyethyl-3-phenylethyl-7-[[2'-

(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine- 2,6-dione;

8-butyl-3,7-dihydro-1-methoxyethyl-3-methoxyethyl-7-[[2'-

(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-

2,6-dione;

8-butyl-3,7-dihydro-1-methoxyethyl-3-carbomethoxymethyl-7- [[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione;

8-propyl-3,7-dihydro-1-methoxyethyl-7-[[2'-(1H-tetrazol-5- yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-propyl-3,7-dihydro-1-methoxyethyl-3-methyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione; 8-propyl-3,7-dihydro-1-methoxyethyl-3-propyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-propyl-3,7-dihydro-1,3-dimethoxyethyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-propyl-3,7-dihydro-1-methoxyethyl-3-phenyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-propyl-3,7-dihydro-1-methoxyethyl-3-cyclopropylmethyl-7-

[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione;

8-propyl-3,7-dihydro-1-methoxyethyl-3-phenylethyl-7-[[2'-

(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine- 2,6-dione;

8-propyl-3,7-dihydro-1-methoxyethyl-3-methoxyethyl-7-[[2'- (1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-

2,6-dione;

8-propyl-3,7-dihydro-1-methoxyethyl-3-carbomethoxymethyl-7- [[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione;

8-pentyl-3,7-dihydro-1-methoxyethyl-7-[[2'-(1H-tetrazol-5- yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-pentyl-3,7-dihydro-1-methoxyethyl-3-methyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-pentyl-3,7-dihydro-1-methoxyethyl-3-propyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-pentyl-3,7-dihydro-1,3-dimethoxyethyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-pentyl-3,7-dihydro-1-methoxyethyl-3-phenyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione; 8-pentyl-3,7-dihydro-1-methoxyethyl-3-cyclopropylmethyl-7-

[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione;

8-pentyl-3,7-dihydro-1-methoxyethyl-3-phenylethyl-7-[[2'- (1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-

2,6-dione;

8-pentyl-3,7-dihydro-1-methoxyethyl-3-methoxyethyl-7-[[2'-

(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-

2,6-dione;

8-pentyl-3,7-dihydro-1-methoxyethyl-3-carbomethoxyaethyl-7-

[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-ethyl-3,7-dihydro-1-methoxyethyl-7-[[2'-(1H-tetrazol-5- yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-ethyl-3,7-dihydro-1-methoxyethyl-3-methyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-ethyl-3,7-dihydro-1-methoxyethyl-3-propyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-ethyl-3,7-dihydro-1,3-dimethoxyethyl-7-[[2'-(1H-tetrazol-

5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-ethyl-3,7-dihydro-1-methoxyethyl-3-phenyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-ethyl-3,7-dihydro-1-methoxyethyl-3-cyclopropylmethyl-7- [[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione;

8-ethyl-3,7-dihydro-1-methoxyethyl-3-phenylethyl-7-[[2'- (1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-

2,6-dione;

8-ethyl-3,7-dihydro-1-methoxyethyl-3-methoxyethyl-7-[[2'- (1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-

2,6-dione; 8-ethyl-3,7-dihydro-1-methoxyethyl-3-carbomethoxymethyl-7-

[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dιone;

8-methyl-3,7-dihydro-1-methoxyethyl-7-[[2'-(1H-tetrazol-5- yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-methyl-3,7-dihydro-1-methoxyethyl-3-methyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-methyl-3,7-dihydro-1-methoxyethyl-3-propyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-methyl-3,7-dihydro-1,3-dimethoxyethyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-methyl-3,7-dihydro-1-methoxyethyl-3-phenyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-methyl-3,7-dihydro-1-methoxyethyl-3-cyclopropylmethyl-7-

[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione;

8-methyl-3,7-dihydro-1-methoxyethyl-3-phenylethyl-7-[[2'-

(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-

2,6-dione;

8-methyl-3,7-dihydro-1-methoxyethyl-3-methoxyethyl-7-[[2'- (1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-

2,6-dione;

8-methyl-3,7-dihydro-1-methoxyethyl-3-carbomethoxymethyl-7-

[[2'- 1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione;

8-cyclohexyl-3,7-dihydro-1-methoxyethyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-cyclohexyl-3,7-dihydro-1-methoxyethyl-3-methyl-7-[[2'-

(1H-tet-azol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine- 2,6-dione; 8-cyclohexyl-3,7-dihydro-1-methoxyethyl-3-propyl-7-[[2'-

(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yi]methyl]-1H-purine- 2,6-dione;

8-cyclohexyl-3,7-dihydro-1,3-dimethoxyethyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-cyclohexyl-3,7-dihydro-1-methoxyethyl-3-phenyl-7-[[2'-

(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-

2,6-dione;

8-cyclohexyl-3,7-dihydro-1-methoxyethyl-3- cyclopropylmethyl-7-[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-

4-yl]methyl]-1H-purine-2,6-dione;

8-cyclohexyl-3,7-dihydro-1-methoxyethyl-3-phenylethyl-7-

[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione;

8-cyclohexyl-3,7-dihydro-1-methoxyethyl-3-methoxyethyl-7- [[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione;

8-cyclohexyl-3,7-dihydro-1-methoxyethyl-3- carbomethoxymethyl-7-[[2'-(1H-tetrazol-5-yl)(1,1'- biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-isopropyl-3,7-dihydro-1-methoxyethyl-7-[[2'-(1H-tetrazol-

5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-isopropyl-3,7-dihydro-1-methoxyethyl-3-methyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-isopropyl-3,7-dihydro-1-methoxyethyl-3-propyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-isopropyl-3,7-dihydro-1,3-dimethoxyethyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-isopropyl-3,7-dihydro-1-methoxyethyl-3-phenyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione; 8-isopropyl-3,7-dihydro-1-methoxyethyl-3-cyclopropylmethyl-

7-[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione;

8-isopropyl-3,7-dihydro-1-methoxyethyl-3-phenylethyl-7- [[2'-(1H-tetrazol-5-yl) (1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione;

8-isopropyl-3,7-dihydro-1-methoxyethyl-3-methoxyethyl-7- [[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione;

8-isopropyl-3,7-dihydro-1-meth1xyethyl-3- carbomethoxymethyl-7-[[2'-(1H-tetrazol-5-yl)(1,1'- biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-neopentyl-3,7-dihydro-1-methoxyethyl-7-[[2'-(1H-tetrazol-

5-yl)(1,1'-biphenyl)-4-yl]methyll-1H-purine-2,6-dione;

8-neopentyl-3,7-dihydro-1-methoxyethyl-3-methyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-neopentyl-3,7-dihydro-1-methoxyethyl-3-propyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-neopentyl-3,7-dihydro-1,3-dimethoxyethyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-neopentyl-3,7-dihydro-1-methoxyethyl-3-phenyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-neopentyl-3,7-dihydro-1-methoxyethyl-3-cyclopropylmethyl-

7-[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2, 6-dione;

8-neopentyl-3, 7-dihydro-1-methoxyethyl-3-phenylethyl-7-

[ [2 '- (1H-tetrazol-5-yl) (1, 1 '-biphenyl) -4-yl]methyl] -1H-purine-2, 6-dione;

8-neoρentyl-3, 7-dihydro-1-methoxyethyl-3-methoxyethyl-7-

[ [2 ' - (1H-tetrazol-5-yl) (1, 1 '-biphenyl) -4-yl]methyl] -1H- purine-2, 6-dione; 8-neopentyl-3,7-dihydro-1-methoxyethyl-3- carbomethoxymethyl-7-[ [2 ' - (1H-tetrazol-5-yl) (1, 1 '- biphenyl) -4-yl]methyl] -1H-purine-2,6-dione;

8-butyl-3,7-dihydro-1-carbomethoxymethyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-butyl-3,7-dihydro-1-carbomethoxymethyl-3-methyl-7-[[2'-

(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl -1H-purine-

2,6-dione;

8-butyl-3,7-dihydro-1-carbomethoxymethyl-3-propyl-7-[[2'-

(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-

2,6-dione;

8-butyl-3,7-dihydro-1-carbomethoxymethyl-3- carbomethoxymethyl-7-[[2'-(1H-tetrazol-5-yl)(1,1'- biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-butyl-3,7-dihydro-1-carbomethoxymethyl-3-phenyl-7-[[2'-

(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-

2,6-dione;

8-butyl-3,7-dihydro-1-carbomethoxymethyl-3- cyclopropylmethyl-7-[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-

4-yl]methyl]-1H-purine-2,6-dione;

8-butyl-3,7-dihydro-1-carbomethoxymethyl-3-phenylethyl-7-

[[2'-(1Hetetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione;

8-butyl-3,7-dihydro-1-carbomethoxymethyl-3-methoxyethyl-7-

[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione;

8-butyl-3,7-dihydro-1,3-dicarbomethoxymethyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-propyl-3,7-dihydro-1-carbomethoxymethyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-propyl-3,7-dihydro-1-carbomethoxymethyl-3-methyl-7-[[2'- (1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-

2,6-dione; 8-propyl-3,7-dihydro-1-carbomethoxymethyl-3-propyl-7-[[2'-

(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-

2,6-dione;

8-propyl-3,7-dihydro-1-carbomethoxymethyl-3- carbomethoxymethyl-7-[[2'-(1H-tetrazol-r-yl)(1,1'- biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-propyl-3,7-dihydro-1-carbomethoxymethyl-3-phenyl-7-[[2'-

(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-

2,6-dione;

8-propyl-3,7-dihydro-1-carbomethoxymethyl-3- cyclopropylmethyl-7-[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-

4-yl]methyl]-1H-purine-2,6-dione;

8-propyl-3,7-dihydro-1-carbomethoxymethyl-3-phenylethyl-7-

[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione;

8-propyl-3,7-dihydro-1-carbomethoxymethyl-3-methoxyethyl-7-

[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione;

8-propyl-3,7-dihydro-1,3-dicarbomethoxymethyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-pentyl-3,7-dihydro-1-carbomethoxymethyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-pentyl-3,7-dihydro-1-carbomethoxymethyl-3-methyl-7-[[2'-

(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-

2,6-dione;

8-pentyl-3,7-dihydro-1-carbomethoxymethyl-3-propyl-7-[[2'-

(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine- 2,6-dione;

8-pentyl-3,7-dihydro-1-carbomethoxymethyl-3- carbomethoxymethyl-7-[[2'-(1H-tetrazol-5-yl)(1,1'- biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-pentyl-3,7-dihydro-1-carbomethoxymethyl-3-phenyl-7-[[2'- (1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-

2,6-dione; 8-pentyl-3,7-dihydro-1-carbomethoxymethyl-3-cyclopropylmethyl-7-[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)- 4-yl]methyl]-1H-purine-2,6-dione;

8-pentyl-3,7-dihydro-1-carbomethoxymethyl-3-phenylethyl-7-[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-pentyl-3,7-dihydro-1-carbomethoxymethyl-3-methoxyethyl-7- [[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-pentyl-3,7-dihydro-1,3-dicarbomethoxymethyl-7-[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-ethyl-3,7-dihydro-1-carbomethoxymethyl-7-[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-ethyl-3,7-dihydro-1-carbomethoxymethyl-3-methyl-7-[[2'- (1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1Hepurine- 2,6-dione;

8-ethyl-3,7-dihydro-1-carbomethoxymethyl-3-propyl-7-[[2*- (1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine- 2,6-dione;

8-ethy1-3,7-dihydro-1-carbomethoxymethyl-3- carbomethoxymethyl-7-[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-ethyl-3,7-dihydro-1-carbomethoxymethyl-3-phenyl-7-[[2'- (1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine- 2,6-dione;

8-ethy1-3,7-dihydro-1-carbomethoxymethyl-3- cyclopropylmethyl-7-[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)- 4-yl]methyl]-1H-purine-2,6-dione;

8-ethyl-3,7-dihydro-1-carbomethoxymethyl-3-phenylethyl-7- [[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione;

8-ethyl-3,7-dihydro-1-carbomethoxymethyl-3-methoxyethyl-7- [[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione; 8-ethyl-3,7-dihydro-1,3-dicarbomethoxymethyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-methyl-3,7-dihydro-1-carbomethoxymethyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-methyl-3,7-dihydro-1-carbomethoxymethyl-3-methyl-7-[[2'-

(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-

2,6-dione;

8-methyl-3,7-dihydro-1-carbomethoxymethyl-3-propyl-7-[[2'-

(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-

2,6-dione;

8-methyl-3,7-dihydro-1-carbomethoxymethyl-3- carbomethoxymethyl-7-[[2'-(1H-tetrazol-5-yl)(1,1'- biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-methyl-3,7-dihydro-1-carbomethoxymethyl-3-phenyl-7-[[2'-

(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-

2,6-dione;

8-methyl-3,7-dihydro-1-carbomethoxymethyl-3- cyclopropylmethyl-7-[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-

4-yl]methyl]-1H-purine-2,6-dione;

8-methyl-3,7-dihydro-1-carbomethoxymethyl-3-phenylethyl-7-

[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione;

8-methyl-3,7-dihydro-1-carbomethoxymethyl-3-methoxyethyl-7-

[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione;

8-methyl-3,7-dihydro-1,3-dicarbomethoxymethyl-7-[[2'-(1H- tetraz1l-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-cyclohexyl-3,7-dihydro-1-carbomethoxymethyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-cyclohexyl-3,7-dihydro-1-carbomethoxymethyl-3-methyl-7- [[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione; 8-cyclohexyl-3,7-dihydro-1-carbomethoxymethyl-3-propyl-7-

[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione;

8-cyclohexyl-3,7-dihydro-1-carbomethoxymethyl-3- carbomethoxymethyl-7-[[2'-(1H-tetrazol-5-yl)(1,1'- biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-cyclohexyl-3,7-dihydro-1-carbomethoxymethyl-3-phenyl-7-

[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione;

8-cyclohexyl-3,7-dihydro-1-carbomethoxymethyl-3- cyclopropylmethyl-7-[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-

4-yl]methyl]-1H-purine-2,6-dione;

8-cyclohexyl-3,7-dihydro-1-carbomethoxymethyl-3- phenylethyl-7-[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4- yl]methyl]-1H-purine-2,6-dione;

8-cyclohexyl-3,7-dihydro-1-carbomethoxymethyl-3- methoxyethyl-7-[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4- yl]methyl]-1H-purine-2,6-dione;

8-cyclohexyl-3,7-dihydro-1,3-dicarbomethoxymethyl-7-[[2'- (1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-

2,6-dione;

8-isopropyl-3,7-dihydro-1-carbomethoxymethyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-isopropyl-3,7-dihydro-1-carbomethoxymethyl-3-methyl-7-

[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione;

8-isopropyl-3,7-dihydro-1-carbomethoxymethyl-3-propyl-7-

[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione;

8-isopropyl-3,7-dihydro-1-carbomethoxymethyl-3- carbomethoxymethyl-7-[[2'-(1H-tetrazol-5-yl)(1,1'- biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-isopropyl-3,7-dihydro-1-carbomethoxymethyl-3-phenyl-7- [[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione; 8-isopropyl-3,7-dihydro-1-carbomethoxymethyl-3- cyclopropylmethyl-7-[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-

4-yl]methyl]-1H-purine-2,6-dione;

8-isopropyl-3,7-dihydro-1-carbomethoxymethyl-3-phenylethyl- 7-[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione;

8-isopropyl-3,7-dihydro-1-carbomethoxymethyl-3-methoxyethyl-7-[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4- yl]methyl]-1H-purine-2,6-dione;

8-isopropyl-3,7-dihydro-1,3-dicarbomethoxymethyl-7-[[2'-

(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-

2,6-dione;

8-neopentyl-3,7-dihydro-1-carbomethoxymethyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-neopentyl-3,7-dihydro-1-carbomethoxymethyl-3-methyl-7-

[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione;

8-neopentyl-3,7-dihydro-1-carbomethoxymethyl-3-propyl-7- [[2'-(1H-tetrazol-5-yl) (1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione;

8-neopentyl-3,7-dihydro-1-carbomethoxymethyl-3- carbomethoxymethyl-7-[[2'-(1H-tetrazol-5-yl)(1,1'- biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-neopentyl-3,7-dihydro-1-carbomethoxymethyl-3-phenyl-7-

[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione;

8-neopentyl-3,7-dihy ro-1-carbomethoxymethyl-3- cyclopropylmethyl-7-[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)- 4-yl]methyl]-1H-purine-2,6-dione;

8-neopentyl-3,7-dihydro-1-carbomethoxymethyl-3-phenylethyl-

7-[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione;

8-neopentyl-3,7-dihydro-1-carbomethoxymethyl-3- methoxyethyl-7-[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4- yl]methyl]-1H-purine-2,6-dione; 8-neopentyl-3,7-dihydro-1,3-dicarbomethoxymethyl-7-[[2'- (1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine- 2,6-dione;

8-butyl-3,7-dihydro-1-ethyl-7-[[2'-(1H-tetrazol-5- yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-buty1-3,7-dihydro-1-propyl-7-[[2'-(1H-tetrazol-5- yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-buty1-3,7-dihydro-1-isobutyl-7-[[2'-(1H-tetrazol-5- yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-butyl-3,7-dihydro-1-phenyl-7-[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-butyl-3,7-dihydro-1-phenylethyl-7-[[2'-(1H-tetrazol-5- yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-propyl-3,7-dihydro-1-methyl-7-[[2'-(1H-tetrazol-5- yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-propyl-3,7-dihydro-1-ethyl-7-[[2'-(1H-tetrazol-5- yl) (1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-propyl-3,7-dihydro-1-propyl-7-[[2'-(1H-tetrazol-5- yl) (1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-propyl-3,7-dihydro-1-isobutyl-7-[[2'-(1H-tetrazol-5- yl) (1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-propyl-3,7-dirydro-1-phenyl-7-[[2'-(1H-tetrazol-5- yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-propyl-3,7-dihydro-1-cyclopropylmethyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-propyl-3,7-dihydro-1-phenylethyl-7-[[2'-(1H-tetrazol-5- yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-pentyl-3,7-dihydro-7-[[2'-(1H-tetrazol-5-yl)(1,1'- biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-pentyl-3,7-dihydro-1-methyl-7-[[2'-(1H-tetrazol-5- yl)(1,1'-biphenyl)-1-yl]methyl]-1H-purine-2,6-dione;

8-pentyl-3,7-dihydro-1-ethyl-7-[[2'-(1H-tetrazol-5- yl)(1,1'- biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-ethyl-3,7-dihydro-7-[[2'-(1H-tetrazol-5-yl)(1,1'- biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-ethyl-3,7-dihydro-1-ethyl-7-[[2'-(1H-tetrazol-5- yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-ethyl-3,7-dihydro-1-phenyl-7-[[2'-(1H-tetrazol-5- yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-ethyl-3,7-dihydro-1-cyclopropylmethyl-7-[[2'-(1H- tetrazol-5-yl) (1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-ethyl-3,7-dihydro-1-carbomethoxymethyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-methyl-3,7-dihydro-7-[[2'-(1H-tetrazol-5-yl)(1,1'- biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-methyl-3,7-dihydro-1-cyclopropylmethyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-methyl-3,7-dihydro-1-phenylethyl-7-[[2'-(1H-tetrazol-5- yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione; 8-methyl-3,7-dihydro-1-methoxyethyl-7-[[2'-(1H-tetrazol-5- yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-cyclohexyl-3,7-dihydro-1-phenyl-7-[[2'-(1H-tetrazol-5- yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-cyclohexyl-3,7-dihydro-1-cyclopropylmethyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-cyclohexyl-3,7-dihydro-1-phenylethyl-7-[[2'-(1H-tetrazol- 5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-isopropyl-3,7-dihydro-7-[[2'-(1H-tetrazol-5-yl)(1,1'- biphenyl) -4-yl]methyl] -1H-purine-2, 6-dione;

8-isopropyl-3, 7-dihydro-1-methyl-7- [ [2 ' - (1H-tetrazol-5- yl) (1, 1 '-biphenyl) -4-yl]methyl]-1H-purine-2, 6-dione;

8-isopropyl-3, 7-dihydro-1-ethyl-7- [ [2 '- (1H-tetrazol-5- yl) (1, 1 '-biphenyl) -4-yl]methyl]-1H-purine-2, 6-dione;

8-isopropyl-3, 7-dihydro-1-propyl-7- [ [2 ' - (1H-tetrazol-5- yl) (1, 1 '-biphenyl) -4-yl]methyl]-1H-purine-2, 6-dione; 8-isopropyl-3,7-dihydro-1-isobutyl-7-[[2'-(1H-tetrazol-5- yl) (1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-isopropyl-3,7-dihydro-1-phenyl-7-[[2'-(1H-tetrazol-5- yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2, one;

8-isopropyl-3,7-dihydro-1-phenylethyl-7-[[2'-(1H-tetrazol-

5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-isopropyl-3,7-dihydro-1-methoxyethyl-7-[[2'-(1H-tetrazol-

5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-neopentyl-3,7-dihydro-7-[[2'-(1H-tetrazol-5-yl)(1,1'- biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-neopentyl-3,7-dihydro-1-methyl-7-[[2'-(1H-tetrazol-5- yl)(1,1'-btphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-neopentyl-3,7-dihydro-1-ethyl-7-[[2'-(1H-tetrazol-5- yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-neopentyl-3,7-dihydro-1-propyl-7-[[2'-(1H-tetrazol-5- yl) (1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-neopentyl-3,7-dihydro-1-phenyl-7-[[2'-(1H-tetrazol-5- yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-neopentyl-3,7-dihydro-1-cyclopropylmethyl-7-[[2'-(1H- tetrazol-5-yl) (1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-neopentyl-3,7-dihydro-1-phenylethyl-7-[[2'-(1H-tetrazol- 5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-neopentyl-3,7-dihydro-1-methoxyethyl-7-[[2'-(1H-tetrazol- 5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-neopentyl-3,7-dihydro-1-carbomethoxymethyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione; 8-butyl-3,7-dihydro-3-methyl-7-[[2'-(1H-tetrazol-5- yl) (1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-butyl-3,7-dihydro-1-ethyl-3-methyl-7-[[2'-(1H-tetrazol-5- yl) (1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-butyl-3,7-dihydro-1-proρyl-3-methyl-7-[[2'-(1H-tetrazol-

5- yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-butyl-3,7-dihydro-1-isobutyl-3-methyl-7-[[2'-(1H- tetrazol-5-yl) (1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-butyl-3,7-dihydro-1-phenyl-3-methyl-7-[[2'-(1H-tetrazol-

5- yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-butyl-3,7-dihydro-1-cyclopropylmethyl-3-methyl-7-[[2'- (1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-

2,6-dione;

8-butyl-3,7-dihydro-1-carbomethoxymethyl-3-methyl-7-[[2'-

(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine- 2,6-dione;

8-propyl-3,7-dihydro-1-ethyl-3-methyl-7-[[2'-(1H-tetrazol- 5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-propyl-3,7-dihydro-1-propyl-3-methyl-7-[[2'-(1H-tetrazol-

5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-propyl-3,7-dihydro-1-isobutyl-3-methyl-7-[[2'-(1H- tetrazol-5-yl) (1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-propyl-3,7-dihydro-1-phenyl-3-methyl-7-[[2'-(1H-tetrazol-

5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione; 8-propyl-3,7-dihydro-1-cyclopropylmethyl-3-methyl-7-[[2'- (1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine- 2,6-dione;

8-propyl-3,7-dihydro-1-phenylethyl-3-methyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-propyl-3,7-dihydro-1-methoxyethyl-3-methyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-propyl-3,7-dihydro-1-carbomethoxymethyl-3-methyl-7-[[2'-

(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine- 2,6-dione;

8-pentyl-3,7-dihydro-3-methyl-7-[[2'-(1H-tetrazol-5- yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-pentyl-3,7-dihydro-1-ethyl-3-m-thyl-7-[[2'-(1H-tetrazol- 5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-pentyl-3,7-dihydro-1-propyl-3-methyl-7-[[2'-(1H-tetrazol- 5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-pentyl-3,7-dihydro-1-isobutyl-3-methyl-7-[ [2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-pentyl-3,7-dihydro-1-phenyl-3-methyl-7-[[2'-(1H-tetrazol-

5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-pentyl-3,7-dihydro-1-cyclopropylmethyl-3-methyl-7-[[2'- (1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-

2,6-dione;

8-pentyl-3, 7-dihydro-1-carbomethoxymethyl-3-methyl-7- [ [2 ' -

(1H-tetrazol-5-yl) (1, 1 ' -biphenyl) -4-yl]methyl] -1H-purine- 2, 6-dione; 8-ethyl-3,7-dihydro-3-methyl-7-[[2'-(1H-tetrazol-5- yl) (1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-ethyl-3,7-dihydro-1-ethyl-3-methyl-7-[[2'-(1H-tetrazol-5- yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-ethyl-3,7-dihydro-1-propyl-3-methyl-7-[[2'-(1H-tetrazol-

5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-ethyl-3,7-dihydro-1-isobutyl-3-methyl-7-[[2'-(1H- tetrazol-5-yl)51,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-ethyl-3,7-dihydro-1-phenyl-3-methyl-7-[[2' -(1H-tetrazol-

5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-ethyl-3,7-dihydro-1-cyclopropylmethyl-3-methyl-7-[[2'-

(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-

2,6-dione;

8-ethyl-3,7-dihydro-1-carbomethoxymethyl-3-methyl-7-[[2'-

(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-

2,6-dione;

8-methyl-3,7-dihydro-3-methyl-7-[[2'-(1H-tetrazol-5- yl)(1,1'-biphen yl]-1H-purine-2, 6-dione;

8-methyl-3,7-dihydro-1-ethyl-3-methyl-7-[[2'-(1H-tetrazol-

5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-methyl-3,7-dihydro-1-propyl-3-methyl-7-[[2'-(1H-tetrazol-

5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-methyl-3,7-dihydro-1-phenyl-3-methyl-7-[[2'-(1H-tetrazol-

5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dionn; 8-methyl-3,7-dihydro-1-cyclopropylmethyl-3-methyl-7-[[2'-

(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-

2,6-dione;

8-methyl-3,7-dihydro-1-carbomethoxymethyl-3-methyl-7-[[2'-

(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-

2,6-dione;

8-cyclohexyl-3,7-dihydro-1-ethyl-3-methyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-cyclohexyl-3, 7-dihydro-1-propyl-3-methyl-7- [ [2 '- (1H- tetrazol-5-yl) (1, 1 ' -biphenyl) -4-yl]methyl] -1H-purine-2, 6- dione;

8-cyclohexyl-3, 7-dihydro-1-isobutyl-3-methyl-7- [ [2 '- (1H- tetrazol-5-yl) (1, 1 '-biphenyl) -4-yl]methyl] -1H-purine-2, 6- dione;

8-cyclohexyl-3,7-dihydro-1-cyclopropylmethyl-3-methyl-7-

[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione;

8-cyclohexyl-3,7-dihydro-1-phenylethyl-3-methyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2, - dione;

8-cyclohexyl-3,7-dihydro-1-methoxyethyl-3-methyl-7-[[2'- (1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine- 2,6-dione; 8-cyclohexyl-3,7-dihydro-1-carbomethoxymethyl-3-methyl-7-

[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione;

8-isopropyl-3,7-dihydro-1-propyl-3-methyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-isopropyl-3,7-dihydro-1-isobutyl-3-methyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-isopropyl-3,7-dihydro-1-phenyl-3-methyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-isopropyl-3,7-dihydro-1-cyclopropylmethyl-3-methyl-7-

[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione;

8-isopropyl-3,7-dihydro-1-methoxyethyl-3-methyl-7-[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-isopropyl-3,7-dihydro-1-carbomethoxymethyl-3-methyl-7-

[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione;

8-neopentyl-3,7-dihydro-3-methyl-7-[[2'-(1H-tetrazol-5- yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-neopentyl-3,7-dihydro-1-ethyl-3-methyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione; 8-neopentyl-3, 7-dihydro-1-propyl-3-methyl-7- [ [2 ' - (1H- tetrazol-5-yl) (1, 1 '-biphenyl) -4-yl]methyl] -1H-purine-2, 6- dione;

8-neopentyl-3,7-dihydro-1-isobutyl-3-methyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-neopentyl-3,7-dihydro-1-cyclopropylmethyl-3-methyl-7-

[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione;

8-neopentyl-3,7-dihydro-1-phenylethyl-3-methyl-7-[[2'-(1H- tetrazol-5-yl)o1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-neopentyl-3,7-dihydro-1-carbomethoxymethyl-3-methyl-7- [[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione;

8-buty1-3,7-dihydro-1-methyl-3-ethyl-7-[[2'-(1H-tetrazol-5- yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-butyl-3,7-dihydro-1-propyl-3-ethyl-7-[[2'-(1H-tetrazol-5- yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-butyl-3,7-dihydro-1-isobutyl-3-ethyl-7-[[2'-(1H-tetrazol-

5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-butyl-3,7-dihydro-1-phenyl-3-ethyl-7-[[2'-(1H-tetrazol-5- yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-butyl-3,7-dihydro-1-cyclopropylmethyl-3-ethyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione; 8-butyl-3,7-dihydro-1-phenylethyl-3-ethyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-butyl-3,7-dihydro-1-methoxyethyl-3-ethyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-butyl-3,7-dihydro-1-carbomethoxymethyl-3-ethyl-7-[[2'-

(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-

2,6-dione;

8-propyl-3,7-dihydro-1-methyl-3-ethyl-7-[[2'-(1H-tetrazol-

5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-propyl-3,7-dihydro-1-propyl-3-ethyl-7-[[2'-(1H-tetrazol- 5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-propyl-3,7-dihydro-1-isobutyl-3-ethyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-propyl-3,7-dihydro-1-phenyl-3-ethyl-7-[[2'-(1H-tetrazol- 5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-propyl-3,7-dihydro-1-cyclopropylmethyl-3-ethyl-7-[[2'-

(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-

2,6-dione;

8-propyl-3,7-dihydro-1-phenylethyl-3-ethyl-7-[[2'-(1H- tetrazol-5-yl) (1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-propyl-3,7-dihydro-1-methoxyethyl-3-ethyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-propyl-3,7-dihydro-1-carbomethoxymethyl-3-ethyl-7-[[2'-

(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine- 2,6-dione;

8-pentyl-3,7-dihydro-3-ethyl-7-[[2'-(1H-tetrazol-5- yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-pentyl-3,7-dihydro-1-methyl-3-ethyl-7-[[2'-(1H-tetrazol-

5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione; 8-pentyl-3,7-dihydro-1-propyl-3-ethyl-7-[[2'-(1H-tetrazol- 5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-pentyl-3,7-dihydro-1-isobutyl-3-ethyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-pentyl-3,7-dihydro-1-phenyl-3-ethyl-7-[[2'-(1H-tetrazol- 5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-pentyl-3,7-dihydro-1-cyclopropylmethyl-3-ethyl-7-[[2'-

(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine- 2,6-dione;

8-pentyl-3,7-dihydro-1-phenylethyl-3-ethyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-pentyl-3,7-dihydro-1-methoxyethyl-3-ethyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-pentyl-3,7-dihydro-1-carbomethoxymethyl-3-ethyl-7-[[2'-

(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-

2,6-dione;

8-ethyl-3,7-dihydro-1-methyl-3-ethyl-7-[[2'-(1H-tetrazol-5- yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-ethyl-3,7-dihydro-1-propyl-3-ethyl-7-[[2'-(1H-tetrazol-5- yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-ethyl-3,7-dihydro-1-isobutyl-3-ethyl-7-[[2'-(1H-tetrazol-

5-yl) (1, 1 '-biphenyl) -4-yl]methyl] -1H-purine-2, 6-dione;

8-ethyl- , 7-dihydro-1-phenyl-3-ethyl-7- [ [2 ' - (1H-tetrazol-5- yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-ethyl-3,7-dihydro-1-cyclopropylmethyl-3-ethyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-ethyl-3,7-dihydro-1-phenylethyl-3-ethyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione; 8-ethyl-3,7-dihydro-1-methoxyethyl-3-ethyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-ethyl-3,7-dihydro-1-carbomethoxymethyl-3-ethyl-7-[[2'- (1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-

2,6-dione;

8-methyl-3,7-dihydro-3-ethyl-7-[[2'-(1H-tetrazol-5- yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-methyl-3, -dihydro-1-methyl-3-ethyl-7-[[2'-(1H-tetrazol- 5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-methyl-3,7-dihydro-1-propyl-3-ethyl-7-[[2'-(1H-tetrazol-

5-yl) (1, 1 '-biphenyl) -4-yl]methyl] -1H-purine-2, 6-dione;

8-methyl-3, 7-dihydro-1-isobutyl-3-ethyl-7- [ [2 '- (1H- tetrazol-5-yl) (1, 1 '-biphenyl) -4-yl]methyl] -1H-purine-2, 6- dione;

8-methyl-3, 7-dihydro-1-phenyl-3-ethyl-7- [ [2 '- (1H-tetrazol-

5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-methyl-3,7-dihydro-1-cyclopropylmethyl-3-ethyl-7-[[2'-

(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine- 2,6-dione;

8-methyl-3,7-dihydro-1-phenylethyl-3-ethyl-7-[[2'-(1H- tetrazol-5-yl) (1, 1 '-biphenyl) -4-yl]methyl] -1H-purine-2, 6- dione;

8-methyl-3,7-dihydro-1-methoxyethyl-3-ethyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-methyl-3,7-dihydro-1-carbomethoxymethyl-3-ethyl-7-[[2'-

(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-

2,6-dione;

8-cyclohexyl-3,7-dihydro-1-methyl-3-ethyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione; 8-cyclohexyl-3,7-dihydro-1-propyl-3-ethyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-cyclohexyl-3,7-dihydro-1-isobutyl-3-ethyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-cyclohexyl-3, 7-dihydro-1-phenyl-3-ethyl-7- [ [2 '- (1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-cyclohexyl-3,7-dihydro-1-cyclopropylmethyl-3-ethyl-7-

[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione;

8-cyclohexyl-3,7-dihydro-1-phenylethyl-3-ethyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-cyclohexyl-3,7-dihydro-1-methoxyethyl-3-ethyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-cyclohexyl-3,7-dihydro-1-carbomethoxymethyl-3-ethyl-7- [[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-isopropyl-3,7-dihydro-3-ethyl-7-[[2'-(1H-tetrazol-5- yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-isopropyl-3, 7-dihydro-1-methyl-3-ethyl-7- [ [2 '- (1H- tetrazol-5-yl) (1, 1 '-biphenyl) -4-yl]methyl] -1H-purine-2, 6- dione;

8-isopropyl-3, 7-dihydro-1-propyl-3-ethyl-7- [ [2 '- (1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-isopropyl-3,7-dihydro-1-isobutyl-3-ethyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-isopropyl-3,7-dihydro-1-phenyl-3-ethyl-7-[[2'-(1H- tetrazol-5-yl) (1, 1 '-biphenyl) -4-yl]methyl] -1H-purine-2, 6- dione; 8-isopropyl-3,7-dihydro-1-cyclopropylmethyl-3-ethyl-7-[[2'- (1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-

2,6-dione;

8-isopropyl-3,7-dihydro-1-phenylethyl-3-ethyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-isopropyl-3,7-dihydro-1-methoxyethyl-3-ethyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]mtthyl]-1H-purine-2,6- dione;

8-isopropyl-3,7-dihydro-1-carbomethoxymethyl-3-ethyl-7- [[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione;

8-neopentyl-3,7-dihydro-3-ethyl-7-[[2' (1H-tetrazol-5- yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-neopentyl-3,7-dihydro-1-methyl-3-ethyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-neopentyl-3,7-dihydro-1-propyl-3-ethyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-neopentyl-3,7-dihydro-1-isobutyl-3-ethyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-neopentyl-3,7-dihydro-1-phenyl-3-ethyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-neopentyl-3,7-dihydro-1-cyclopropylmethyl-3-ethyl-7-[[2'-

(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-

2,6-dione;

8-neopentyl-3,7-dihydro-1-phenylethyl-3-ethyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-neopentyl-3,7-dihydro-1-methoxyethyl-3-ethyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione; 8-neopentyl-3,7-dihydro-1-carbomethoxymethyl-3-ethyl-7-

[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione;

8-butyl-3,7-dihydro-3-propyl-7-[[2'-(1H-tetrazol-5- yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-butyl-3,7-dihydro-1-methyl-3-propyl-7-[[2'-(1H-tetrazol-

5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-butyl-3,7-dihydro-1-ethyl-3-propyl-7-[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-butyl-3,7-dihydro-1-phenyl-3-propyl-7-[[2'-(1H-tetrazol-

5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-butyl-3,7-dihydro-1-cyclopropylmethyl-3-propyl-7-[[2'-

(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-

2,6-dione;

8-butyl-3,7-dihydro-1-carbomethoxymethyl-3-propyl-7-[[2'- (1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine- 2,6-dione;

8-propyl-3,7-dihydro-1-methyl-3-propyl-7-[[2'-(1H-tetrazol- 5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-propyl-3,7-dihydro-1-ethyl-3-propyl-7-[[2'1H-tetrazol-

5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-propyl-3,7-dihydro-1-isobutyl-3-propyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione; 8-propyl-3,7-dihydro-1-phenyl-3-propyl-7-[[2'-(1H-tetrazol-

5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-propyl-3,7-dihydro-1-cyclopropylmethyl-3-propyl-7-[[2'-

(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine- 2,6-dione;

8-propyl-3,7-dihydro-1-phenylethyl-3-propyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyle-1H-purine-2,6- dione;

8-propyl-3,7-dihydro-1-methoxyethyl-3-propyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-propyl-3,7-dihydro-1-carbomethoxymethyl-3-propyl-7-[[2'-

(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-

2,6-dione;

8-pentyl-3,7-dihydro-3-propyl-7-[[2'-(1H-tetrazol-5- yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-pentyl-3,7-dihydro-1-methyl-3-propyl-7-[[2'-(1H-tetrazol-

5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-pentyl-3, 7-dihydro-1-ethyl-3-proρyl-7- [ [2 '- (1H-tetrazol- 5-yl) (1, 1 ' -biphenyl) -4-yl]methyl] -1H-purine-2, 6-dione;

8-pentyl-3, 7-dihydro-1-isobutyl-3-propyl-7- [ [2 '- (1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-pentyl-3,7-dihydro-1-phenyl-3-propyl-7-[[2'-(1H-tetrazol- 5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-pentyl-3,7-dihydro-1-cyclopropylmethyl-3-propyl-7-[[2'-

(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-

2,6-dione;

8-pentyl-3,7-dihydro-1-methoxyethyl-3-propyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione; 8-pentyl-3,7-dihydro-1-carbomethoxymethyl-3-propyl-7-[[2'-

(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-

2,6-dione;

8-ethyl-3, 7-dihydro-3-propyl-7- [ [2 ' - (1H-tetrazol-5- yl) (1, 1 '-biphenyl) -4-yl]methyl] -1H-purine-2, 6-dione;

8-ethyl-3, 7-dihydro-1-methyl-3-propyl-7- [ [2 '- (1H-tetrazol-

5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-ethyl-3,7-dihydro-1-ethyl-3-propyl-7-[[2'-(1H-tetrazol-5- yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-ethyl-3,7-dihydro-1-phenyl-3-propyl-7-[[2'-(1H-tetrazol-

5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione 8-ethyl-3,7-dihydro-1-cyclopropylmethyl-3-propyl-7-[[2'-

(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-

2,6-dione;

8-ethyl-3,7-dihydro-1-phenylethyl-3-proρyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-ethyl-3,7-dihydro-1-carbomethoxymethyl-3-propyl-7-[[2'- (1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-

2,6-dione;

8-methyl-3,7-dihydro-3-propyl-7-[[2'-(1H-tetrazol-5- yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-methyl-3,7-dihydro-1-methyl-3-propyl-7-[[2'-(1H-tetrazol- 5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-methyl-3,7-dihydro-1-ethyl-3-propyl-7-[[2'-(1H-tetrazol-

5-yl) (1, 1 '-biphenyl) -4-yl]methyl] -1H-purine-2, 6-dione;

8-methyl-3, 7-dihydro-1-isobutyl-3-propyl-7- [ [2 '- (1H- tetrazol-5-yl) (1, 1 '-biphenyl) -4-yl]methyl] -1H-purine-2, 6- dione; 8-methyl-3, 7-dihydro-1-phenyl-3-propyl-7- [ [2 ' - (1H-tetrazol-

5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-methyl-3,7-dihydro-1-cyclopropylmethyl-3-propyl-7-[[2'-

(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine- 2,6-dione;

8-methyl-3,7-dihydro-1-phenylethyl-3-propyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purne-2,6- dione;

8-methyl-3,7-dihydro-1-carbomethoxymethyl-3-propyl-7-[[2'-

(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-

2,6-dione;

8-cyclohexyl-3,7-dihydro-1-ethyl-3-propyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,-6- dione;

8-cyclohexyl-3,7-dihydro-1-isobutyl-3-propyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-cyclohexyl-3,7-dihydro-1-cyclopropylmethyl-3-propyl-7- [[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione;

8-cyclohexyl-3, 7-dihydro-1-phenylethyl-3-propyl-7- [ [2 '- (1H- tetrazol-5-yl) (1, 1 '-biphenyl) -4-yl]methyl] -1H-purine-2, 6- dione; 8-cyclohexyl-3,7-dihydro-1-methoxyethyl-3-propyl-7-[[2'- (1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine- 2,6-dione;

8-cyclohexyl-3,7-dihydro-1-carbomethoxymethyl-3-propyl-7- [[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione;

8-isopropyl-3,7-dihydro-3-propyl-7-[[2'-(1H-tetrazolr5- yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-isopropyl-3,7-dihydro-1-ethyl-3-propyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-isopropyl-3,7-dihydro-1-cyclopropylmethyl-3-propyl-7- [[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione;

8-isopropyl-3,7-dihydro-1-carbomethoxymethyl-3-propyl-7- [[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione;

8-neopentyl-3,7-dihydro-3-propyl-7-[[2'-(1H-tetrazol-5- yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione; 8-neopentyl-3,7-dihydro-1-methyl-3-propyl-7-[[2'-(1H- tetrazol-5-yl) (1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-neopentyl-3,7-dihydro-1-ethyl-3-propyl-7-[[2'-(1H- tetrazol-5-yl) (1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-neopentyl-3,7-dihydro-1-isobutyl-3-propyl-7-[[2'-(1H- tetrazol-5-yl) (1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-neopentyl-3,7-dihydro-1-phenyl-3-propyl-7-[[2'-(1H- tetrazol-5-yl) (1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-neopentyl-3,7-dihydro-1-cyclopropylmethyl-3-propyl-7-

[[2'-(1H-tetrazol-5-yl) (1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione;

8-neopentyl-3,7-dihydro-1-phenylethyl-3lpropyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-neopentyl-3,7-dihydro-1-methoxyethyl-3-propyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-neopentyl-3,7-dihydro-1-carbomethoxymethyl-3-propyl-7-

[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione;

8-butyl-3,7-dihydro-1-methyl-3-isobutyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-butyl-3,7-dihydro-1-ethyl-3-isobutyl-7-[[2'-(1H-tetrazol-

5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-butyl-3,7-dihydro-1-propyl-3-isobutyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-butyl-3,7-dihydro-1,3-isobutyl-7-[[2'-(1H-tetrazol-5- yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione; 8-butyl-3,7-dihydro-1-phenyl-3-isobutyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-butyl-3,7-dihydro-1-cyclopropylmethyl-3-isobutyl-7- (1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-

2,6-dione;

8-butyl-3,7-dihydro-1-phenylethyl-3-isobutyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-butyl-3,7-dihydro-1-methoxyethyl-3-isobutyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-butyl-3,7-dihydro-1-carbomethoxymethyl-3-isobutyl-7-[[2'-

(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine- 2,6-dione;

8-propyl-3,7-dihydro 3-isobutyl-7-[[2'-(1H-tetrazol-5- yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-propyl-3,7-dihydro-1-methyl-3-isobutyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-propyl-3,7-dihydro-1-ethyl-3-isobutyl-7-[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-propyl-3,7-dihydro-1-propyl-3-isobutyl-7-[[2'-(1H- tetrazol-5-yl) (1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-propyl-3,7-dihydro-1,3-isobutyl-7-[[2'-(1H-tetrazol-5- yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-propyl-3,7-dihydro-1-phenyl-3-isobutyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-propyl-3,7-dihydro-1-cyclopropylmethyl-3-isobutyl-7-[[2'- (1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-

2,6-dione; 8-propyl-3,7-dihydro-1-phenylethyl-3-isobutyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-propyl-3,7-dihydro-1-methoxyethyl-3-isobutyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-propyl-3,7-dihydro-1-carbomethoxymethyl-3-isobutyl-7- [[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl -4-yl]methyl]-1H- purine-2,6-dione;

8-pentyl-3,7-dihydro-3-isobutyl-7-[[2'-(1H-tetrazol-5- yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-pentyl-3,7-dihydro-1-ethyl-3-isobutyl-7-[[2'-(1H- tetrazol-5-yl) (1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-pentyl-3,7-dihydro-1-propyl-3-isobutyl-7-[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-pentyl-3,7-dihydro-1,3-isobutyl-7-[[2'-(1H-tetrazol-5- yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-pentyl-3,7-dihydro-1-phenyl-3-isobutyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-pentyl-3,7-dihydro-1-cyclopropylmethyl-3-isobutyl-7-[[2'-

(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-

2,6-dione;

8-pentyl-3,7-dihydro-1-phenylethyl-3-isobutyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-pentyl-3,7-dihydro-1-methoxyethyl-3-isobutyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione; 8-pentyl-3,7-dihydro-1-carbomethoxymethyl-3-isobutyl-7-

[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione;

8-ethyl-3,7-dihydro-3-isobutyl-7-[[2'-(1H-tetrazol-5- yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-ethyl-3,7-dihydro-1-methyl-3-isobutyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl methyl]-1H-purine-2,6- dione;

8-ethyl-3,7-dihydro-1-ethyl-3-isobutyl-7-[[2'-(1H-tetrazol- 5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-ethyl-3,7-dihydro-1,3-isobutyl-7-[[2'-(1H-tetrazol-5- yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-ethyl-3,7-dihydro-1-phenyl-3-isobutyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-ethyl-3,7-dihydro-1-cyclopropylmethyl-3-isobutyl-7-[[2'- (1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-

2,6-dione;

8-ethyl-3,7-dihydro-1-phenylethyl-3-isobutyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-ethyl-3,7-dihydro-1-methoxyethyl-3-isobutyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-ethyl-3,7-dihydro-1-carbomethoxymethyl-3-isobutyl-7-[[2'- (1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine- 2,6-dione;

8-methyl-3,7-dihydro-3-isobutyl-7-[[2'-(1H-tetrazol-5- yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-methyl-3,7-dihydro-1-methyl-3-isobutyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione; 8-methyl-3, 7-dihydro-1-ethyl-3-isobutyl-7- [ [2 ' - (1H- tetrazol-5-yl) (1, 1 '-biphenyl) -4-yl]methyl] -1H-purine-2, 6- dione;

8-methyl-3,7-dihydro-1,3-isobutyl-7-[[2'-(1H-tetrazol-5- yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-methyl-3,7-dihydro-1-phenyl-3-isobutyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-methyl-3,7-dihydro-1-cyclopropylmethyl-3-isobutyl-7-[[2'-

(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-

2,6-dione;

8-methyl-3,7-dihydro-1-phenylethyl-3-isobutyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-methyl-3,7-dihydro-1-methoxyethyl-3-isobutyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-methyl-3,7-dihydro-1-carbomethoxymethyl-3-isobutyl-7-

[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione;

8-cyclohexyl-3,7-dihydro-1-methyl-3-isobutyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-cyclohexyl-3,7-dihydro-1,3-isobutyl-7-[[2'-(1H-tetrazol-

5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione; 8-cyclohexyl-3,7-dihydro-1-phenyl-3-isobutyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-cyclohexyl-3,7-dihydro-1-cyclopropylmethyl-3-isobutyl-7- [[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione;

8-cyclohexyl-3,7-dihydro-1-phenylethyl-3-isobutyl-7-[[2'-

(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-

2,6-dione;

8-cyclohexyl-3,7-dihydro-1-methoxyethyl-3-isobutyl-7-[[2'-

(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-

2,6-dione;

8-yyclohexyl-3,7-dihydro-1-carbomethoxymethyl-3-isobutyl-7-

[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione;

8-isopropyl-3,7-dihydro-3-isobutyl-7-[[2'-(1H-tetrazol-5- yl) (1, 1 '-biphenyl) -4-yl]methyl] -1H-purine-2, 6-dione;

8-isopropyl-3, 7-dihydro-1-methyl-3-isobutyl-7- [ [2'- (1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-isoproρyl-3,7-dihydro-1-ethyl-3-isobutyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-isopropyl-3,7-dihydro-1-propyl-3-isobutyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-isopropyl-3,7-dihydro-1,3-isobutyl-7-[[2'-(1H-tetrazol-5- yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-isopropyl-3,7-dihydro-1-phenyl-3-isobutyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-isopropyl-3,7-dihydro-1-cyclopropylmethyl-3-isobutyl-7-

[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione; 8-isopropyl-3,7-dihydro-1-phenylethyl-3-isobutyl-7-[[2'- (1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-

2,6-dione;

8-isopropyl-3,7-dihydro-1-methoxyethyl-3-isobutyl-7-[[2'- (1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-

2,6-dione;

8-isopropyl-3,7-dihydro-1-carbomethoxymethyl-3-isobutyl-7- [[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione;

8-neopentyl-3,7-dihydro-3-isobutyl-7-[[2'-(1H-tetrazol-5- yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-neopentyl-3,7-dihydro-1-methyl-3-isobutyl-7-[[2'-(1H- tetrazol-5-yl) (1,1'-biphenyl)-4-el]methyl]-1H-purine-2,6- dione;

8-neopentyl-3,7-dihydro-1-ethyl-3-isobutyl-7-[[2'-(1H- tetrazol-5-yl) (1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-neopentyl-3,7-dihydro-1-propyl-3-isobutyl-7-[[2'-(1H- tetrazol-5-yl) (1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-neopentyl-3,7-dihydro-1,3-isobutyl-7-[[2'-(1H-tetrazol-5- yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-neopentyl-3,7-dihydro-1-phenyl-3-isobutyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-neopentyl-3,7-dihydro-1-cyclopropylmethyl-3-isobutyl-7-

[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione;

8-neopentyl-3,7-dihydro-1-phenylethyl-3-isobutyl-7-[[2'- (1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-

2,6-dione;

8-neopentyl-3,7-dihydro-1-methoxyethyl-3-isobutyl-7-[[2'-

(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-

2,6-dione; 8-neopentyl-3,7-dihydro-1-carbomethoxymethyl-3-isobutyl-7- [[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione;

8-butyl-3,7-dihydro-3-phenyl-7-[[2'-(1H-tetrazol-5- yl) (1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-butyl-3,7-dihydro-1-methyl-3-phenyl-7-[[2'-(1H-tetrazol-

5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-butyl-3,7-dihydro-1-ethyl-3-phenyl-7-[[2'-(1H-tetrazol-5-yl) (1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-butyl-3,7-dihydro-1-isobutyl-3-phenyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-butyl-3,7-dihydro-1,3-phenyl-7-[[2'-(1H-tetrazol-5- yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

2,6-dione;

8-butyl-3,7-dihydro-1-methoxyethyl-3-phenyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-butyl-3,7-dihydro-1-carbomethoxymethyl-3-phenyl-7-[[2'- (1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine- 2,6-dione;

8-propyl-3,7-dihydro-3-phenyl-7-[[2'-(1H-tetrazol-5- yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-propyl-3,7-dihydro-1-methyl-3-phenyl-7-[[2'-(1H-tetrazol- 5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-propyl-3,7-dihydro-1-ethyl-3-phenyl-7-[[2'-(1H-tetrazol- 5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-propyl-3,7-dihydro-1-propyl-3-phenyl-7-[[2'-(1H-tetrazol- 5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione; 8-propyl-3, 7-dihydro-1-isobutyl-3-phenyl-7- [ [2 ' - (1H- tetrazol-5-yl) (1, 1 ' -biphenyl) -4-yl]methyl] -1H-purine-2, 6- dione;

8-propyl-3, 7-dihydro-1, 3-phenyl-7- [ [2 ' - (1H-tetrazol-5- yl) (1, 1 '-biphenyl) -4-yl]methyl] -1H-purine-2, 6-dione;

8-propyl-3,7-dihydro-1-cyclopropylmethyl-3-phenyl-7-[[2'-

(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-

2,6-dione;

8-propyl-3,7-dihydro-1-carbomethoxymethyl-3-phenyl-7-[[2'-

(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]mthyl]-1H-purine-

2,6-dione;

8-pentyl-3,7-dihydro-1-methyl-3-phenyl-7-[[2'-(1H-tetrazol-

5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-pentyl-3,7-dihydro-1-ethyl-3-phenyl-7-[[2'-(1H-tetrazol-

5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-pentyl-3,7-dihydro-1-isobutyl-3-phenyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-pentyl-3,7-dihydro-1,3-phenyl-7-[[2'-(1H-tetrazol-5- yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-pentyl-3,7-dihydro-1-cyclopropylmethyl-3-phenyl-7-[[2'-

(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-

2,6-dione;

8-pentyl-3,7-dihydro-1-phenylethyl-3-phenyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione; 8-pentyl-3,7-dihydro-1-methoxyethyl-3-phenyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

2,6-dione;

8-ethyl-3,7-dihydro-3-phenyl-7-[[2'-(1H-tetrazol-5- yl) (1, 1 '-biphenyl) -4-yl]methyl]-1H-purine-2, 6-dione;

8-ethyl-3, 7-dihydr3-1-methyl-3-phenyl-7- [ [2 '- (1H-tetrazol- 5-yl) (1, 1 ' -biphenyl) -4-yl]methyl] -1H-purine-2, 6-dione;

8-ethyl-3, 7-dihydro-1-ethyl-3-phenyl-7- [ [2 '- (1H-tetrazol-5- yl) (1, 1 '-biphenyl) -4-yl]methyl] -1H-purine-2, 6-dione;

8-ethy1l3,7-dihydro-1-propyl-3-phenyl-7-[[2'-(1H-tetrazol-

5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-ethyl-3,7-dihydro-1-isobutyl-3-phenyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-ethyl-3,7-dihydro-1,3-phenyl-7-[[2'-(1H-tetrazol-5- yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-ethyl-3,7-dihydro-1-cyclopropylmethyl-3-phenyl-7-[[2'-

(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-

2,6-dione;

8-ethyl-3,7-dihydro-1-carbomethoxymethyl-3-phenyl-7-[[2'- (1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-

2,6-dione;

8-methyl-3,7-dihydro-3-phenyl-7-[[2'-(1H-tetrazol-5- yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-methyl-3,7-dihydro-1-methyl-3-phenyl-7-[[2'-(1H-tetrazol- 5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6 dione; 8-methyl-3,7-dihydro-1-ethyl-3-phenyl-7-[[2'-(1H-tetrazol-

5-yl) (1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-methyl-3,7-dihydro-1-propyl-3-phenyl-7-[[2'-(1H-tetrazol-

5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-methyl-3,7-dihydro-1-isobutyl-3-phenyl-7-[[2'-(1H- tetrazol-5-yl) (1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-methyl-3,7-dihydro-1,3-phenyl-7-[[2'-(1H-tetrazol-5- yl) (1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-methyl-3,7-dihydro-1-cyclopropylmethyl-3-phenyl-7-[[2'- (1H-tetrazol-5-yl) (1,1'-biphenyl)-4-yl]methyl]-1H-purine-

2,6- ione;

8-methyl-3,7-dihydro-1-carbomethoxymethyl-3-phenyl-7-[[2'- (1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-

2,6-dione;

8-cyclohexyl-3,7-dihydro-1-methyl-3-phenyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-cyclohexyl-3,7-dihydro-1-ethyl-3-phenyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-cyclohexyl-3,7-dihydro-1,3-phenyl-7-[[2'-(1H-tetrazol-5- yl) (1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-cyclohexyl-3,7-dihydro-1-cyclopropylmethyl-3-phenyl-7-

[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione;

8-cyclohexyl-3,7-dihydro-1-phenylethyl-3-phenyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-cyclohexyl-3,7-dihydro-1-methoxyethyl-3-phenyl-7-[[2'-

(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine- 2,6-dione;

8-cyclohexyl-3,7-dihydro-1-carbomethoxymethyl-3-phenyl-7-

[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione;

8-isopropyl-3,7-dihydro-1-ethyl-3-phenyl-7-[[2'-(1H- tetrazol-5-yl) (1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-isopropyl-3,7-dihydro-1-propyl-3-phenyl-7-[[2'-(1H- tetrazol-5-yl) (1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-isoproρyl-3,7-dihydro-1,3-phenyl-7-[[2'-(1H-tetrazol-5- yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-isopropyl-3,7-dihydro-1-cyclopropylmethyl-3-phenyl-7-

[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione;

8-isopropyl-3,7-dihydro-1-phenylethyl-3-phenyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione; 8-isopropyl-3,7-dihydro-1-methoxyethyl-3-phenyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-isopropyl-3,7-dihydro-1-carbomethoxymethyl-3-phenyl-7- [[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione;

8-neop ntyl-3,7-dihydro-3-phenyl-7-[[2'-(1H-tetrazol-5- yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-neopentyl-3,7-dihydro-1-methyl-3-phenyl-7-[[2'-(1H- tetrazol-5-yl) (1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-neopentyl-3,7-dihydro-1-isobutyl-3-phenyl-7-[[2'-(1H- tetrazol-5-yl) (1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-neopentyl-3,7-dihydro-1,3-phenyl-7-[[2'-(1H-tetrazol-5- yl) (1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-neopentyl-3,7-dihydro-1-cyclopropylmethyl-3-phenyl-7-

[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione;

8-neopentyl-3,7-dihydro-1-carbomethoxymethyl-3-phenyl-7-

[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione; 8-butyl-3,7-dihydro-3-cyclopropylmethyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-butyl-3,7-dihydro-1-methyl-3-cyclopropylmethyl-7-[[2'- (1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine- 2,6-dione;

8-butyl-3,7-dihydro-1-ethyl-3-cyclopropylmethyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-buphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-butyl-3,7-dihydro-1-propyl-3-cyclopropylmethyl-7-[[2'-

(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-

2,6-dione;

8-butyl-3,7-dihydro-1-isobutyl-3-cyclopropylmethyl-7-[[2'-

(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine- 2,6-dione;

8-butyl-3,7-dihydro-1-phenyl-3-cyclopropylmethyl-7-[[2'-

(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine- 2,6-dione;

8-butyl-3,7-dihydro-1-phenylethyl-3-cyclopropylmethyl-7- [[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione;

8-butyl-3,7-dihydro-1-methoxyethyl-3-cyclopropylmethyl-7-

[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione;

4-yl]methyl]-1H-purine-2,6-dione;

8-propyl-3,7-dihydro-3-cyclopropylmethyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-propyl-3,7-dihydro-1-methyl-3-cyclopropylmethyl-7-[[2'-

(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-

2,6-dione;

2,6-dione; 8-propyl-3,7-dihydro-1-propyl-3-cyclopropylmethyl-7-[[2'-

(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-

2,6-dione;

8-propyl-3,7-dihndro-1-isobutyl-3-cyclopropylmethyl-7-[[2'- (1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-

2,6-dione;

8-propyl-3,7-dihydro-1-phenyl-3-cyclopropylmethyl-7-[[2'-

(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-

2,6-dione;

8-propyl-3,7-dihydro-1-phenylethyl-3-cyclopropylmethyl-7-

[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione;

8-propyl-3,7-dihydro-1-methoxyethyl-3-cyclopropylmethyl-7-

[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione;

4-yl]methyl]-1H-purine-2,6-dione;

8-pentyl-3,7-dihydro-3-cyclopropylmethyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-pentyl-3,7-dihydro-1-methyl-3-cyclopropylmethyl-7-[[2'-

(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-

2,6-dione;

8-pentyl-3,7-dihydro-1-ethyl-3-cyclopropylmethyl-7-[[2'-

(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-

2,6-dione;

8-pentyl-3,7-dihydro-1-propyl-3-cyclopropylmethyl-7-[[2'-

(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine- 2,6-dione;

8-pentyl-3,7-dihydro-1-isobutyl-3-cyclopropylmethyl-7-[[2'-

(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine- 2,6-dione;

8-pentyl-3,7-dihydro-1-phenyl-3-cyclopropylmethyl-7-[[2'- (1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine- 2,6-dione; 8-pentyl-3,7-dihydro-1-phenylethyl-3-cyclopropylmethyl-7-

[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione;

8-pentyl-3,7-dihydro-1-methoxyethyl-3-cyclopropylmethyl-7- [[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]-ethyl]-1H- purine-2,6-dione;

8-pentyl-3,7-dihydro-1-carbomethoxymethyl-3- cyclopropylmethyl-7-[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-

4-yl]methyl]-1H-purine-2,6-dione;

8-ethyl-3,7-dihydro-3-cyclopropylmethyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-ethyl-3,7-dihydro-1-methyl-3-cyclopropylmethyl-7-[[2'-

(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine- 2,6-dione;

8-ethyl-3,7-dihydro-1-propyl-3-cyclopropylmethyl-7-[[2'- (1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-

2,6-dione;

8-ethyl-3,7-dihydro-1-isobutyl-3-cyclopropylmethyl-7-[[2'-

(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-

2,6-dione;

8-ethyl-3,7-dihydro-1-phenyl-3-cyclopropylmethyl-7-[[2'-

(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-

2,6-dione;

8-ethyl-3,7-dihydro-1-phenylethyl-3-cyclopropylmethyl-7-

[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione;

8-ethyl-3,7-dihydro-1-carbomethoxymethyl-3- cyclopropylmethyl-7-[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-

4-yl]methyl]-1H-purine-2,6-dione; 8-methyl-3,7-dihydro-3-cyclopropylmethyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-methyl-3,7-dihydro-1-methyl-3-cyclopropylmethyl-7-[[2'- (1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-

2,6-dione;

8-methyl-3 7-dihydro-1-ethyl-3-cyclopropylmethyl-7-[[2'-

(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-

2,6-dione;

8-methyl-3,7-dihydro-1-propyl-3-cyclopropylmethyl-7-[[2'-

(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-

2,6-dione;

8-methyl-3,7-dihydro-1-isobutyl-3-cyclopropylmethyl-7-[[2'-

(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine- 2,6-dione;

8-methyl-3,7-dihydro-1-phenyl-3-cyclopropylmethyl-7-[[2'-

(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine- 2,6-dione;

8-methyl-3,7-dihydro-1-phenylethyl-3-cyclopropylmethyl-7- [[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione;

8-methyl-3,7-dihydro-1-methoxyethyl-3-cyclopropylmethyl-7-

[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione;

8-methyl-3,7-dihydro-1-carbomethoxymethyl-3- cyclopropylmethyl-7-[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)- 4-yl]methyl]-1H-purine-2,6-dione;

8-cyclohexyl-3,7-dihydro-1-ethyl-3-cyclopropylmethyl-7- [[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione; 8-cyclohexyl-3,7-dihydro-1-propyl-3-cyclopropylmethyl-7-

[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione;

8-cyclohexyl-3,7-dihydro-1-isobutyl-3-cyclopropylmethyl-7- [[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]mtthyl]-1H- purine-2,6-dione;

8-cyclohexyl-3,7-dihydro-1-phenyl-3-cyclopropylmethyl-7-

[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione;

8-cyclohexyl-3,7-dihydro-1-phenylethyl-3-cyclopropylmethyl-

7-[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione;

8-cyclohexyl-3,7-dihydro-1-methoxyethyl-3- cyclopropylmethyl-7-[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)- 4-yl]methyl]-1H-purine-2,6-dione;

4-yl]methyl]-1H-purine-2,6-dione;

8-isopropyl-3,7-dihydro-1-methyl-3-cyclopropylmethyl-7-

[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione;

8-isopropyl-5-7-dihydro-1-ethyl-3-cyclopropylmethyl-7-[[2'- (1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-

2,6-dione;

8-isopropyl-3,7-dihydro-1-propyl-3-cyclopropylmethyl-7- [[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione;

8-isopropyl-3,7-dihydro-1-isobutyl-3-cyclopropylmethyl-7- [[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione;

8-isopropyl-3,7-dihydro-1-phenyl-3-cyclopropylmethyl-7- [[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione; 8-isopropyl-3,7-dihydro-1-phenylethyl-3-cyclopropylmethyl-

7-[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione;

8-isopropyl-3,7-dihydro-1-methoxyethyl-3-cyclopropylmethyl- 7-[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione;

8-isopropyl-3,7-dihydro-1-carbomethoxymethyl-3- cyclopropylmethyl-7-[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-

4-yl]methyl]-1H-purine-2,6-dione;

8-neopentyl-3,7-dihydro-3-cyclopropylmethyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- diote;

8-neopentyl-3,7-dihydro-1-methyl-3-cyclopropylmethyl-7-

[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione;

8-neopentyl-3,7-dihydro-1-ethyl-3-cyclopropylmethyl-7-[[2'-

(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-

2,6-dione;

8-neopentyl-3,7-dihydro-1-propyl-3-cyclopropylmethyl-7- [[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione;

8-neopentyl-3,7-dihydro-1-isobutyl-3-cyclopropylmethyl-7- [[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione;

8-neopentyl-3,7-dihydro-1-phenyl-3-cyclopropylmethyl-7-

[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione;

8-neopentyl-3,7-dihydro-1-phenylethyl-3-cyclopropylmethyl-

7-[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione;

8-neopentyl-3,7-dihydro-1-methoxyethyl-3-cyclopropylmethyl- 7-[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione;

8-neopentyl-3,7-dihydro-1-carbomethoxymethyl-3- cyclopropylmethyl-7-[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-

4-yl]methyl]-1H-purine-2,6-dione; 8-butyl-3,7-dihydro-3-phenylethyl-7-[[2'-(1H-tetrazol-5- yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-butyl-3,7-dihydro-1-phenyl-3-phenylethyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]meth l]-1H-purine-2,6- dione;

8-butyl-3,7-dihydro-1-cyclopropylmethyl-3-phenylethyl-7-

[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione;

8-butyl-3,7-dihydro-1-methoxyethyl-3-phenylethyl-7-[[2'-

(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-

2,6-dione;

8-butyl-3,7-dihydro-1-carbomethoxymethyl-3-phenylethyl-7- [[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione;

8-propyl-3,7-dihydro-3-phenylethyl-7-[[2'-(1H-tetrazol-5- yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-propyl-3,7-dihydro-1-ethyl-3-phenylethyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione; 8-propyl-3,7-dihydro-1-propyl-3-phenylethyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-propyl-3,7-dihydro-1-phenyl-3-phenylethyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-propyl-3,7-dihydro-1-cyclopropylmethyl-3-phenylethyl-7-

[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-l-yl]methyl]-1H- purine-2,6-dione;

8-propyl-3,7-dihydro-1-methoxyethyl-3-phenylethyl-7-[[2'-

(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine- 2,6-dione;

8-propyl-3,7-dihydro-1-carbomethoxymethyl-3-phenylethyl-7-

[[2'-(1H-tetrazol-5-y1)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione;

8-pentyl-3,7-dihydro-1-methyl-3-phenylethyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-pentyl-3,7-dihydro-1-ethyl-3-phenylethyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-pentyl-3,7-dihydro-1-propyl-3-ρhenylethyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-pentyl-3,7-dihydro-1-phenyl-3-phenylethyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione; 8-pentyl-3,7-dihydro-1-cyclopropylmethyl-3-phenylethyl-7-

[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione;

2,6-dione;

8-pentyl-3,7-dihydro-1-carbomethoxymethyl-3-phenylethyl-7-

[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione;

8-ethyl-3,7-dihydro-3-phenylethyl-7-[[2'-(1H-tetrazol-5- yl)(1,1'-biphenyl)-4-yl]m-thyl]-1H-purine-2,6-dione;

8-ethyl-3,7-dihydro-1-propyl-3-phenylethyl-7-[[2'-(1H- tetrazol-5-yl) (1, 1 '-biphenyl) -4-yl]methyl] -1H-purine-2, 6- dione;

8-ethyl-3,7-dihydro-1-isobutyl-3-phenylethyl-7-[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-ethyl-3,7-dihydro-1-cyclopropylmethyl-3-phenylethyl-7-

[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione;

8-ethyl-3,7-dihydro-1-methoxyethyl-3-phenylethyl-7- (1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-

2,6-dione;

8-ethyl-3,7-dihydro-1-carbomethoxymethyl-3-phenylethyl-7- [[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione; 8-methyl-3,7-dihydro-3-phenylethyl-7-[[2'-(1H-tetrazol-5- yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-methyl-3,7-dihydro-1-methyl-3-phenylethyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-methyl-3,7-dihydro-1-ethyl-3-phenylethyl-7-[[2'-(1H- tetrazol-5-yl) (1, 1 ' -biphenyl) -4-yl]methyl] -1H-purine-2, 6 - dione;

8-methyl-3,7-dihydro-1-propyl-3-phenylethyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-methyl-3,7-dihydro-1-phenyl-3-phenylethyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl-methyl]-1H-purine-2,6- dione;

8-methyl-3,7-dihydro-1-cyclopropylmethyl-3-phenylethyl-7-

[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione;

8-methyl-3, 7-dihydro-1-methoxyethyl-3-phenylethyl-7- [ [2 ' -

(1H-tetrazol-5-yl) (1, 1 ' -biphenyl) -4-yl]methyl] -1H-purine-

2, 6-dione;

8-methyl-3,7-dihydro-1-carbomethoxymethyl-3-phenylethyl-7- [[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione;

8-cyclohexyl-3,7-dihydro-3-phenylethyl-7-[[2'-(1H-tetrazol-

5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-cyclohexyl-3,7-dihydro-1-methyl-3-phenylethyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-cyclohexyl-3,7-dihydro-1-ethyl-3-phenylethyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione; 8-cyclohexyl-3,7-dihydro-1-propyl-3-phenylethyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-cyclohexyl-3,7-dihydro-1-isobutyl-3-phenylethyl-7-[[2'- (1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine- 2,6-dione;

8-cyclohexyl-3,7-dihydro-1-cyclopropylmethyl-3-phenylethyl- 7-[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione;

8-cyclohexyl-3,7-di-ydro-1-methoxyethyl-3-phenylethyl-7-

[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione;

8-isopropyl-3,7-dihydro-3-phenylethyl-7-[[2'-(1H-tetrazol- 5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-isopropyl-3,7-dihydro-1-methyl-3-phenylethyl-7-[[2 ' -(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-isopropyl-3,7-dihydro-1-ethyl-3-phenylethyl-7- tetrazol-5-yl)(1,1'-bipheny l]methyl]-1H-purine-2,6- dione;

8-isopropyl-3,7-dihydro-1-propyl-3-phenylethyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-isopropyl-3,7-dihydro-1-isobutyl-3-phenylethyl-7-[[2'-

(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-

2,6-dione;

8-isopropyl-3,7-dihydro-1-phenyl-3-phenylethyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione; 8-isopropyl-3,7-dihydro-1-cyclopropylmethyl-3-phenylethyl-

7-[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione;

8-isopropyl-3,7-dihydro-1-methoxyethyl-3-phenylethyl-7- [[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione;

8-isopropyl-3,7-dihydro-1-carbomethoxymethyl-3-phenylethyl- 7-[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-neopentyl-3,7-dihydro-3-phenylethyl-7-[[2'-(1H-tetrazol-

5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-neopentyl-3,7-dihydro-1-propyl-3-phenylethyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-neopentyl-3,7-dihydro-1-isobutyl-3-phenylethyl-7-[[2'-

(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-

2,6-dione;

8-neopentyl-3,7-dihydro-1-phenyl-3-phenylethyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-neopentyl-3,7-dihydro-1-cyclopropylmethyl-3-phenylethyl-

7-[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione;

8-neopentyl-3,7-dihydro-1-methoxyethyl-3-phenylethyl-7-

[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione;

8-neopentyl-3,7-dihydro-1-carbomethoxymethyl-3-phenylethyl-

7-[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione; 8-butyl-3,7-dihydro-3-methoxyethyl-7-[[2'-(1H-tetrazol-5- yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2 6-dione;

8-butyl-3,7-dihydro-1-phenylethyl-3-methoxyethyl-7-[[2'- (1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine- 2,6-dione;

8-butyl-3,7-dihydro-1-carbomethoxymethyl-3-methoxyethyl-7- [[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione;

8-propyl-3,7-dihydro-3-methoxyethyl-7-[[2'-(1H-tetrazol-5- yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-propyl-3,7-dihydro-1-ethyl-3-methoxyethyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione; 8-propyl-3,7-dihydro-1-propyl-3-methoxyethyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-propyl-3,7-dihydro-1-isobutyl-3-methoxyethyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-propyl-3,7-dihydro-1-phenyl-3-methoxyethyl-7-[[2 ' -(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-propyl-3,7-dihydro-1-cyclopropylmethyl-3-methoxyethyl-7-

[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione;

8-propyl-3,7-dihydro-1-phenylethyl-3-methoxyethyl-7-[[2'-

(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine- 2,6-dione;

8-propyl-3,7-dihydro-1-carbomethoxymethyl-3-methoxyethyl-7-

[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione;

8-pentyl-3,7-dihydro-3-methoxyethyl-7-[[2'-(1H-tetrazol-5- yl)(1,1'-biphenyl)-4-yl]methyl]-1H-pur ne-2,6-dione;

8-pentyl-3,7-dihydro-1-methyl-3-methoxyethyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-pentyl-3,7-dihydro-1-ethyl-3-methoxyethyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-pentyl-3,7-dihydro-1-phenyl-3-methoxyethyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione; 8-pentyl-3,7-dihydro-1-cyclopropyImethyl-3-methoxyethyl-7-

[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine--,6-dione;

8-pentyl-3,7-dihydro-1-phenylethyl-3-methoxyethyl-7-[[2'- (1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-

2,6-dione;

8-pentyl-3,7-dihydro-1-carbomethoxymethyl-3-methoxyethyl-7-

[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione;

8-ethyl-3,7-dihydro-3-methoxyethyl-7-[[2'-(1H-tetrazol-5- yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-ethyl-3,7-dihydro-1-isobutyl-3-methoxyethyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-ethyl-3,7-dihydro-1-cyclopropylmethyl-3-methoxyethyl-7-

[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione;

8-ethyl-3,7-dihydro-1-phenylethyl-3-methoxyethyl-7-[[2'- (1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-

2,6-dione;

8-ethyl-3,7-dihydro-1-carbomethoxymethyl-3-methoxyethyl-7- [[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione; 8-methyl-3,7-dihydro-3-methoxyethyl-7-[[2'-(1H-tetrazol-5- yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-methyl-3,7-dihydro-1-methyl-3-methoxyethyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-methyl-3,7-dihydro-1-ethyl-3-methoxyethyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-methyl-3,7-dihydro-1-propyl-3-methoxyethyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-methyl-3,7-dihydro-1-phe yl-3-methoxyethyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-methyl-3,7-dihydro-1-cyclopropylmethyl-3-methoxyethyl-7-

[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione;

8-methyl-3,7-dihydro-1-phenylethyl-3-methoxyethyl-7-[[2'-

(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-

2,6-dione;

8-methyl-3, 7-dihydro-1-carbomethoxymethyl-3-methoxyethyl-7- [[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-cyclohexyl-3,7-dihydro-1-methyl-3-methoxyethyl-7-[[2'-

(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-

2,6-dione;

8-cyclohexyl-3,7-dihydro-1-ethyl-3-methoxyethyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione; 8-cyclohexyl-3,7-dihydro-1-propyl-3-methoxyethyl-7-[[2'-

(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine- 2,6-dione;

8-cyclohexyl-3,7-dihydro-1-isobutyl-3-methoxyethyl-7-[[2'- (1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-

2,6-dione;

8-cyclohexyl-3,7-dihydro-1-phenyl-3-methoxyethyl-7-[[2'- (1H-tetrazol-5-yl)(1,1;-biphenyl)-4-yl]methyl]-1H-purine- 2,6-dione;

8-cyclohexyl-3,7-dihydro-1-phenylethyl-3-methoxyethyl-7-

[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione;

8-isopropyl-3,7-dihydro-3-methoxyethyl-7-[[2'-(1H-tetrazol- 5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-isopropyl-3,7-dihydro-1-methyl-3-methoxyethyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-isopropyl-3,7-dihydro-1-ethyl-3-methoxyethyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-isopropyl-3,7-dihydro-1-propyl-3-methoxyethyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-isopropyl-3,7-dihydro-1-isobutyl-3-methoxyethyl-7-[[2'-

(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-

2,6-dione;

8-isopropyl-3, 7-dihydro-1-phenyl-3-methoxyethyl-7- [ [2 ' - (1H- tetrazol-5-yl) (1, 1 '-biphenyl) -4-yl]methyl] -1H-purine-2, 6 - dione; 8-isopropyl-3,7-dihydro-1-cyclopropylmethyl-3-methoxyethyl-

7-[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione;

8-isopropyl-3,7-dihydro-1-phenylethyl-3-methoxyethyl-7- [[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione;

8-isopropyl-3,7-dihydro-1-carbomethoxymethyl-3- methoxyethyl-7-[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4- yl]methyl]-1H-purine-2,6-dione;

8-neopentyl-3,7-dihydro-3-methoxyethyl-7-[[2'-(1H-tetrazol-

5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-neopentyl-3,7-dihydro-1-methyl-3-methoxyethyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-neopentyl-3,7-dihydro-1-propyl-3-methoxyethyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-neopentyl-3,7-dihydro-1-isobutyl-3-methoxyethyl-7-[[2'-

(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-

2,6-dione;

8-neopentyl-3,7-dihydro-1-phenyl-3-methoxyethyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-neopentyl-3,7-dihydro-1-cyclopropylmethyl-3-methoxyethyl-

7-[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione;

8-neopentyl-3,7-dihydro-1-phenylethyl-3-methoxyethyl-7-

[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione;

8-neopentyl-3,7-dihydro-1-carbomethoxymethyl-3- methoxyethyl-7- [ [2 ' - (1H-tetrazol-5-yl) (1, 1 ' -biphenyl) -4- yl]methyl] -1H-purine-2, 6-dione; 8-butyl-3,7-dihydro-3-carbomethoxymethyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-butyl-3,7-dihydro-1-meyhyl-3-carbomethoxymethyl-7-[[2'- (1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-

2,6-dione;

8-butyl-3,7-dihydro-1-ethyl-3-carbomethoxymethyl-7-[[2'-

(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-

2,6-dione;

8-butyl-3,7-dihydro-1-propyl-3-carbomethoxymethyl-7-[[2'-

(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-

2,6-dione;

8-butyl-3,7-dihydro-1-isobutyl-3-carbomethoxymethyl-7-[[2'-

(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine- 2,6-dione;

8-butyl-3,7-dihydro-1-phenyl-3-carbomethoxymethyl-7-[[2'-

(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-

2,6-dione;

8-butyl-3,7-dihydro-1-phenylethyl-3-carbomethoxymethyl-7-

[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione;

8-butyl-3,7-dihydro-1-methoxyethyl-3-carbomethoxymethyl-7-

[[2 '-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione;

8-propyl-3,7-dihydro-3-carbomethoxymethyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-propyl-3,7-dihydro-1-methyl-3-carbomethoxymethyl-7-[[2'- (1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-

2,6-dione;

8-propyl-3, 7-dihydro-1-ethyl-3-carbomethoxymethyl-7- [ [2 ' - (1H-tetrazol-5-yl) (1, 1' -biphenyl) -4-yl]methyl] -1H-purine-

2, 6-dione; 8-propyl-3,7-dihydro-1-propyl-3-carbomethoxymethyl-7-[[2'-

(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-

2,6-dione;

8-propyl-3,7-dihydro-1-isobutyl-3-carbomethoxymethyl-7- [[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione;

8-propyl-3,7-dihydro-1-phenyl-3-carbomethoxymethyl-7-[[2'-

(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-

2,6-dione;

8-propyl-3,7-dihydro-1-cyclopropylmethyl-3-carbomethoxymethyl-7-[[2'-(1H-tetrazol-5-yl)(1,1'- biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-propyl-3,7-dihydro-1-phenylethyl-3-carbomethoxymethyl-7-

[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione;

8-propyl-3,7-dihydro-1-methoxyethyl-3-carbomethoxymethyl-7-

[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione;

8-pentyl-3,7-dihydro-1-methyl-3-carbomethoxymethyl-7-[[2'-

(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-

2,6-dione;

8-pentyl-3,7-dihydro-1-ethyl-3-carbomethoxymeth l-7-[[2'-

(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-

2,6-dione;

8-pentyl-3,7-dihydro-1-propyl-3-carbomethoxymethyl-7-[[2'-

(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine- 2,6-dione;

8-pentyl-3,7-dihydro-1-isobutyl-3-carbomethoxymethyl-7-

[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione;

8-pentyl-3,7-dihydro-1-phenyl-3-carbomethoxymethyl-7-[[2'- (1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine- 2,6-dione; 8-pentyl-3,7-dihydro-1-cyclopropylmethyl-3- carbomethoxymethyl-7-[[2'-(1H-tetrazol-5-yl)(1,1'- biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-pentyl-3,7-dihydro-1-phenylethyl-3-carbomethoxymethyl-7- [[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione;

8-pentyl-3,7-dihydro-1-methoxyethyl-3-carbomethoxymethyl-7-

[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione;

8-ethyl-3,7-dihydro-3-carbomethoxymethyl-7-[[2'-(1H- teyrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-ethyl-3,7-dihydro-1-methyl-3-carbomethoxymethyl-7-[[2'-

(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine- 2,6-dione;

8-ethyl-3,7-dihydro-1-ethyl-3-carbomethoxymethyl-7-[[2'-

(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine- 2,6-dione;

8-ethyl-3,7-dihydro-1-propyl-3-carbomethoxymethyl-7-[[2'- (1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-

2,6-dione;

8-ethyl-3,7-dihydro-1-isobutyl-3-carbomethoxymethyl-7-[[2'-

(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine- 2,6-dione;

8-ethyl-3,7-dihydro-1-phenyl-3-carbomethoxymethyl-7-[[2'-

(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-

2,6-dione;

8-ethyl-3,7-dihydro-1-phenylethyl-3-carbomethoxymethyl-7-

[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione;

8-ethyl-3,7-dihydro-1-methoxyethyl-3-carbomethoxymethyl-7- [[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione; 8-methyl-3,7-dihydro-3-carbomethoxymethyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-methyl-3,7-dihydro-1-ethyl-3-carbomethoxymethyl-7-[[2'- (1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine- 2,6-dione;

8-methyl-3,7-dihydro-1-propyl-3-carbomethoxymethyl-7-[[2'- (1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine- 2,6-dione;

8-methyl-3,7-dihydro-1-isobutyl-3-carbomethoxymethyl-7- [[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-methyl-3,7-dihydro-1-phenyl-3-carbomethoxymethyl-7-[[2'- (1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine- 2,6-dione;

8-methyl-3,7-dihydro-1-cyclopropylmethyl-3-carbomethoxymethyl-7-[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-methyl-3,7-dihydro-1-phenylethyl-3-carbomethoxymethyl-7- [[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-methyl-3,7-dihydro-1-methoxyethyl-3-carbomethoxymethyl-7- [[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-cyclohexyl-3,7-dihydro-3-carbomethoxymethyl-7-[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-cyclohexyl-3,7-dihydro-1-methyl-3-carbomethoxymethyl-7- [[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-cyclohexyl-3,7-dihydro-1-ethyl-3-carbomethoxymethyl-7-[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione; 8-cyclohexyl-3,7-dihydro-1-propyl-3-carbomethoxymethyl-7-

[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione;

8-cyclohexyl-3,7-dihydro-1-isobutyl-3-carbomethoxymethyl-7- [[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione;

8-cyclohexyl-3,7-dihydro-1-phenyl-3-carbomethoxymethyl-7-

[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione;

8-cyclohexyl-3,7-dihydro-1-phenylethyl-3- carbomethoxymethyl-7-[[2'-(1H-tetrazol-5-yl)(1,1'-- biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-isopropyl-3,7-dihydro-1-methyl-3-carbomethoxymethyl-7-

[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione;

8-isopropyl-3,7-dihydro-1-ethyl-3-carbomethoxymethyl-7-

[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione;

8-isopropyl-3,7-dihydro-1-propyl-3-carbomethoxymethyl-7-

[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione;

8-isopropyl-3,7-dihydro-1-isobutyl-3-carbomethoxymethyl-7- [[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione;

8-isopropyl-3,7-dihydro-1-phenyl-3-carbomethoxymethyl-7- [[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione; 8-isopropyl-3,7-dihydro-1-cyclopropylmethyl-3- carbomethoxymethyl-7-[[2'-(1H-tetrazol-5-yl)(1,1'- biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-isopropyl-3,7-dihydro-1-phenylethyl-3-carbomethoxymethyl- 7-[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione;

8-isopropyl-3,7-dihydro-1-methoxyethyl-3- carbomethoxymethyl-7-[[2'-(1H-tetrazol-5-yl)(1,1'- biphenyl)-4-yl]methyl]-1H-purine-2,6-dioee;

8-neopentyl-3,7-dihydro-3-carbomethoxymethyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-neopentyl-3,7-dihydro-1-methyl-3-carbomethoxymethyl-7-

[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione;

8-neopentyl-3,7-dihydro-1-ethyl-3-carbomethoxymethyl-7-

[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione;

8-neopentyl-3,7-dihydro-1-propyl-3-carbomethoxymethyl-7- [[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione;

8-neopentyl-3,7-dihydro-1-isobutyl-3-carbomethoxymethyl-7-

[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione;

8-neopentyl-3,7-dihydro-1-phenyl-3-carbomethoxymethyl-7-

[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione;

8-neopentyl-3, 7-dihydro-1-cyclopropylmethyl-3

carbomethoxymethyl-7-[[2'-(1H-tetrazol-5-yl)(1,1'- biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-neopentyl-3,7-dihydro-1-phenylethyl-3-carbomethoxymethyl-

7-[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione;

8-neopentyl-3,7-dihydro-1-methoxyethyl-3- carbomethoxymethyl-7-[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione; 4'-[[8-propyl-1,2,3,6-tetrahydro-3-(methyl)-2,6-dioxo-7H- purin-7-yl]methyl][1,1'-biphenyl-2-carboxylic acid;

4'-[[8-propyl-1,2,3,6-tetrahydro-3-(propyl)-2,6-dioxo-7H- purin-7-yl]methyl][1,1'-biphenyl-2-carboxylic acid;

4'-[[8-propyl-1,2,3,6-tetrahydro-1-methyl-3-2,6-dioxo-7H-purin-7-yl]methyl][1,1'-biphenyl-2-carboxylic acid;

4'-[[8-propyl-1,2,3,6-tetrahydro-1,3-dimethyl-2,6-dioxo-7H- purin-7-yl]methyl][1,1'-biphenyl-2-carboxylic acid;

4'-[[8-propyl-1,2,3,6-tetrahydro-1-methyl-3-propyl-2,6- dioxo-7H-purin-7-yl]methyl][1,1'-biphenyl-2-carboxylie acid;

4'-[[8-propyl-1,2,3,6-tetrahydro-1-propyl-2,6-dioxo-7H- purin-7-yl]methyl] [1, 1 ' -biphenyl-2-carboxylic acid;

4 '- [ [8-propyl-1, 2, 3, 6-tetrahydro-1-propyl-3-methyl-2, 6- dioxo-7H-purin-7-yl]methyl] [1, 1 ' -biphenyl-2-carboxylic acid;

4'-[[8-propyl-1,2,3,6-tetrahydro-1,3-dipropyl-2,6-dioxo-7H- purin-7-yl]methyl][1,1'-biphenyl-2-carboxylic acid;

4'-[[8-butyl-1,2,3,6-tetrahydro-3-(methyl)-2,6-dioxo-7H- purin-7-yl]methyl][1,1'-biphenyl-2-carboxylic acid;

4'-[[8-butyl-1,2,3,6-tetrahydro-3-(propyl)-2,6-dioxo-7H-purin-7-yl]methyl][1,1'-biphenyl-2-carboxylic acid;

4'-[[8-butyl-1,2,3,6-tetrahydro-1-methyl-3-2,6-dioxo-7H- purin-7-yl]methyl][1,1'-biphenyl-2-carboxylic acid;

4'-[[8-butyl-1,2,3,6-tetrahydro-1,3-dimethyl-2,6-dioxo-7H- purin-7-yl]methyl][1,1'-biphenyl-2-carboxylie acid;

4'-[[8-butyl-1,2,3,6-tetrahydro-1-methyl-3-propyl-2,6- dioxo-7H-purin-7-yl]methyl] [1, 1 ' -biphenyl-2-carboxylic acid;

4'-[[8-butyl-1,2,3,6-tetrahydro-1-propyl-2,6-dioxo-7H- purin-7-yl]methyl][1,1'-biphenyl-2-carboxylic acid;

4'-[[8-butyl-1,2,3,6-tetrahydro-1-propyl-3-methyl-2,6- dioxo-7H-purie-7-yl]methyl][1,1'-biphenyl-2-carboxylic acid;

4'-[[8-butyl-1,2,3,6-tetrahydro-1,3-dipropyl-2,6-dioxo-7H- purin-7-yl]methyl][1,1'-biphenyl-2-carboxylic acid; 4'-[[8-pentyl-1,2,3,6-tetrahydro-3-(methyl)-2,6-dioxo-7H- purin-7-yl]methyl][1,1'-biphenyl-2-carboxylic acid;

4'-[[8-pentyl-1,2,3,6-tetrahydro-3-(propyl)-2,6-dioxo-7H- purin-7-yl]methyl][1,1'-biphenyl-2-carboxylic acid;

4'-[[8-pentyl-1,2,3,6-tetrahydro-1-methyl-3-2,6-dioxo-7H- purin-7-yl]methyl][1,1'-biphenyl-2-carboxylic acid;

4'-[[8-pentyl-1,2,3,6-tetrahydro-1,3-dimethyl-2,6-dioxo-7H- purin-7-yl]methyl][1,1'-biphenyl-2-carboxylic acid;

4'-[[8-pentyl-1,2,3,6-tetrahydro-1-methyl-3-propyl-2,6- dioxo-7H-purin-7-yl]methyl][1, '-biphenyl-2-carboxylic acid;

4'-[[8-pentyl-1,2,3,6-tetrahydro-1-propyl-2,6-dioxo-7H- purin-7-yl]methyl][1,1'-biphenyl-2-carboxylic acid;

4'-[[8-pentyl-1,2,3,6-tetrahydro-1-propyl-3-methyl-2,6- dioxo-7H-purin-7-yl]methyl][1,1'-biphenyl-2-carboxylic acid;

4'-[[8-pentyl-1,2,3,6-tetrahydro-1,3-dipropyl-2,6-dioxo-7H- purin-7-yl]methyl][1,1'-biphenyl-2-carboxylic acid;

4'-[[8-cyclohexyl-1,2,3,6-tetrahydro-3-(methyl)-2,6-dioxo- 7H-purin-7-yl]methyl][1,1'-biphenyl-2-carboxylic acid;

4'-[[8-cyclohexyl-1,2,3,6-tetrahydro-3-(propyl)-2,6-dioxo- 7H-purin-7-yl]methyl][1,1'-biphenyl-2-carboxylic acid;

4'-[[8-cyclohexyl-1,2,3,6-tetrahydro-1-methyl-3-2,6-dioxo-7H-purin-7-yl]methyl][1,1'-biphenyl-2-carboxylic acid;

4'-[[8-cyclohexyl-1,2,3,6-tetrahydro-1,3-dimethyl-2,6- dioxo-7H-purin-7-yl]methyl][1,1'-biphenyl-2-carboxylic acid;

4'-[[8-cyclohexyl-1,2,3,6-tetrahydro-1-methyl-3-propyl-2,6- dioxo-7H-purin-7-yl]methyl][1,1'-biphenyl-2-carboxylic acid;

4'-[[8-cyclohexyl-1,2,3,6-tetrahydro-1-propyl-2,6-dioxo-7H- purin-7-yl]methyl][1,1'-biphenyl-2-carboxylic acid;

4'-[[8-cyclohexyl-1,2,3,6-tetrahydro-1-propyl-3-methyl-2,6- dioxo-7H-purin-7-yl]methyl][1,1'-bipheny1-2-carboxylie acid; 4'-[[8-cyclohexyl-1,2,3,6-tetrahydro-1,3-dipropyl-2,6- dioxo-7H-purin-7-yl]methyl][1,1'-biphenyl-2-carboxylic acid;

8-buty1-3,7-dihydro-1-methyl-3-propyl-7-[[2'-(1H-tetrazol- 5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-butyL-3,7-dihydro-1-propyl-3-methyl-7-[[2'-(1H-tetrazol- 5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-buty1-3,7-dihydro-1-methyl-3-isobutyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-butyl-3,7-dihydro-1-(cyclopropyl-methyl)-3-methyl-7-[[2'-

(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine- 2,6-dione;

8-butyl-3,7-dihydro-1-methyl-3-(cyclopropyl-methyl)-7-[[2'-

(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine- 2,6-dione;

8-butyl-3,7-dihydro-1-methyl-3-phenyl-7-[[2'-(1H-tetrazol-

5-yl) (1, 1 ' -biphenyl) -4-yl]methyl] -1H-purine-2, 6-dione;

8-butyl-3, 7-dihydro-3-propyl-7- [ [2' - (1H-tetrazol-5- yl) (1, 1 '-biphenyl) -4-yl]methyl] -1H-purine-2, 6-dione;

8-butyl-3, 7-dihydro-1-propyl-7- [ [2 ' - (1H-tetrazol-5- yl) (1, 1 '-biphenyl) -4-yl]methyl] -1H-purine-2, 6-dione;

8-butyl-3, 7-dihydro-1-methyl-7- [ [2 ' - (1H-tetrazol-5- yl)(1,1'-biphenyl)-4-yl]methyl)-6-oxo-2-thioxo-1H-purine;

8-butyl-3,7-dihydro-1-(3-hydroxypropyl)-3-methyl-7-[[2'-

(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-

2,6-dione;

8-buty1-3,7-dihydro-1-(2-carbomethoxy-ethyl)-3-methyl-7- [[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione; 8-butyl-3,7-dihydro-1-(2-hydroxyethyl)-1-methyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-butyl-3,7-dihydro-1-methyl-3-(prop-2-en-1-yl)-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-butyl-3,7-dihydro-1-propyl-3-methyl-7-[[2'-(1H-tetrazol-

5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-thione;

8-butyl-3,7-dihydro-1-methyl-3-isobutyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- thione;

8-butyl-3,7-dihydro-1-(cyclopropyl-methyl)-3-methyl-7-[[2'- (1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-

2,6-thione;

8-butyl-3,7-dihydro-1-methyl-3-(cyclopropyl-methyl)-7-[[2'-

(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-

2,6-thione;

8-butyl-3,7-dihydro-1-methyl-3-phenyl-7-[[2'-(1H-tetrazol-

5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-thione;

8-butyl-3,7-dihydro-3-propyl-7-[[2'-(1H-tetrazol-5- yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-thione;

8-butyl-3,7-dihydro-1-propyl-7-[[2'-(1H-tetrazol-5- yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-thione;

8-cyclohexyl-3,7-dihydro-1,3-dimethyl-7-[[2'-(1H-tetrazol-

5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-cyclohexyl-3,7-dihydro-1,3-dipropyl-7-[[2'-(1H-tetrazol- 5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione; 8-cyclohexyl-3,7-dihydro-1-methyl-3-isobutyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-cyclohexyl-3,7-dihydro-1-(cyclopropyl-methyl)-3-methyl-7- [[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione;

8-cyclohexyl-3,7-dihydro-1-methyl-3-(cyclopropyl-methyl)-7-

[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione;

8-cyclohexyl-3,7-dihydro-1-methyl-3-phenyl-7-[[2'-(1H- tetrazol-5-yl)(1 1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-cyclohexyl-3,7-dihydro-1-methyl-7-[[2'-(1H-tetrazol-5- yl)(1,1'-biphenyl)-4-yl]methyl]-6-oxo-2-thioxo-1H-purine;

8-cyclohexyl-3,7-dihydro-1-(3-hydroxypropyl)-3-methyl-7-

[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione;

8-cyclohexyl-3,7-dihydro-1-(2-carbomethoxy-ethyl)-3-methyl- 7-[[2'-(1H-tetrazol-5-yl) (1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione;

8-cyclohexyl-3,7-dihydro-1-(2-hydroxyethyl)-1-methyl-7-

[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione;

8-cyclohexyl-3,7-dihydro-1-methyl-3-(prop-2-en-1-yl)-7- [[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione;

8-cyclohexyl-3,7-dihydro-1-propyl-3-methyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- thione; 8-cyclohexyl-3,7-dihydro-1,3-dipropyl-7-[[2'-(1H-tetrazol-

5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-cyclohexyl-3,7-dihydro-1-methyl-3-isobutyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- thione;

8-cyclohexyl-3,7-dihydro-1-(cyclopropyl-methyl)-3-methyl-7-

[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-thione;

8-cyclohexyl-3, 7-dihydro-1-methyl-3- (cyclopropyl-methyl) -7- [ [2 '- (1H-tetrazol- -yl) (1, 1 '-biphenyl) -4-yl]methyl] -1H- purine-2, 6-thione;

8-cyclohexyl-3,7-dihydro-1-methyl-3-phenyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- thione;

8-cyclohexyl-3,7-dihydro-3-propyl-7-[[2'-(1H-tetrazol-5- yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-thione;

8-cyclohexyl-3,7-dihydro-1-propyl-7-[[2'-(1H-tetrazol-5- yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-thione;

8-pentyl-3,7-dihydro-1-methyl-3-propyl-7-[[2'-(1H-tetrazol-

5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-pentyl-3,7-dihydro-1-propyl-3-methyl-7-[[2'-(1H-tetrazol-

5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-pentyl-3,7-dihydro-1,3-dipropyl-7-[[2'-(1H-tetrazol-5- yl)(1,1'-biphenyl)-4-yl]methyl]-lH-purine-2,6-dione;

8-pentyl-3,7-dihydro-1-(cyclopropyl-methyl)-3-methyl-7-

[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione;

8-pentyl-3,7-dihydro-1-methyl-3-(cyclopropyl-methyl)-7-

[ [2 ' - (1H-tetrazol-5-yl) (1, 1 ' -biphenyl) -4-yl]methyl] -1H- purine-2, 6-dione; 8-pentyl-3,7-dihydro-1-methyl-3-phenyl-7-[[2'-(1H-tetrazol-

5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-pentyl-3,7-dihydro-1-methhl-7-[[2'-(1H-tetrazol-5- yl) (1,1'-biphenyl)-4-yl]methyl]-6-oxo-2-thioxo-1H-purine;

8-pentyl-3,7-dihydro-1-(3-hydroxypropyl)-3-methyl-7-[[2'-

(1H-tetrazol-5-yl) (1,1'-biphenyl)-4-yl]methyl]-1H-purine-

2,6-dione;

8-pentyl-3,7-dihydro-1-(2-carbomethoxy-ethyl)-3-methyl-7- [[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione;

8-pentyl-3,7-dihydro-1-(2-hydroxyethyl)-1-methyl-7-[[2'- (1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-

2,6-dione;

8-pentyl-3,7-dihydro-1-methyl-3-(prop-2-en-1-yl)-7-[[2'- (1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-

2,6-dione;

8-pentyl-3,7-dihydro-1-propyl-3-methyl-7-[[2'-(1H-tetrazol-

5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-thione; 8-pentyl-3,7-dihydro-1,3-dipropyl-7-[[2'-(1H-tetrazol-5- yl) (1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-pentyl-3,7-dihydro-1-methyl-3-isobutyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- thione;

8-pentyl-3,7-dihydro-1-(cyclopropyl-methyl)-3-methyl-7- [[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-thione;

8-pentyl-3,7-dihydro-1-methyl-3-(cyclopropyl-methyl)-7- [[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-thione; 8-pentyl-3,7-dihydro-1-methyl-3-phenyl-7-[[2'-(1H-tetrazol-

5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-thione;

8-pentyl-3,7-dihydro-3-propyl-7-[[2'-(1H-tetrazol-5- yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-thione;

8-pentyl-3,7-dihydro-1-propyl-7-[[2'-(1H-tetrazol-5- yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-thione;

8-(propen-2-yl)-3,7-dihydro-1-methyl-7-[[2'-(1H-tetrazol-5- yl)(1,1'-biphenyl)-4-yl]methyl]-6-oxo-2-thioxo-1H-purine;

8-(propen-2-yl)-3,7-dihydro-1-methyl-7-[[2'-(1H-tetrazol-5- yl)(1,1'-bi henyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-(propen-2-yl)-3,7-dihydro-1-(3-hydroxypropyl)-3-methyl-7-

[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione;

8-(propen-2-yl)-3,7-dihydro-1-(2-carbomethoxy-ethyl)-3- methyl-7-[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4- yl]methyl]-1H-purine-2,6-dione;

8-(propen-2-yl)-3,7-dihydro-1-(2-hydroxyethyl)-1-methyl-7-

[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione;

8-(propen-2-yl)-3,7-dihydro-1-methyl-3-(prop-2-en-1-yl)-7-

[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione;

8-(propen-2-yl)-3,7-dihydro-1-propyl-3-methyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- thione;

8-(propen-2-yl)-3,7-dihydro-1,3-dipropyl-7-[[2'-(1H- tetrazol-5-yl) (1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-(propen-2-yl)-3,7-dihydro-1-methyl-3-isobutyl-7-[[2'-(1H- tetrazol-5-yl) (1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- thione;

8-(buten-2-yl)-3,7-dihydro-1-methyl-7-[[2'-(1H-tetrazol-5- yl) (1,1'-biphenyl)-4-yl]methyl]-6-oxo-2-thioxo-1H-purine;

8-(buten-2-yl)-3,7-dihydro-1-methyl-7-[[2'-(1H-tetrazol-5- yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione; 8-(buten-2-yl)-3,7-dihydro-1-(3-hydroxypropyl)-3-methyl-7-

[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione;

8-(buten-2-yl)-3,7-dihydro-1-(2-carbomethoxy-ethyl)-3- methyl-7-[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4- yl]methyl]-1H-purine-2,6-dione;

8-(buten-2-yl)-3,7-dihydro-1-(2-hydroxyethyl)-1-methyl-7-

[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione;

8-(buten-2-yl)-3,7-dihydro-1-methyl-3-(prop-2-en-1-yl)-7-

[[2'-y1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-IH- purine-2,6-dione;

8-(buten-2-yl)-3,7-dihydro-1-propyl-3-methyl-7-[[2'-(1H- tetrazol-5-yl) (1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- thione;

8-(buten-2-yl)-3,7-dihydro-1,3-dipropyl-7-[[2'-(1H- tetrazol-5-yl )(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-(buten-2-yl)-3,7-dihydro-1-methyl-3-isobutyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- thione;

8-(buten-2-yl)-3,7-dihydro-1-methyl-7-[[2'-(1H-tetrazol-5- yl)(1,1'-biphenyl)-4-yl]methyl]-6-oxo-2-thioxo-1H-purine;

8-(buten-2-yl)-3,7-dihydro-1-methyl-7-[[2'-(1H-tetrazol-5- yl) (1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-(buten-2-yl)-3,7-dihydro-1-(3-hydroxypropyl)-3-methyl-7-

[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione;

8-(buten-2-yl)-3,7-dihydro-1-(2-hydroxyethyl)-1-methyl-7- [[2'-(1H-tetrazol-5-yl) (1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione; 8-(buten-2-yl)-3,7-dihydro-1-methyl-3-(prop-2-en-1-yl)-7- [[2'-(1H-tetrazol-5-yl) (1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione;

8-(buten-2-yl)-3,7-dihydro-1,3-dipropyl-7-[[2'-(1H- tetrazol-5-yl) (1,1'-biphenyl)-4-yl7methyl]-1H-purine-2,6- dione;

8-(buten-2-yl)-3,7-dihydro-1-methyl-3-isobutyl-7-[[2'-(1H- tetrazol-5-yl) (1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- thione;

8-(cyclohex-3-en-1-yl)-3,7-dihydro-1-methyl-3-isobutyl-7-

[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-thione;

8-(cyclohex-3-en-1-yl)-3,7-dihydro-1-methyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-6-oxo-2-thioxo-

1H-purine;

8-(cyclohex-3-en-1-yl)-3,7-dihydro-1-methyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-propyl-3,7-dihydro-1,3-dimethyl-7-[[2'-(1H-tetrazol-5- yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-propyl-3,7-dihydro-1-propyl-3-methyl-7-[[2'-(1H-tetrazol-

5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-propyl-3,7-dihydro-1,3-dipropyl-7-[[2'-(1H-tetrazol-5- yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-propyl-3,7-dihydro-1-(cyclopropyl-methyl)-3-methyl-7-

[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione; 8-propyl-3,7-dihydro-1-methyl-3-(cyclopropyl-methyl)-7-

[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione;

8-propyl-3,7-dihydro-1-methyl-7-[[2'-(1H-tetrazol-5- yl) (1,1'-biphenyl)-4-yl]methyl]-6-oxo-2-thioxo-1H-purine; 8-propyl-3,7-dihydro-1-methyl-7-[[2'-(1H-tetrazol-5- yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-propyl-3,7-dihydro-1-(3-hydroxypropyl)-3-methyl-7-[[2'- (1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-

2,6-dione;

8-propyl-3,7-dihydro-1-(2-carbomethoxy-ethyl)-3-methyl-7-

[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione;

8-propyl-3,7-dihydro-1-(2-hydroxyethyl)-1-methyl-7-[[2'- (1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine- 2,6-dione;

8-propyl-3,7-dihydro-1-methyl-3-(prop-2-en-1-yl)-7-[[2'- (1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine- 2,6-dione;

8-propyl-3,7-dihydro-1-propyl-3-methyl-7-[[2'-(1H-tetrazol- 5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-thione; 8-propyl-3,7-dihydro-1,3-dipropyl-7-[[2'-(1H-tetrazol-5- yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione; 8-propyl-3,7-dihydro-1-methyl-3-isobutyl-7-[[2'-(1H-tetrazol- 5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-thione;

8-propyl-3,7-dihydro-1-(cyclopropyl-methyl)-3-methyl-7-[[2'- (1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- thione;

8-propyl-3,7-dihydro-1-methyl-3-(cyclopropyl-methyl)-7-[[2'- (1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- thione;

8-propyl-3,7-dihydro-1-methyl-3-phenyl-7-[[2'-(1H-tetrazol-5- yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-thione;

8-propyl-3,7-dihydro-3-propyl-7-[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-thione; and 8-propyl-3,7-dihydro-1-propyl-7-[[2'-(1H-tetrazol-5- yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-thione.

A family of compounds of more particular interest within Formula II consists of the following compounds:

8-(buten-2-yl)-3,7-dihydro-1-methyl-3-propyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-butyl-3,7-dihydro-1-methyl-3-propyl-7-[[2'-(1H-tetrazol-5- yl) (1,1'-biphenyl)-4-yl]methye]-1H-purine-2,6-dione;

8-butyl-3,7-dihydro-1-propyl-3-methyl-7-[[2'-(1H-tetrazol-5- yl) (1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-butyl-3,7-dihydro-1,3-dipropyl-7-[[2'-(1H-tetrazol-5- yl) (1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-butyl-3,7-dihydro-1-methyl-3-isobutyl-7-[[2'-(1H-tetrazol-5- yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-butyl-3,7-dihydro-1-(cyclopropyl-methyl)-3-methyl-7-[[2'- (1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione; 8-butyl-3,7-dihydro-1-methyl-3-(cyclopropyl-methyl)-7-[[2'-

(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-butyl-3,7-dihydro-1-methyl-3-phenyl-7-[[2'-(1H-tetrazol-5- yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-butyl-3,7-dihydro-3-propyl-7-[[2'-(1H-tetrazol-5-yl)(1,1'- biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-propyl-3,7-dihydro-3-propyl-7-[[2'-(1H-tetrazol-5-yl) (1,1'- biphenyl)-4-yl]methyl]-1H-purine-r,6-dione;

8-propyl-3,7-dihydro-1-methyl-3-propyl-7-[[2'-(1H-tetrazol-5- yl ) (1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-butyl-3,7-dihydro-1-propyl-7-[[2'-(1H-tetrazol-5-yl)(1,1'- biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-butyl-3,7-dihydro-1-methyl-7-[[2'-(1H-tetrazol-5-yl)(1,1'- biphenyl)-4-yl]methyl]-6-oxo-2-thioxo-1H-purine;

8-butyl-3,7-dihydro-1-methyl-7-[[2'-(1H-tetrazol-5-yl)(1,1'- biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-butyl-3,7-dihydro-1-methyl-3-propyl-7-[[2'-(1H-tetrazol-5- yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-butyl-3,7-dihydro-1-methyl-3-isobutyl-7-[[2'-(1H-tetrazol-5 yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-butyl-3,7-dihydro-1-(cyclopropyl-methyl)-3-methyl-7-[[2'- (1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-butyl-3,7-dihydro-1-methyl-3-(cyclopropyl-methyl)-7-[[2'- (1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione; 8-butyl-3,7-dihydro-1-methyl-3-phenyl-7-[[2'-(1H-tetrazol-5- yl) (1,1'-biphenyl)-4-yl]methyl]y1H-purine-2,6-dione;

8-butyl-3,7-dihydro-1-propyl-7-[[2'-(1H-tetrazol-5-yl) (1,1'- biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-butyl-3,7-dihydro-1-methyl-7-[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-butyl-3,7-dihydro-1-(3-hydroxypropyl)-3-methyl-7-[[2'-(1H- tetrazol-5-yl)(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-

1H-purine-2,6-dione;

8-butyl-3,7-dihydro-1-(2-carbomethoxy-ethyl)-3-methyl-7-[[2'- (1H-tetrazol-5-yl) (1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-butyl-3,7-dihydro-1-(2-hydroxyethyl)-1-methyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-butyl-3,7-dihydro-1-methyl-3-(prop-2-en-1-yl)-7-[[2'-(1H- tetrazol-5-yl) (1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-butyl-3,7-dihydro-1-propyl-3-methyl-7-[[2'-(1H-tetrazol-5- yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-thione;

8-butyl-3,7-dihydro-1-methyl-3-isobutyl-7-[[2'-(1H-tetrazol-5- yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-thione;

8-butyl-3,7-dihydro-1-(cyclopropyl-methyl)-3-methyl-7-[[2'- (1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- thione;

8-butyl-3,7-dihydro-1-methyl-3-(cyclopropyl-methyl)-7-[[2'-

(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- thione; 8-butyl-3,7-dihydro-1-methyl-3-phenyl-7-[[2'-(1H-tetrazol-5- yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-thione;

8-butyl-3,7-dihydro-3-propyl-7-[[2'-(1H-tetrazol-5-yl)(1,1'- biphenyl)-4-yl]methyl]-1H-purine-2,6-thione;

8-butyl-3,7-dihydro-1-propyl-7-[[2'-(1H-tetrazol-5-yl)(1,1'- biphenyl)-4-yl]methyl]-1H-purine-2,6-thione;

8-cyclohexyl-3,7-dihydro-1,3-dimethyl-7-[[2'-(1H-tetrazol-5- yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-cyclohexyl-3,7-dihydro-1,3-dipropyl-7-[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-cyclohexyl-3,7-dihydro-1-(cyclopropyl-methyl)-3-methyl-7-

[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine- 2,6-dione;

8-cyclohexyl-3,7-dihydro-1-methyl-3-(cyclopropyl-methyl)-7-

[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine- 2,6-dione;

8-cyclohexyl-3, 7-dihydro-3-propyl-7-[ [2 ' - (1H-tetrazol-5- yl) (1, 1 ' -biphenyl) -4-yl]methyl] -1H-purine-2, 6-dione;

8-cyclohexyl-3, 7-dihydro-1-propyl-7- [ [2 ' - (1H-tetrazol-5- yl) (1, 1 '-biphenyl) -4-yl]methyl] -1H-purine-2, 6-dione;

8-cyclohexyl-3, 7-dihydro-1-methyl-7- [ [2 ' - (1H-tetrazol-5- yl) (1, 1 ' -biphenyl) -4-yl]methyl] -6-oxo-2-thioxo-1H-purine; 8-cyclohexyl-3, 7-dihydro-1-methyl-7- [ [2 ' - (1H-tetrazol-5- yl)(1,1'-biphenyl)-4-yl]methyl]-1H-puriny-2,6-dione;

8-cyclohexyl-3,7-dihydro-1-(3-hydroxypropyl)-3-methyl-7-[[2'-

(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-cyclohexyl-3,7-dihydro-1-(2-carbomethoxy-ethyl)-3-methyl-7-

[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine

2,6-dione;

8-cyclohexyl-3,7-dihydro-1-(2-hydroxyethyl)-l-methyl-7-[[2'- (1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-cyclohexyl-3,7-dihydro-1-methyl-3-(prop-2-en-1-yl)-7-[[2'-

(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-cyclohexyl-3,7-dihydro-1-propyl-3-methyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- thione;

8-cyclohexyl-3,7-dihydro-1,3-dipropyl-7-[[2'-(1H-tetrazol-5- yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-cyclohexyl-3,7-dihydro-1-(cyclopropyl-methyl)-3-methyl-7-

[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine- 2,6-thione;

8-cyclohexyl-3,7-dihydro-1-methyl-3-(cyclopropyl-methyl)-7- [[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine- 2,6-thione;

8-cyclohexyl-3,7-dihydro-1-propyl-7-[[2'-(1H-tetrazol-5- yl) (1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-thione;

8-pentyl-3,7-dihydro-1,3-dimethyl-7d[[2'-(1H-tetrazol-5- yl) (1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-pentyl-3,7-dihydro-1-methyl-3-propyl-7-[[2'-(1H-tetrazol-5-yl) (1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-pentyl-3,7-dihydro-1-propyl-3-methyl-7-[[2'-(1H-tetrazol-5- yl) (1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-pentyl-3,7-dihydro-1,3-dipropyl-7-[[2'-(1H-tetrazol-5- yl) (1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-pentyl-3,7-dihydro-1-methyl-3-isobutyl-7-[[2'-(1H-tetrazol- 5-yl) (1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-pentyl-3,7-dihydro-1-(cyclopropyl-methyl)-3-methyl-7-[[2'-

(1H-tetrazol-5-yl) (1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-pentyl-3,7-dihydro-1-methyl-3-(cyclopropyl-methyl)-7-[[2'-

(1H-tetrazol-5-yl) (1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-pentyl-3,7-dihydro-1-methyl-3-phenyl-7-[[2'-(1H-tetrazol-5- yl) (1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-pentyl-3,7-dihydro-3-propyl-7-[[2'-(1H-tetrazol-5-yl) (1,1'- biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-pentyl-3,7-dihydro-1-propyl-7-[[2'-(1H-tetrazol-5-yl) (1,1'- biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-pentyl-3,7-dihydro-1-methyl-7-[[2'-(1H-tetrazol-5-yl) (1,1'- biphenyl)-4-yl]methyl]-6-oxo-2-thioxo-1H-purine;

8-pentyl-3,7-dihydro-1-methyl-7-[[2'-(1H-tetrazol-5-yl) (1,1'- biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-pentyl-3,7-dihydro-1-(3-hydroxypropyl)-3-methyl-7-[[2'-(1H- tetrazol-5-yl) (1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-pentyl-3,7-dihydro-1-(2-carbomethoxy-ethyl)-3-methyl-7-[[2'-

(1H-tetrazol-5-yl) (1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione; 8-pentyl-3,7-dihydro-1-(2-hydroxyethyl)-1-methyl-7-[[2'-(1H- tetrazol-5-yl) (1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-pentyl-3,7-dihydro-1-methyl-3-(prop-2-en-1-yl)-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-pentyl-3,7-dihydro-1-propyl-3-methyl-7-[[2'-(1H-tetrazol-5- yl) (1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-thione;

8-pentyl-3,7-dihydro-l-methyl-3-isobutyl-7-[[2'-(1H-tetrazol-

5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-thione;

8-pentyl-3,7-dihydro-1-(cyclopropyl-methyl)-3-methyl-7-[[2'- (1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- thione;

8-pentyl-3,7-dihydro-1-methyl-3-(cyclopropyl-methyl)-7-[[2'-

(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- thione;

8-pentyl-3,7-dihydro-1-methyl-3-phenyl-7-[[2'-(1H-tetrazol-5- yl) (1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-thione;

8-pentyl-3,7-dihydro-3-propyl-7-[[2'-(1H-tetrazol-5-yl) (1,1'- biphenyl)-4-yl]methyl]-1H-purine-2,6-thione;

8-pentyl-3,7-dihydro-1-propyl-7-[[2'-(1H-tetrazol-5-yl) (1,1'- biphenyl)-4-yl]methyl]-1H-purine-2,6-thione;

8-(propen-2-yl)-3,7-dihydro-1-methyl-7-[[2'-(1H-tetrazol-5- yl) (1,1'-biphenyl)-4-yl]methyl]-6-oxo-2-thioxo-1H-purine;

8-(propen-2-yl)-3,7-dihydro-1-methyl-7-[[2'-(1H-tetrazol-5- yl) (1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-(propen-2-yl)-3,7-dihydro-1-(3-hydroxypropyl)-3-methyl-7- [[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-

2, 6-dione;

8-(propen-2-yl)-3,7-dihydro-1-(2-carbomethoxy-ethyl)-3-methyl-

7-[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione; 8-(propen-2-yl)-3,7-dihydro-1-(2-hydroxyethyl)-1-methyl-7-

[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-

2,6-dione;

8-(propen-2-yl)-3,7-dihydro-1-methyl-3-(prop-2-en-l-yl)-7- [[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-

2,6-dione;

8-(propen-2-yl)-3,7-dihydro-1,3-dipropyl-7-[[2'-(1H-tetrazol-

5-yl) (1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-(propen-2-yl)-3,7-dihydro-1-methyl-3-isobutyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- thione;

8-(buten-2-yl)-3,7-dihydro-1-(3-hydroxypropyl)-3-methyl-7- [[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-

2,6-dione;

8-(buten-2-yl)-3,7-dihydro-1-(2-carbomethoxy-ethyl)-3-methyl-

7-[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione;

8-(buten-2-yl)-3,7-dihydro-1-(2-hydroxyethyl)-1-methyl-7-[[2'- (1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-(buten-2-yl)-3,7-dihydro-1-methyl-3-(prop-2-en-l-yl)-7-[[2'- (1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-(buten-2-yl)-3,7-dihydro-1-propyl-3-methyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- thione; 8-(buten-2-yl)-3,7-dihydro-1,3-dipropyl-7-[[2'-(1H-tetrazol-5- yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-(buten-2-yl)-3,7-dihydro-1-methyl-7-[[2'-(1H-tetrazol-5- yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-(buten-2-yl)-3,7-dihydro-1-(3-hydroxypropyl)-3-methyl-7-

[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-

2,6-dione;

8-(buten-2-yl)-3,7-dihydro-1-(2-carbomethoxy-ethyl)-3-methyl-

7-[[2'-(1H-tetrazol-5-yl) (1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione;

8-(buten-2-yl)-3,7-dihydro-1-(2-hydroxyethyl)-1-methyl-7-[[2'-

(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-(buten-2-yl)-3,7-dihydro-1,3-dipropyl-7-[[2'-(1H-tetrazol-5- yl) (1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-(cyclohex-3-en-1-yl)-3,7-dihydro-1-methyl-3-isobutyl-7-[[2'-

(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- thione; 8-(cyclohex-3-en-1-yl)-3,7-dihydro-1-methyl-7-[[2'-(1H-tetrazol-5-yl) (1,1'-biphenyl)-4-yl]methyl]-6-oxo-2-thioxo-1H- purine;

8-(cyclohex-3-en-1-yl)-3,7-dihydro-1-methyl-7-[[2'-(1H- tetrazol-5-yl) (1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-propyl-3,7-dihydro-1,3-dimethyl-7-[[2'-(1H-tetrazol-5- yl) (1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-propyl-3,7-dihydro-1-methyl-3-propyl-7-[[2'-(1H-tetrazol-5- yl) (1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-propyl-3,7-dihydro-1-propyl-3-methyl-7-[[2'-(1H-tetrazol-5- yl) (1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-propyl-3,7-dihydro-1,3-dipropyl-7-[[2'-(1H-tetrazol-5- yl) (1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-propyl-3,7-dihydro-1-methyl-3-isobutyl-7-[[2'-(1H-tetrazol-

5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-propyl-3,7-dihydro-1-(cyclopropyl-methyl)-3-methyl-7-[[2'-

(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-propyl-3,7-dihydro-1-methyl-3-(cyclopropyl-methyl)-7-[[2'- (1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-propyl-3,7-dihydro-1-methyl-3-phenyl-7-[[2'-(1H-tetrazol-5- yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-propyl-3,7-dihydro-3-propyl-7-[[2'-(1H-tetrazol-5-yl)(1,1'- biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-propyl-3,7-dihydro-1-propyl-7-[[2'-(1H-tetrazol-5-yl)(1,1'- biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-propyl-3,7-dihydro-1-methyl-7-[[2'-(1H-tetrazol-5-yl) (1,1'- biphenyl)-4-yl]methyl]-6-oxo-2-thioxo-1H-purine;

8-propyl-3,7-dihydro-1-methyl-7-[[2'-(1H-tetrazol-5-yl) (1,1'- biphenyl)-4-yl]methyl]-1H-purine-2,6-dione; 8-propyl-3,7-dihydro-1-(3-hydroxyproρyl)-3-methyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-propyl-3, 7-dihydro-1- (2-carbomethoxy-ethyl) -3-methyl-7- [ [2' - (1H-tetrazol-5-yl) (1, 1 ' -biphenyl) -4-yl]methyl] -1H-purine-2, 6- dione;

8-propyl-3,7-dihydro-1-(2-hydroxyethyl)-1-methyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-propyl-3,7-dihydro-1-methyl-3-(prop-2-en-1-yl)-7-[[2'-(1H- tetrazol-5-yl) (1, 1 ' -biphenyl) -4-yl]methyl] -1H-purine-2, 6 - dione;

8-propyl-3, 7-dihydro-1-propyl-3-methyl-7- [ [2 ' - (1H-tetrazol-5- yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-thione;

8-proρyl-3,7-dihydro-1,3-dipropyl-7-[[2'-(1H-tetrazol-5- yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-propyl-3,7-dihydro-1-methyl-3-isobutyl-7-[[2'-(1H-tetrazol-

5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-thione;

8-propyl-3,7-dihydro-1-methyl-3-(cyclopropyl-methyl)-7-[[2'-

(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- thione;

8-propyl-3,7-dihydro-3-propyl-7-[[2'-(lH-tetrazol-5-yl)(1,1'- biphenyl)-4-yl]methyl]-1H-purine-2,6-thione; and

8-propyy-3,7-dihydro-1-propyl-7-[[2'-(1H-tetrazol-5-yl)(1,1'- biphenyl)-4-yl]methyl]-1H-purine-2,6-thione.

A family of compounds of even more particular interest within Formula II consists of the following

compounds: 8-(buten-2-yl)-3,7-dihydro-1-methyl-3-propyl-7-[[2'-(1H- tetrazol-5-yl) (1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-butyl-3,7-dihydro-1,3-dimethyl-7-[[2'-(1H-tetrazol-5- yl) (1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-butyl-3,7-dihydro-1-methyl-3-propyl-7-[[2'-(1H-tetrazol-5- yl) (1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-butyl-3,7-dihydro-1-methyl-3-(cyclopropyl-methyl)-7-[[2'-

(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-propyl-3,7-dihydro-3-propyl-7-[[2'-(1H-tetrazol-5-yl) (1,1'- biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-propyl-3,7-dihydro-1-methyl-3-propyl-7-[[2'-(1H-tetrazol-5- yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-butyl-3,7-dihydro-1-methyl-7-[[2'-(1H-tetrazol-5-yl)(1,1'- biphenyl)-4-yl]methyl]-6-oxo-2-thioxo-1H-purine; and

8-butyl-3,7-dihydro-1-methyl-7-[[2'-(1H-tetrazol-5-yl)(1,1'- biphenyl)-4-yl]methyl]-1H-purine-2,6-dione. GENERAL SYNTHETIC PROCEDURES

The compounds of the invention can be synthesized in accordance to the following procedures which are modeled upon a subset of biphenylmethyl carboxylic acid or

biphenylmethyl tetrazole compounds of the family of compounds of Formula II. The reactions are performed in a solvent appropriate to the reagent and material employed and suitable to the transformation being performed. Some of the steps will involve reagents and substrates with functionality that will require protection. For the synthetic description and examples which follow, abbreviations which have been used have the following meanings:

CHCl ₃ = chloroform

DMF = dimethylformamide

DMSO = dimethylsulf oxide

g = gram

MeOH = methanol

min = minute

h = hour

mol = mole

mmol = millimole

mw = molecular weight

TIC = thin layer chromatography

Trt = trityl

AIBN = 2, 2 ' -azobisisobutyronitrile

KtBuO = potassium t-butoxide

Other abbreviations may be explained in the text. A. Synthesis of the xanthine nuclei.

A versatile general synthesis of the purines involves cyclization of the appropriate 4,5-diaminouracil to complete the purine ring. The cyclization of the appropriate aromatic diamine can be accomplished with a rather large number of reagents, ring closure of the purine ring can occur by the action of numerous reagents and the appropriate

4,5-diaminopyrimidine. The method of preparation of a

4,5-diaminopyrimidine followed by cyclization to give a purine is referred to as the Traube synthesis, since Wilhelm Traube was responsible for most of the early work. The starting 1,3-dialkyl-4,5-diaminouracil 4 have been prepared from N,N'-dialkylureas 1 and cyanoacetic acid. The condensation between N,N'-dialkylureas 1 and cyanoacetic acid to give the 1,3-dialkyl-4-aminourocil 2 is best performed by heating at a temperature between 30° and 80°C equimolecular amounts of the starting materials in the presence of two equivalents of acetic anhydride in acetic acid as solvent for several hours.

The formation of the 1,3-dialkyl-4-aminouracile 2 can also be catalyzed by a base such as sodium ethoxyde in a wet solvent such as ethanol. In the latter case, the reaction is normally brought about at reflux temperature of ethanol for 10-30 hours. Usually when R⁰ and R¹ have not the same value, a mixture of isomeric 1,3-dialkyl-aminouracile 2 is formed. The two isomeric compounds may be present in any ratio depending upon the nature of the R1, R2 substituants (J. H. Speer et al., J. Am . Chem. Soc., 75, 114-115, 1953). The aminouracile compounds can be converted to the corresponding 1,3-dialkyl-5-nitroso-4-aminouracile 3.

derivative by treatment of the uracile with an inorganic nitrite salt in a solvent or mixture of solvents such as water, alcohol, acetic acid, dimethylformamide or dioxane. The reaction is preferably performed at a temperature between 0°C and room temperature. The nitrosoaminouracile derivative 3 can be reduced to the 4,5-diamino uracile 4 with the help of hydrogen in the presence of a hydrogenation catalyst such as Raney nickel, platinum or palladium on charcoal, with metals such as iron, tin or zinc in the presence of an acid, with salt such as iron (II) sulfate, tin (II) chloride or with sodium dithionite or sodium hyposulfite in a solvent such as water, water/ethanol, methanol, glacial acetic acid, ethyl acetate or dimethylformamide at temperatures between 0°C and 50°C but preferably at a temperature around room temperature.

The subsequent cyclocondensation reaction toward the 1,3,8-trisubstituted xanthine 5 is carried out by heating at elevated temperatures, between 110° and 300°C, a mixture of one part of diaminouracile 4 wwith about four parts of a carboxylic acid of formula R-CO₂H (wherein R is the

substituant to be introduced at the 8 position of the

resulting xanthine). The reaction last for a period of time between 30 min and 48 hrs, depending on the temperature at which it is performed.

The preparation of xanthine 6 (Scheme 2) which is substituted with an hydride group on the N-l nitrogen, follows essentially the same procedure as described above in scheme 1 with the notable exception that the cyclization of a monoalkyl urea 7 to the aminouracile is better performed in the presence of a base, such as sodium ethoxide in an inert solvent such as ethanol. Advantageously, the reaction mixture is heated for several hours, if required to reflux under an inert anhydrous atmosphere to complete the reaction.

Another route to trialkylxanthine nuclei 5 is derived from the method reported by J. Donat and E. Carstens

(Cham . Bar., 92, 1500-1504, 1959). The treatment of

theophylline 8 with crotylbromide afford in modest yield

8-crotylitheophylline 9. The reaction is carried out with crotylbromide on chloride as the alkylating agent,

advantageously in a solvent or mixture of solvents such as methylene chloride, dioxane, water or dimethylformamide in the presence of a base such as an hydroxyde or a carbonate salt of an alkali, triethylamine or sodium hydride, preferably at temperatures between room temperature and 50°C. The double bond in 9 can be reduced to a single bond (as in 10),

preferably with hydrogen in the presence of a hydrogenation catalyst such as Raney Nickel, platinum or palladium on charcoal in a solvent such as ethanol, methanol, ethylacetate or acetic acid at temperatures ranging between 0°C and 50°C.

B. Synthesis of biphenyltetrazoly l derivatives

In Scheme 4, a biphenylcarboxylic acid ester 11 is converted to the cyanoderivative 12 by a method described by J. A. Krynitsky et al [org. Synth. Coll., 3, 698 (1955)] and J. Cason [Org. Synth. Coll., 3, 169 (1955)]. The acid obtained by saponification of ester 11 is transformed into the acid chloride which in turn is converted into the primary carboxamide eventually dehydrated to cyano derivative 12. The cyano derivative 12 is reacted by a 1,3-dipolar cycloaddition with trialkyltin azide to produce the corresponding tetrazole 13 as described by K. Sisido et al [J . organomgtal. Chem., 33, 337-46 (1971)]. The reaction is advantageously performed with an excess of the trialkyltin azide in refluxing toluene or dimethylformamide as inert solvent. The N-(trimethyl- stannyl) tetrazole 13 can be converted to the free tetrazole by bubbling dry gaseous hydrochloric acid in an ethereal or alcoholic solution or by treatment with aqueous sodium hydroxyde. Intermediate free tetrazole is reacted with an aralkylhalide, such as trityl chloride, which will provide a removable protecting group for the tetrazole. This reaction is best performed with trityl chloride in an inert solvent such as dichloromethane in the presence of at least one equivalent of a non-nucleophilic base such as pyridine or a trialkylamine. The bromination of 14 into the benzyl bromide 15 is performed with N-bromosuccinimide in the presence of AIBN or dibenzolyperoxide in an inert solvent such as carbon tetrachloride, the reaction medium being heated at a

temperature from 40°C to reflux of the solvent used. In some cases, it is advantageous to convert the cyanoderivative 12 into the corresponding 4-bromomethyl-2-cyano-biphenyl 16. The bromination is performed according to the procedures described above for the conversion of 14 to 15.

The 4-bromomethyl-2'-cyano-(1,1'biphenyl) derivative 16 may further be converted to the azide derivative 17 by heating at a temperature between 80°C and 120°C a mixture of 16 and of an inorganic azide salt in a high boiling solvent (preferably polar) or mixture of solvents such as dimethylformamide, toluene, xylene, N-methylpyrididone isopropanol or water. The azide 17 can be reduced to the amine 18 preferably with hydrogen in the presence of an hydrogenation catalyst such as platinum or palladium on charcoal in a solvent or mixture of solvents such as methanol, ethanol, chloroforme or acetic acid at temperatures ranging between 20°C and 50°C. C. Alkylation of the xanthine nuclei

The conversion of xanthine compounds to compound of Formula I is carried out by alkylation at the N-7 nitrogen with a derivative of type 15 as the alkylating agent (Scheme 6). The leaving group in 15 can be an halogen (with the exception of fluorine) group, a tosylate or a mesylate;

preferably a bromine atom is the leaving group. The reaction solvent can be methylene chloride, tetrahydrofurane, dioxane, water, dimethylformamide or dimethylsulfoxide and the presence of an acid binding agent such as sodium, potassium or cesium carbonate, sodium hydroxyde, triethylamine, potassium t- butoxyde, sodium hydride is required. The reaction is best performed at a temperature between 0°C and 120°C.

The alkylated xanthine derivative 17 can then be deprotected to the compounds of Formula II. A suitable method as described by Greene in "Protective Group in Organic

Synthesi s " Wiley-Interscience, 1980, can be used to remove the triphenylmethyl group. Such methods include hydrogenation in the presence of a catalyst such as palladium or platinum and hydrolysis under basic or acidic conditions. The reaction is performed in a solvent or a mixture of solvents such as acetone, water, glacial acetic acid, a lower alcohol

preferably at temperatures between 0°C and 100°C, for example at temperatures between room temperature and 50°C.

Another route to compounds of Formula II involves the alkylation with a biphenylnitrile derivative 16 of a xanthine derivative 5 or 10 (Scheme 6). The leaving group in 16 can be an halogen (with the exception of fluorine) group, a tosylate or a mesylate; preferably a bromine atom is the leaving group. The reaction solvent can be methylene

chloride, acetonitrile, tetrahydrofurane, dioxane, water. dimethylformamide or dimethylsulfoxide and the presence of an acid binding agent such as sodium, potassium or cesium carbonate, sodium hydroxyde, triethylamine, potassium

t-butoxyde, sodium hydride is required. The reaction is best performed at a temperature between 0°C and 120°C. The alkylated xanthine derivative 19 can then be transformed into a compound of Formula I by converting the . cyanide group into a tetrazole. Trialkyltinazide (K. Sisido, J. Organometal Chem., 33, 337-66, 1971) is preferably used in a high boiling temperature solvent.. The N(trimethylstanyl) intermediate is converted to the free tetrazole by the action of dilute acid. The tetrazole can also be generated by heating the cyanide derivative 19 with sodium oxide acid amonium chloride in dimethylformamide at a temperature close to reflux

temperature.

Another synthesis for compounds of Formula II utilizes the 4-amino-5-methoxycarbonyl-imidazole derivatives 24 as a pivotal intermediate. The imidazoles 24 are available from Thorpe-Ziegler cyclization of appropriate cyano

derivatives 23 as described in Scheme 5. N'- cyanoacetimidoester 21 are available from the reaction between an imidate hydrochloride 20 [P. Reynard and R. C. Moreau,

Bull. Soc. Chem. Fr., 2997, 1964] and cyanoamidine following the general procedures described by W. Lowski in Synthesis, 1971, 263 or K. R. Huffman and F. R. Schaefer in J. Org.

Chem., 28, 1816 (1963). From the reaction between the

cyanoimidate 21 and a 4-aminomethyl-2'-cyano-(1,1'-biphenyl) derivative, 18, the N' -cyanoamidine 22 is isolated. The reaction is advantageously carried out in a solvent or mixture of solvents such as methylene chloride, chloroforme, methanol, ethanol, acetonitrile or dimethylformamide in the presence of a non-nucleophilic inorganic base such as sodium carbonate or a tertiary organic base such as triethylamine. diisopropylethylamine or pyridine which may simultaneously act as the solvent, at temperatures between -25°C and 250°C, but preferably at temperatures between -10°C and the boiling point of the solvent which is used. Reaction between the

cyanoamidine 22 and α-bromo or α-chloro-ethylacetate in dimethylformamide or acetonitrile in the presence of a non- nucleophilic base such as potassium carbonate or trietlylamine at temperatures between 60-80°C (as described by K. Gewald and G. Heinhold in Monatshefte für Chemie, 107, 1413-21 (1976)) provide the N, N-dialkyl-N'-cyanoamidine 23. The derivative

23 can be converted to the 4-amino-5-alcoxycarbonyl-imidazole

24 under base catalysis. Preferably a base such as sodium or potassium alcoholate is used in a solvent or a mixture of solvents such as methanol, ethanol, t-butanol,

dimentylformamide or tetrahydrofurane at temperatures between 20°C and the boiling temperature of the solvent which is used.

The imidazole derivatives 24 are precursors to the xanthine derivatives 25. Reactions of 24 with isocyanate and thioisocyanite (R'-NCX wherein, R' and have the values in Formula I) take place very readily usually at temperatures ranging between 50°C and 150°C in solvents or mixture of solvents such as dimethylformamide, xylene, toluene preferably in the presence of a organic tertiary base such as

trietylamine or pyridine, which can also be used as solvent, and/or of a alkali salt of a lower alkyl alcohol. The xanthines 25 can be transformed into compounds of Formula II by transformations similar to those described in scheme 3.

SCHEME 1

i. NC-CH₂-CO₂H ii. HNO₂. iii. PtO₂, H₂. iv. C₄H₉CO₂H

SCHEME 2

i. NCCH2CO2H, NaOEth; HNO₂. ii. PtO₂, H₂. iii. C₄H₉CO₂H

SCHEME 3

i. Crotyl bromide; base. ii. Hydrogen gas 45psi; Pd on C. SCHEME 4

SCHEME 5

R⁰ andX² have the previously defined values of Formula I SCHEME 6

Formula II compound wherein R⁰, R¹ and R² have the previously defined values. The following examples are provided to illustrate the present invention and are not intended to limit the scope thereof. Those skilled in the art will readily understand that known variations of the conditions and processes of the following preparative procedures can be used to prepare these compounds. All temperatures expressed are in degrees centigrade.

Example 1

8-(2E-butenyl)-3,7-dihydro-1,3-dimethyl-7-[[2'-(1H-tetrazol-5- yl) [1,1'-biphenyl]-4-yl]methyl]-1H-purine-2,6-dione;

Step A: 8-crotyl-theophylline

A mixture of 60g sodium methylate, 180g theophylline and one liter of methanol was stirred for 2 hr at 40°C. After removal of the solvent in vacuo, 750 ml water and 150g crotyl bromide were added and the mixture was stirred for 6 hours. A precipitate is filtered off, washed with methanol. The methanol filtratre was concentrated to a solid which was recrystallized from boiling water to yield 4g of the desired product (m.p.: 230-235°C).

¹H NMR (CDCI₃, δppm): 5.7 (m, 2H); 3.65 (s, 3H);

3.6 (d, 2H); 3.45 (s, 3H); 1.95 (bs, 1H, exchangeable); 1.72 (m, 3H). Elemental analysis (Calcd for C₁₁H₁₄N₄O2, found):

C, 56.40, 56.23; H, 6.02, 5.98; N, 23.91, 23.69. Ste p B: 8-(2E-butenyl) -3,7-dihydro-1,3-dimethyl-7-[[2'-(N- triphenylmethyl-1H-tetrazol -5-yl) [1,1'-biphenyl]-4- yl]methyl]-1H-purine-2,6-dione An aliquot of 0.5g (2.1 mmol) of 8-crotyl- theophilline was dissolved in 35 ml of dry dimethylformamide and 2.3 ml of a 1N solution of potassium t-butoxide in tetrahydrofuran were added. After stirring at 25°C for 10 min., 1.6 g (2.8 mmol) of N-triphenylmethyl-5- [2(4'- bromomethylbiphenyl-2-yl] tetrazole were added at once. The mixture was stirred at 25°C for 16 hr. After removal of the solvents, the residue was partitioned between chloroform and water and the organic phase purified by chromatography on a silicagel column. (eluant: 10% ethyl acetate in

dichloromethane). The desired product was obtained in a yield of 65% (1g).

¹H NMR (CDCI₃, δ ppm): 7.95 (d, 1H, J_HH = 7 Hz); 7.45 (m, 2H); 7.5-6.95 (unresolved signals, 20H); 5.45 (m, 4H); 3.62 (s, 3H); 3.4 (s, 3H); 3.3 (d, 2H); 1.65 (d, 3H).

Step C: 8-(2E -butenyl)-3,7-dihydro-1,3-dimethyl-7-[[2'-91H- tetrazol -5-yl)[1,1'-biphenl] -4-yl]methyl]-1H-Purine-2,6-dione The protected tetrazole derivative isolated in step b was stirred for 16 hr in 25 ml acetic acid containing 10% water. After removal of the solvent, the residue was disolved in ethyl acetate and the desired product precipitated with hexane. The filtered solid (m.p. = 187.5-187.6°C) weighed 450 mg. ¹ H NMR (δ ppm, DMSO): 7.5-7.7 (unresolved signals; 4H); 7.11 (AB quartet, 4H0); 5.6 (s, 2H); 3.23 (s, 3H); 3.45 (s, 3H); 2.65 (t, 2H); 1.5 (m, 2H); 1.3 (m, 2H; 0.85 (t, 3H). FAB MS (M+H) : 469.

Elemental analysis (C₂₅ H₂₄N₈O₂)

C H N

Theory: 64.01 5.16 23.91

Found: 63.92 5.19 23.46

Example 2

8-butyl-3,7-dihydro-1,3-dimethyl-7-[[2'-(1H-tetrazol-5-yl) [1,1'-biphenyl]-4-yl]methyl]-1H-purine-2,6-dione;

Step A: 8-butyl-3,7-dihydro-1,3-di menthyl-7-1H-purine-2,6- dione

An aliquot of the 8-crothyl theophilline obtained in step a) of Example 4 was hydrogenated (3 hr, 45 psi H₂) in 200 ml C₂H₅OH and 0.8g of 10% Pd/C catalyst. After filtering out the catalyst, the crude product was identified as the desired material (m.p.: 232-235°C).

Step B: 8-butyl-3,7-dihydrom-1,3-dimethyl-7-[[2'-(N- triphenylmethyl-1H-tetrazol-5-yl) [1,1'-biphenyl]-4- yl]methyl]-1H-purine-2,6-dione.

A mixture of 0.5g (2.1 mmol) of 8-butyltheophylline (from step a), 25 ml dry dimethylformamide, and 2.4 ml in potassium t-butoxide in tetrahydrofuran were stirred for 10 min at 25°C. N-triphenylmethyl-5-[2(4'-bromomethylbiphenyl-2- yl] tetrazole (1.8g, 3.15 mmol at 70%) was added and the reaction stirred at 25°C for 16 hr. After removal of the solvents, the residue was chromatographyed on silicagel gel using 5% ethyl acetate in chloroform as the eluant. The product eluted after ~400 ml of eluate and isolated as an oil after removal of the solvent. ¹ H NMR (CDCI₃, δ ppm): 7.9 (d,

1H), 7.45 (m, 2H); 7.4-6.9 (unresolved signals; 20H); 5.45 (s, 2H); 3.6 (s, 3H); 3.4 (s, 3H); 2.6 (t, 2H); 1.6 9m, 2H); 1.3 (m, 2H; 1.85 (t, 3H).

The protected tetrazole derivative isolated in step b was stirred for 16 hr in 25 ml acetic acid containing 10% water. After removal of the solvent, the residue was disolved in ethyl acetate and the desired product precipitated with hexane. The filtered solid (m.p. = 187.5-187°C) weighed 450 mg.

¹H NMR (δ ppm, DMSO) : 7.5-7.7 (unresolved signals; 4H); 7.11 (AB quartet, 4H; 5.6 (s, 2H); 3.23 (s, 3H); 3.45 (s, 3H); 2.65 (t, 2H); 1.5 (m, 2H); 1.3 (m, 2H; 0.85 (t, 3H).

FAB MS (M+H) : 469.

Elemental analysis (C₂₅H₂₆N₈O₂)

C H N

Theory: 63.81 5.57 23.81

Found: 63.42 5.67 23.42

Example 3

8-butyl-3,7-dihydro-1-methyl-3-propyl-7-[[2'-(1H-tetrazol-5- yl) [1,1-biphenyl]-4-yl]methyl]-1H-purine-6-one-2-thione

This compound was prepared following the procedure of Example 2.

1H(NMR, 350 MH_z, CDCI₃): δ 8.05 (d, 1H); 7.6 (m,2H); 7.4

(d,1H); 7.2 (AB quartet; 1H); 5.55 (S,2H); 4.05 (t,2H); 3.3

(5,3n); 2.75 (t,2H); 1.75 (m;6H); 1.4 (m,3H); 0.95 (m, 6H). mp (0°) = 144.6-152.4.

FAB MS: 499. HRMS: calcd for C₂₇H₃₀N₈O₂ 499.2570 (M+H; found: 499.2563.

Example 4

8-butyl-3,7-dihydro-1-propyl-3-methyl-7-[[2'-(1H-tetrazol-5- yl) [1,1'-biphenyl]-4-yl]methyl-1H-purine-2,6-dione;

This compound was prepared in an analogous manner. ¹H NMR (350 MHz, CDCI₃) : δ 8.10 (d, 1H); 7.6 (m,2H); 7.4

(ol,2H); 7.2 (AB quartet; 4H); 7.55 (s,2H); 3.9 (t,2H); 3.9 (t,2H); 3.55 (t,2H); 1.7 (unresolved signals; 6H); 1.42 (m,2H); 0.95 (m, 6H). mp (°C) = 175.9 - 176.3.

FAB MS = 498.59 (M+H+).

Example 5

8-butyl-3, 7-dihydro-1, 3-diproρyl-7- [ [2 ' - (1H-tetrazol-5-yl) [1, 1 ' -biphenyl] -4-yl]methyl-1H-purine-2, 6-dione.

Step A: 1, 3-dipropyl-6-aminouracil Stoichiometric quantities (2.95g) of di-n- propylurea (5g) and of cyanoacetic acid were heated with 10ml of acetic anhydride and 10cc of acetic acid for three hours at 60°C. Acetic acid and excess anhydride were then removed under reduced pressure without raising the temperature of the reaction mixture. The residue was dissolved in about 100cc of water, made alkaline with sodium carbonate and boiled for about two hours. The products crystallized on cooling giving white solid collected by filtration. ¹H NMR (δ ppm, CDCI₃):

4.95 (1H, s); 3.85 (2H+2H,m); 1.7 (2H, m); 1.6 (2H, m); 1.0 (3H, t); 0.95 (3H, t). Step B: 1,3-dipropyl-5-nitroso-6-aminouracil

To an ice-cold solution of 4g of the 1,3-dipropyl- 6-aminouracil prepared as above in 40% HOAC, were added dropwise 2g of sodium nitrite in 10 mL of H₂O. The reaction mixture turned purple and after a few minutes a precipitate formed, which was filtered and dried to yield 4g of

nitrosouracil. Step C: 1,3-dipropyl-5,6-diamino uracil

A solution of 4g of 1,3-dipropyl-5-nitroso-6-amino uracil in was stirred under atm H₂ pressure over platinum oxide. After completion (1h) of hydrogenation, the catalyst was removed by filtration under nitrogen and the solvent evaporated in vacuo. The crystals were dried overnight in a vacuum dessicator, at 50°C. Yield: 3g.

Step D: 8-n-butyl-1,3-dipropyl xanthine,

A mixture of 3g of 1.3-dipropyl-5, 6-diaminouracil was heated at 150-160°C for 4 hrs. The reaction mixture was cooled to 25°C and aqueous solution of sodium hydrogeno carbonate was added until alkaline. A brown precipitate formed which was filtered, dried and recrystallized from hexane. This yielded lg of slightly yellow solid.

Step E : 8-buty -3,7-dihydro-1,3-dipropyl-7-([[2'-N- triphenylmethyl,-1H-tetrazol-5-yl) [1,1'-biphenyl]-4- yl]methyl]-1H-purine -2,6-dione.

A mixture of 1g of 8-n-butyl-1,3-dipropyl xanthine, 1g of 4-bromo methyl-2'-cyano-biphenyl acid and 1.5 gof potassium carbonate were stirred in 25ml acetonitrile at 60°C¹ for 12 hrs. The solids were removed by filtration, and the residue concentrated under vacuum. Chromatography on SiO₂ with a 3:7 mixture of ethylacetate:hexane provided 1.92g of a yellow oil.

¹H NMR (CDCl₃, δ ppm): 7.75 (d,1H); 7.65 (t, 1H); 7.55 (d, 2H, Jkh = 7Hz); 7.45 (m, 2H); 7.3 (d, 2H; JHH = 7Hz); 5.6 (S, 2H); 4.12 (t, 2H) 3.95 (t, 2H); 2.7 (t, 2H); 1.85 (m, 2H); 1.7 (m, 4H); 1.35 (m, 2H); 0.95 (m, 9H).

Step F: 8-buty -3.7-dihydro-1,3-dipropyl-7-[[2'-(1H-tetrazol-

5-yl) [1,1'-biphenyl]-4-yl]methyl-1H-purine-2,6-dione. To the product (1.92g) isolated in step e above, were added 1.2g of trimethyltinazide in 50 ml toluene. The mixture was stirred at reflux temperature for 4 days. The toluene was removed under vacuum and 50 ml ethanol were added. Dry gazeous HCl was bubbled through the solution for 15 min and let stir for 3 hrs. After aqueous work-up, the final product was chromatographied on SiO₂ with 5% ethylacetate in hexane and then 100% ethylacetate (chromatotron). The resulting oil was dissolved in 1% NaOH (80 ml) and then acidified to pH 4 with concentrated HCl under good stirring to obtain a white precepitate. The solids were collected by filtration and dried. Yield: 1.5g of a white powder (m.p. = 60 - 63°C).

Elemental analysis (C₂₉H₃₄N₈O₂.0.3 H₂O):

C H N

Theory: 65.46 6.55 21.06

Found: 65.22 6.51 20.33

¹ H NMR (CDCI₃ δ ppm): 8.1 (d, 1H, J_HH = 7Hz); 7.6 (m, 2H); 7.4 (d, 1H, J_HH = 7Hz); 7.15 (m, 4H); 5.5 (s, 2H); 4.1 (t, 2H); 3.9 (t, 2H); 2.7 (t, 2H); 1.8 (m, 2H) ; 1.7 (m, 4H); 1.4 (m, 2H); 0.95 (m, 9H).

Example 6

8-(2E-butenyl)-3,7-dihydro-1-methyl-3-isobutyl-7-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1H-purine-2,6-dione

This compound was prepared in a manner analogous to Example 2.

1H NMR(350 MHz, CDCI₃): δ 8.00 (d, 1H); 7.55 (m,2H); 7.4

(d,2H); 5.45 (s,2H); 3.9 (d,2H); 3.27 (s,3H); 2.15 (2H, 1H); 1.65 (m, 2H); 1.4 (m,2H); 0.9 (m, 9H).

mp (°C) = 165.1-166.3.

Elemental Analysis (C₂₈H₃₂N₈O₂)

C H N

Theory: 65.60 6.29 21.86

Found: 65.65 6.35 21.65 Example 7

8-butyl-3,7-dihydro-1-cyclopropylmethyl-3-methyl-7- [[2'-(1H- tetrazol-5-yl) [1,1'-biphenyl]-4-yl]methyl-1H-purine-2,6- dione.

Step A: 1(3)-methyl-3(1)cyclgpropylmethyl-6-amino uracil.

Cyanoacetic acid (32.5g, 0.38 mol), acetic

anhydride (1 mole, 102g) and N-isopropylmethyl-N'-methyl urea (50g, 0.38mol) were mixed in 120 ml glaceal acetic acid and stirred at 60°C for 3 hrs. The reaction mixture was

concentrated, 800ml H₂O and NaHCO₃ added to pH=8. The resulting mixture was stirred at 80°C for 3 hrs. Upon cooling tan crystals deposited which were filtered and dried. By TLC SiO₂ MeOH/CHCl₃ 1/10), this solid (50g; mp 86-99°C) was a mixture of the two isomers. ¹³ C ¹H NMR indicate a ratio about 2:1 in favor of the 1-cyclopropyl-3-methyl-isomer.

¹ H NMR (CDCl₃, δ ppm): 5.75 (bs, 2H); 4.75 (s, 1H); 3.6 (d, 2H); 3.05 (s, 3H); 1.0 (m, 1H); 0.05-0.15 (m, 5H). ¹³C (CDCI₃, δ ppm): 163.6; 154.9; 152.5; 77.4; 45.86; 28.091; 10.5; 4.1 (3-methyl-1-cyclopropylmethyl-6-aminouracil). ¹H NMR (CDCI₃ , δ ppm) : 5.75 (bs, 2H) ; 4 .75 (s, 1H) ; 3.55 (d, 2H) ; 3.15 (s, 3H) ; 1.0 (m, 1H) ; 0.05-0.15 (m, 5H) . ¹³C (CDCI₃, δ ppm): 163.5; 155.37; 152.6; 77.4; 45.58; 29.7; 10.3; 4.4-(1-methyl-3-cyclopropylmethyl-6-aminouracil).

Step B : 1(3)-methyl-3(1)-cyclopropylmethyl-5-nitroso-6- aminonracil

To an ice-cold solution of 10g (0.1 mole) of the mixture of isomeric amino uraciles isolated above in 40% acetic acid was added dropwise 7.6g (0.11 mole) of sodium nitrite in 10 ml water. The reaction mixture turned purple and after a few minutes a precipitate formed, which was filtered and dried to yield 19g of nitrosouracil.

Step C: 1(3)-methyl-3(1)-cyclopropylmethyl-5,6-diaminouracil To a suspension in 100 ml hot water of 10g (0.045 mole) of the mixture of isomers obtained in step a, 18g of sodium hydrosulfite were added. After a few minutes an additional 1.4g was added to complete discoloration of the solution. After standing 15 hr at 4°C, a tan precipitate was collected and air dried.

Step D: 8-butyl-3,7-dihydro -1(3)-methyl-3(1)-cyclopropyl- methyl-1H-purine-2,6-dione An aliquot (5g) of the diaminouracils from step e was stirred with 25 ml valeric acid at 160°C for 60 hr. The excess valeric acid was distilled off and diethyl ether added to the residue. A beige precipitate (2g) was collected, which identified as the 5-acylamino derivatives (J. Ruttink, Rec. Trav. Chim. 65, 751 (1946)). This solid was then stirred at 120°C in 40 ml sodium hydroxyde 30% for 1 hr. Water was added to dissolve most of the material. A small insoluble fraction was filtered off and acid was added to the filtrate (pH=3). The precipitate which formed was isolated and dried. Protron NMR still indicated the 2:1 mixture of isomers.

¹H NMR (CDCl₃, δ ppm): 4.05 + 3.95 (d + d, 2H); 3.65 + 3.47 (s + s; 3H); 2.87 (m, 2H); 1.8 (m, 2H), 1.4 (m, 2H).

Step E : 8-butyl -3,7-dihydro-3(1)-cyclopropylmethyl-1(3)- methyl-7-[[2'-(N-triphenylmethyl-1H-tetrazol-5-yl) [1,1'- biphenyl]-4-yplmethyl]-1H purine-2,6-dione A mixture of 555 mg (2 mmol) of the xanthine isomers mixture from step d, of 1.25g (2.1 mmol) of N- triphenylmethyl-5- [2- (4'-bromomethyl biphenyl-2-yl]tetrazole and 0.5g potassium carbonate (3.6 mmol) were stirred in 15 ml acetonitrile at 100-110°C for 3 hr. The solid were filtered off and the filtrate concentrated under vacuum. The resulting oil was chromatographied on SiO₂ with 2.5% ethylacetate in chloroforme which yielded 0.7g of the mixture of the two xanthine isomers. Step F: 8-butyl-3,7-dihyriro-3 (1) -cyclopropylmethyl-1 (3) - methyl-7-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yllmethyl]-

1H purine-p2,6-dione

The material isolted in step e was dissolved in 25 ml acetic acid containing 10% water. After stirring for 16 hr, the mixture was lyophilized and the resulting mixture purified by reverse phase high performance liquid

chromatography (C₁₈, Acetonitrile/water: 45/55). The first eluting isomer (130 mg, m.p. = 117-122°C) was identified as the 1-cyclopropylmethyl-3-methyl isomer on basis of the proton NMR spectrum. ¹H NMR (CDCl₃, δ ppm): 8.0 (d, 1H); 7.6 (m, 2H); 7.4 (d, 1H); 7.1 (m, 4H); 5.5 (s, 2H); 3.85 (d, 2H); 3.55 (s, 3H); 2.7 (t, 2H); 1.75 (m, 2H); 1.4 (m, 2H); 0.9 (t, 3H); 0.2 (m, 5H).

HRMS (C₂₈H₃₀O₂N₈):

Theory: 511.2570

Found: 511.2542;

Example 8

8-butyl-3,7-dihydro-1-methyl-3-cyclopropylmethyl-7-[[2'-(1H-tetrazol-5-yl) [1,1'-biphenyl]-4-yl]methyl-1H-purine-2,6- dione.

The slow eluting isomer of the mixture synthesized in Example 7 was isolated in a 110 mg. yield and characterized as follows: 1H NMR (CDCI₃, δ ppm): 8.05 (d, 1H); 7.6 (m, 2H);

7.4 (d, 1H); 7.15 (m, 4H); 5.5 (s, 2H); 4.05 (d, 2H); 3.3 (s, 3H); 2.7 (t, 2H); 1.75 (m, 2H); 1.4 (m, 2H); 0.9 (t, 3H); 0.25

(m, 5H).

HRMS (C₂₈H₃₀O₂N₈):

Theory: 511.2570

Found: 511.2595; Example 9

8-butyl-3,7-dihydro-1-methyl-3-phenyl-7-[[2'-(1H-tetrazol-5-yl) [1,1'-biphenyl]-4-yl]methyl]-1H-purine-2,6-dione;

This compound was prepared in an analogous manner to Example 2.

¹H NMR(350 MH_z, CDCI₃: δ 8.05 (d,2H); 7-7.6 (unresolved signals; 12H); 5.5 (s,2H); 3.3 (s,3H); 2.6 (t,2H); 1.6 (m,2H); 1.3 (m,2H); 0.45 (t,3H) .

mp (°C) = 125-128.

Elemental Analysis (C₃₀H₂₈O₂.0.1H₂O):

C H N

Theory: 65.44 5.49 20.35

Found: 65.22 5.23 20.03 Example 10

8-butyl-3,7-dihydro-3-propyl-7-[[2'-(1H-tetrazol-5-yl)[1,1' biphenyl]-4-yl]methyl]-1H-purine-2,6-dione;

¹H NMR (300 MHz, CDCI₃): δ 9.89 (S,1H), 7.90 (D, 1H), 7.45 (M,2H), 7.25 (M,1H), 6.95 (s,4H), 5.34 (s,2H), 4.00 (t,2H), 2.70 (t,2H), 1.88-1.60 (m, 4H), 1.40 (m,2H), 1.00-0.85 (m, 6H) mp (°C) = 203.2, 203.3, 204.8.

Example 11

8-propyl-3,7-dihydro-3-propyl-7-[[2'-(1H-tetrazol-5-yl) [1,1'- biphenyl]-4-yl]methyl]-1H-purine-2,6-dione;

¹H NMR (300 MHz, DMSO): δ 7.72-7.65 (m,2H), 7.60-7.50 (m,2H), 7.20-7.05 (dd,4H), 5.50 (s,2H), 3.88 (t,2H), 2.63 (t,2H), 1.68 (m,2H), 1.55 (m,2H), 0.87 (m, 6H) . mp (°C) = 228.3-228.5 HRMS (C₂₆H₂₈N₈O₂, M + H).

Theory: 471.2257

Found: 471.2291

Example 12

8-propyl-3,7-dihydro-1-methyl-3-propyl-7-[[2'-(1H-tetrazol-5- yl) [1,1'-biphenyl]-4-yl]methyl]-1H-purine-2,6-dione;

¹H NMR (300 MHz, DMSO): δ 7.75-7.50 (m, 4H), 7.20-7.04 (dd, 4H), 5.59 (s,2H), 3.95 (t,2H), 3.25 (s,3H), 2.65 (t,2H), 1.73 (m,2H), 1.58 (m,2H), 0.90 (m, 6H) . mp (°C) = 122.6-122.7 mp (°C) : 122.6-122.7

Elemental Analysis (C₂₆H₂₈N₈O₂.1.25H₂O):

C H N

Theory: 61.61 6.02 22.10

Found: 61.82 6.15 21.78

BIOLOGICAL EVALUATION

Assay A: Angiotensin II Binding Activity Compounds of the invention were tested for ability to bind to the smooth muscle angiotensin II receptor using a rat uterine membrane preparation. Angiotensin II (All) was purchased from Peninsula Labs. ¹²⁵I-angiotensin II (specific activity of 2200 Ci/mmol) was purchased from Du Pont-New England Nuclear. Other chemicals were obtained from Sigma Chemical Co. This assay was carried out according to the method of Douglas et al [Endocrinology, 106, 120-124 (1980)].

Rat uterine membranes were prepared from fresh tissue. All procedures were carried out at 4°C. Uteri were stripped of fat and homogenized in phosphate-buffered saline at pH 7.4 containing 5 mM EDTA. The homogenate was centrifuged at 1500 x g for 20 min., and the supernatant was recentrifuged at

100,000 x g for 60 min. The pellet was resuspended in buffer consisting of 2 mM EDTA and 50 mM Tris-HCl (pH 7.5) to a final protein concentration of 4 mg/ml. Assay tubes were charged with 0.25 ml of a solution containing 5 mM MgCl₂, 2 mM EDTA,

0.5% bovine serum albumin, 50 mM Tris-HCl, pH 7.5 and ¹²⁵I-AII (approximately 10⁵ cpm) in the absence or in the presence of unlabelled ligand. The reaction was initiated by the addition of membrane protein and the mixture was incubated at 25°C for 60 min. The incubation was terminated with ice-cold 50 mM Tris-HCl (pH 7.5) and the mixture was filtered to separate membrane-bound labelled peptide from the free ligand. The incubation tube and filter were washed with ice-cold buffer. Filters were assayed for radioactivity in a Micromedic gamma counter. Nonspecific binding was defined as binding in the presence of 10 μM of unlabelled All. Specific binding was calculated as total binding minus nonspecific binding. The receptor binding affinity of an All antagonist compound was indicated by the concentration (IC₅₀) of the tested All antagonist which gives 50% displacement of the total

specifically bound ¹²⁵I-AII from the high affinity All receptor. Binding data were analyzed by a nonlinear least- squares curve fitting program. Results are reported in

Table I.

Assay B: In Vitro Vascular Smooth Muscle-Response for All

The compounds of the invention were tested for antagonist activity in rabbit aortic rings. Male New Zealand white rabbits (2-2.5 kg) were sacrificed using an overdose of pentobarbital and exsanguinated via the carotid arteries. The thoracic aorta was removed, cleaned of adherent fat and connective tissue and then cut into 3-mm ring segments. The endothelium was removed from the rings by gently sliding a rolled-up piece of filter paper into the vessel lumen. The rings were then mounted in a water-jacketed tissue bath, maintained at 37°C, between moveable and fixed ends of a stainless steel wire with the moveable end attached to an FT03 Grass transducer coupled to a Model 7D Grass Polygraph for recording isometric force responses. The bath was filled with 20 ml of oxygenated (95% oxygen/5% carbon dioxide) Krebs solution of the following composition (mM) : 130 NaCl, 15

NaHCO₃, 15 KCl, 1.2 NaH₂PO₄, 1.2 MgSO₄, 2.5 CaCl₂, and 11.4 glucose. The preparations were equilibrated for one hour before approximately one gram of passive tension was placed on the rings. Angiotensin II concentration-response curves were then recorded (3 X 10^-10 to 1 X 10^-5 M). Each concentration of All was allowed to elicit its maximal contraction, and then All was washed out repeatedly for 30 minutes before

rechallenging with a higher concentration of All. Aorta rings were exposed to the test antagonist at 10^-5 M for 5 minutes before challenging with All. Adjacent segments of the same aorta ring were used for all concentration-response curves in the presence or absence of the test antagonist. The

effectiveness of the test compound was expressed in terms of pA₂ values and were calculated according to H.O. Schild [Br. J. Pharmacol. Chemother., 2,189-206 (1947)]. The pA₂ value is the concentration of the antagonist which increases the EC₅₀ value for All by a factor of 2. Each test antagonist was evaluated in aorta rings from two rabbits. Results are reported in Table I.

Assay C: In Vivo Intraduodenal Pressor Assay Response for All Αntagonists

Male Sprague-Dawley rats weighing 225-300 grams were anesthetized with Inactin (100 mg/kg, i.p.) and catheters were implanted into the trachea, femoral artery, femoral vein and duodenum. Arterial pressure was recorded from the femoral artery catheter on a Gould chart recorder (Gould, Cleveland, OH). The femoral vein catheter was used for injections of angiotensin II, mecamylamine and atropine. The tracheal catheter allows for airway patency, and the duodenal catheter was used for intraduodenal (i.d.) administration of test compounds. After surgery, the rats were allowed to

equilibrate for 30 minutes. Mecamylamine (3 mg/kg, 0.3 ml/kg) and atropine (400 ug/kg, 0.3 ml/kg) were then given i.v. to produce ganglion blockade. These compounds were administered every 90 minutes throughout the test procedure. Angiotensin II was given in bolus doses i.v. (30 ng/kg in saline with 0.5% bovine serum albumin, 0.1 ml/kg) every 10 minutes three times or until the increase in arterial pressure produced was within 3 mmHg for two consecutive All injections. The last two All injections were averaged and were taken as the control All pressor response. Ten minutes after the final control All injection, the test compound (dissolved in sodium bicarbonate) was administered i.d. at a dose of 30 mg/kg in a volume of 0.2 ml. Angiotensin II injections were then given 5, 10, 20, 30, 45, 60, 75, 90, and 120 minutes after administration of the test compound and response of arterial pressure was monitored. The response to All was calculated as percent of the control response and then the percent inhibition is calculated as 100 minus the percent control response. Duration of action of a test compound was defined as the time from peak percent inhibition to 50% of peak. One compound at one dose was tested in each rat. Each test compound was tested in two rats and the values for the two rats were averaged. Results are reported in Table I.

NT = NOT TESTED

¹Assay A: Angiotensin II Binding Activity

2Assay B: In Vitro Vascular Smooth Muscle Response

³Assay C: In Vivo Intraduodenal Pressor Response

Also embraced within this invention is a class of pharmaceutical compositions comprising one or more compounds of Formula II in association with one or more non-toxic, pharmaceutically acceptable carriers and/or diluents and/or adjuvants (collectively referred to herein as "carrier" materials) and, if desired, other active ingredients. The compounds of the present invention may be administered by any suitable route, preferably in the form of a pharmaceutical composition adapted to such a route, and in a dose effective for the treatment intended. Therapeutically effective doses of the compounds of the present invention required to prevent or arrest the progress of the medical condition are readily ascertained by one of ordinary skill in the art. The compounds and composition may, for example, be administered intra- vascularly, intraperitoneally, subcutaneously, intramuscularly or topically.

For oral administration, the pharmaceutical composition may be in the form of, for example, a tablet, capsule, suspension or liquid. The pharmaceutical composition is preferably made in the form of a dosage unit containing a particular amount of the active ingredient. Examples of such dosage units are tablets or capsules. These may with advantage contain an amount of active ingredient from about 1 to 250 mg, preferably from about 25 to 150 mg. A suitable daily dose for a mammal may vary widely depending on the condition of the patient and other factors. However, a dose of from about 0.01 to 3000 mg/kg body weight, particularly from about 1 to 100 mg/kg body weight, may be appropriate.

The active ingredient may also be administered by injection as a composition wherein, for example, saline, dextrose or water may be used as a suitable carrier. A

suitable daily dose is from about 0.01 to 100 mg/kg body weight injected per day in multiple doses depending on the disease being treated. A preferred daily dose would be from about 1 to 30 mg/kg body weight. Compounds indicated for prophylactic therapy will preferably be administered in a daily dose generally in a range from about 0.1 mg to about 100 mg per kilogram of body weight per day. A more preferred dosage will be a range from about 1 mg to about 100 mg per kilogram of body weight. Most preferred is a dosage in a range from about 1 to about 50 mg per kilogram of body weight per day. A suitable dose can be administered, in multiple subdoses per day. These sub-doses may be administered in unit dosage forms. Typically, a dose or sub-dose may contain from about 1 mg to about 100 mg of active compound per unit dosage form. A more preferred dosage will contain from about 2 mg to about 50 mg of active compound per unit dosage form. Most preferred is a dosage form containing from about 3 mg to about 25 mg of active compound per unit dose.

The dosage regimen for treating a disease condition with the compounds and/or compositions of this invention is selected in accordance with a variety of factors, including the type, age, weight, sex and medical condition of the patient, the severity of the disease, the route of

administration, and the particular compound employed, and thus may vary widely.

For therapeutic purposes, the compounds of this invention are ordinarily combined with one or more adjuvants appropriate to the indicated route of administration. If administered per os, the compounds may be admixed with lactose, sucrose, starch powder, cellulose esters of alkanoic acids, cellulose alkyl esters, talc, stearic acid, magnesium stearate, magnesium oxide, sodium and calcium salts of phosphoric and sulfuric acids, gelatin, acacia gum, sodium alginate, polyvinylpyrrolidone, and/or polyvinyl alcohol, and then tableted or encapsulated for convenient administration. Such capsules or tablets may contain a controlled-release formulation as may be provided in a dispersion of active compound in hydroxypropylmethyl cellulose. Formulations for parenteral administration may be in the form of aqueous or non-aqueous isotonic sterile injection solutions or

suspensions. These solutions and suspensions may be prepared from sterile powders or granules having one or more of the carriers or diluents mentioned for use in the formulations for oral administration. The compounds may be dissolved in water, polyethylene glycol, propylene glycol, ethanol, corn oil, cottonseed oil, peanut oil, sesame oil, benzyl alcohol, sodium chloride, and/or various buffers. Other adjuvants and modes of administration are well and widely known in the

pharmaceutical art.

Although this invention has been described with respect to specific embodiments, the details of these

embodiments are not to be construed as limitations.

Claims

What Is Claimed Is : 1. A compound of Formula I:

wherein m is a number selected from one to four, inclusive; wherein the dotted line between seven- and eight-positions and the eight- and nine-positions represents optionally a double bond; wherein each of X¹ and X² is independently selected from oxygen atom and sulfur atom; wherein each of R⁰ and R¹ is independently selected from hydrido, alkyl, hydroxyalkyl, haloalkyl, cycloalkyl,

cycloalkylalkyl, aralkyl, aryl, aroylalkyl, alkylalkoxyalkyl, alkylcarbonyl, alkylcarbonylalkyl, alkylcarbonyloxyalkyl, alkoxycarbonylalkyl, alkenyl, cycloalkenyl, aralkoxycarbonyl, alkynyl, cyanoalkyl, aminoalkyl, monoalkylaminoalkyl,

dialkylaminoalkyl, mercaptoalkyl, mercaptocarbonylalkyl, mercaptothiocarbonylalkyl, alkylthiocarbonylalkyl,

alkylthiothiocarbonylalkyl, arylthiocarbonylalkyl,

arylthiothiocarbonylalkyl, aralkylthiocarbonylalkyl,

alkylthiocarbonyl, alkylsulfinyl, alkylsulfonyl,

aralkylsulfinyl, aralkylsulfonyl, arylsulfinyl, arylsulfonyl, heteroaryl having one or more ring atoms selected from oxygen, sulfur and nitrogen atoms, and radicals of the formula

wherein X is oxygen atom or sulfur atom with z being a number selected from one to four, inclusive; wherein each of R¹² and R¹³ is independently selected from hydrido, alkyl, cycloalkyl, cyano, amino, monoalkylamino, dialkylamino, hydroxyalkyl, cycloalkylalkyl, alkoxyalkyl, aralkyl and aryl, and wherein R¹² and R¹³ taken together may form a heterocyclic group having five to seven ring members including the nitrogen atom of said amido radical and which heterocyclic group may further contain one or more hetero atoms as ring members selected from oxygen, nitrogen and sulfur atoms and which heterocyclic group may be saturated or partially unsaturated; wherein each of R² through R¹¹ is independently selected from hydrido, alkyl, hydroxyalkyl, halo, haloalkyl, cycloalkyl, cycloalkylalkyl, cycloalkylhaloalkyl, cycloalkylcarbonyl, formyl, alkoxy, aralkyl, aralkylhaloalkyl, aryl, aroyl, aryloxy, aryloxyalkyl, aralkoxy, alkoxyalkyl, alkylcarbonyl, alkylcarbonylalkyl, alkoxycarbonyl, alkenyl, cycloalkenyl, alkynyl, cyano, nitro, carboxyl, carboxyalkyl,

alkylcarbonyloxy, alkylcarbonyloxyalkyl, alkoxycarbonylalkyl, aralkoxycarbonylalkyl, aralkylcarbonyloxyalkyl,

aralkylthiocarbonylthio, alkylthiocarbonyl,

aralkylthiocarbonylthio, mercapto, alkylsulfinyl,

alkylsulfonyl, aralkylsulfinyl, aralkylsulfonyl, arylsulfinyl, arylsulfonyl, phthalimido, phthalimidoalkyl, heteroaryl, heteroarylalkyl, cycloheteroalkyl, cycloheteroalkylalkyl and cycloheteroalkylcarbonylalkyl wherein each of said heteroaryl- and cyclohetero-containing groups has one or more ring atoms selected from oxygen, sulfur and nitrogen atoms, and wherein each of R² through R¹¹ may be further independently selected from amino and amido radicals of the formula K

wherein X is oxygen atom or sulfur atom; wherein each r is a number independently selected from zero to six, inclusive; wherein each of R¹⁴ through R²⁶ is independently selected from hydrido, alkyl, cycloalkyl, cyano, amino, monoalkylamino, dialkylamino, hydroxyalkyl, cycloalkylalkyl, alkoxyalkyl, aralkyl and aryl, and wherein R¹⁴ and R¹⁵ taken together, R¹⁶ and R¹⁷ taken together, R¹⁸ and R¹⁹ taken together, R²¹ and R²² taken together and R²³ and R²⁴ taken together may each form a heterocyclic group having five to seven ring members including the nitrogen atom of said amino or amido radical and which heterocyclic group may further contain one or more hetero atoms as ring members selected from oxygen, nitrogen and sulfur atoms and which heterocyclic group may be saturated or partially unsaturated; and wherein each of R³ through R¹¹ may be further

independently selected from hydroxy and acidic moieties of the formula

-Y_nA wherein n is a number selected from zero through three, inclusive, and wherein A is an acidic group selected to contain at least one acidic hydrogen atom, and the amide, ester and salt derivatives of said acidic moieties;

wherein Y is a spacer group independently selected from one or more of alkyl, cycloalkyl, cycloalkylalkyl, alkenyl, alkynyl, aryl, aralkyl and heteroaryl having one or more ring atoms selected from oxygen, sulfur and nitrogen atoms; and wherein any of the foregoing R¹ through R²⁶, Y and A groups having a substitutable position may be substituted by one or more groups independently selected from hydroxy, alkyl, alkenyl, alkynyl, aralkyl, hydroxyalkyl, haloalkyl, halo, oxo, alkoxy, aryloxy, aralkoxy, aralkylthio, alkoxyalkyl,

cycloalkyl, cycloalkylalkyl, aryl, aroyl, cycloalkenyl, cyano, cyanoamino, nitro, alkylcarbonyloxy, alkoxycarbonyloxy, alkylcarbonyl, alkoxycarbonyl, aralkoxycarbonyl, carboxyl, mercapto, mercaptocarbonyl, alkylthio, arylthio,

alkylthiocarbonyl, alkylsulfinyl, alkylsulfonyl,

haloalkylsulfonyl, aralkylsulfinyl, aralkylsulfonyl,

arylsulfinyl, arylsulfonyl, heteroaryl having one or more ring atoms selected from oxygen, sulfur and nitrogen atoms, and amino and amido radicals of the formula

wherein D is selected from oxygen atom and sulfur atom and R³² is selected from hydrido, alkyl, cycloalkyl, cycloalkylalkyl, aralkyl and aryl; wherein each of R²⁷, R²⁸, R²⁹, R³⁰, R³¹, R³³ and R³⁴ is independently selected from hydrido, alkyl, cycloalkyl, cyano, hydroxyalkyl, haloalkyl, cycloalkylalkyl, alkoxyalkyl, alkylcarbonyl, alkoxycarbonyl, carboxyl,

alkylsulfinyl, alkylsulfonyl, arylsulfinyl, arylsulfonyl, haloalkylsulfinyl, haloalkylsulfonyl, aralkyl and aryl, and wherein each of R²⁷, R²⁸, R²⁹, R³⁰, R³¹, R³³ and R³⁴ is further independently selected from amino and amido radicals of the formula

wherein X is oxygen atom or sulfur atom;

wherein each of R³⁵, R³⁶, R³⁷, R³⁸, R³⁹ and R⁴⁰ is

independently selected from hydrido, alkyl, cycloalkyl, cyano, hydroxyalkyl, cycloalkylalkyl, alkoxyalkyl, haloalkylsulfinyl, haloalkylsulfonyl, aralkyl and aryl, and wherein each of R²⁸ and R²⁹ taken together and each of R³⁰ and R³¹ taken together may form a heterocyclic group having five to seven ring members including the nitrogen atom of said amino or amido radical, which heterocyclic group may further contain one or more hetero atoms as ring members selected from oxygen, nitrogen and sulfur atoms and which heterocyclic group may be saturated or partially unsaturated; with the proviso that R⁰, R¹, and R² cannot all simultaneously be hydrido; or a tautomer thereof or a pharmaceutically-acceptable salt thereof.

2. Compound of Claim 1 of Formula II:

wherein m is one; wherein each of X¹ and X² is independently selected from oxygen atom and sulfur atom; wherein each of R⁰ and R¹ is independently selected from hydrido, alkyl,

hydroxyalkyl, haloalkyl, cycloalkyl, cycloalkylalkyl, aralkyl, aryl, alkoxyalkyl, mercaptoalkyl, alkoxycarbonylalkyl, alkylcarbonyloxyalkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkynyl, alkylsulfonyl, aralkylsulfonyl, arylsulfonyl, heteroaryl having one or more ring atoms selected from oxygen, sulfur and nitrogen atoms, and amido radicals of the formula

cycloalkylhaloalkyl, cycloalkylcarbonyl, alkoxy, aralkyl, aralkylhaloalkyl, aryl, aroyl, aryloxy, aryloxyalkyl,

aralkoxy, alkoxyalkyl, alkylcarbonyl, alkoxycarbonyl, alkenyl, cycloalkenyl, alkynyl, cycloalkynyl, cyano, nitro, carboxyl, carboxyalkyl, alkylcarbonyloxy, alkylcarbonyloxyalkyl, alkoxycarbonylalkyl, aralkoxycarbonylalkyl,

aralkylcarbonyloxyalkyl, mercaptocarbonyl,

mercaptothiocarbonyl, mercaptoalkyl, alkoxycarbonyloxy, alkylthio, cycloalkylthio, cycloalkylalkylthio,

alkylthiocarbonyl, alkylcarbonylthio, alkylthiocarbonyloxy, alkylthiocarbonylthio, alkylthiothiocarbonyl,

alkylthiothiocarbonylthio, arylthio, arylthiocarbonyl, arylcarbonylthio, arylthiocarbonyloxy, arylthiocarbonylthio, arylthiothiocarbonyl, arylthiothiocarbonylthio, aralkylthio, aralkylthiocarbonyl, aralkylcarbonylthio,

aralkylthiocarbonyloxy, aralkylthiocarbonylthio,

aralkylthiocarbonyl, aralkylthiocarbonylthio, mercapto, alkylsulfinyl, alkylsulfonyl, aralkylsulfinyl. aralkylsulfonyl, arylsulfinyl, arylsulfonyl, phthalimido, phthalimidoalkyl, heteroaryl, heteroarylalkyl,

cycloheteroalkyl, cycloheteroalkylalkyl and

cycloheteroalkylcarbonylalkyl wherein each of said heteroaryl- and cycloheteroalkyl-containing groups has one or more hetero ring atoms selected from oxygen, sulfur and nitrogen atoms, and wherein each of R² through R¹¹ may be further

independently selected from amino and amido radicals of the formula

wherein X is selected from oxygen atom or sulfur atom; wherein each r is a number independently selected from zero to six, inclusive; wherein each of R¹⁴ through R²⁶ is independently selected from hydrido, alkyl, cycloalkyl, cyano, amino, monoalkylamino, dialkylamino, hydroxyalkyl, cycloalkylalkyl, alkoxyalkyl, aralkyl and aryl; wherein each of R³ through R¹¹ is independently selected from hydrido, hydroxy, alkyl, hydroxyalkyl, halo, haloalkyl, cycloalkyl, cycloalkylalkyl, alkoxy, aralkyl, aryl, aroyl, aryloxy, aralkoxy, alkoxyalkyl, alkylcarbonyl, alkoxycarbonyl, alkenyl, cycloalkenyl, alkynyl, cycloalkynyl, cyano, nitro, carboxyl, alkylcarbonyloxy, mercaptocarbonyl,

mercaptothiocarbonyl, alkoxycarbonyloxy, alkylthio. alkylthiocarbonyl, alkylcarbonylthio, alkylthiocarbonyloxy, alkylthiocarbonylthio, alkylthiothiocarbonyl, arylthio, arylthiocarbonyl, arylcarbonylthio, arylthiocarbonyloxy, arylthiothiocarbonyl, aralkylthio, aralkylthiocarbonyl, aralkylcarbonylthio, aralkylthiocarbonyloxy,

aralkylthiocarbonylthio, aralkylthiocarbonyl,

aralkylthiocarbonylthio, mercapto, alkylsulfonyl,

aralkylsulfonyl and arylsulfonyl, and amino and amido radicals of the formula

wherein X is oxygen atom or sulfur atom;

wherein each of R¹⁴, R¹⁵, R¹⁶, R¹⁷, R¹⁸ and R¹⁹ is

independently selected from acidic moieties of the formula

-Y_nA wherein n is a number selected from zero through three, inclusive; wherein A is an acidic group selected from acids containing one or more atoms selected from oxygen, sulfur, phosphorus and nitrogen atoms, and wherein said acidic group is selected to contain at least one acidic hydrogen atom, and the amide, ester and salt derivatives of said acidic moieties; wherein Y is a spacer group independently selected from one or more of alkyl, cycloalkyl, cycloalkylalkyl, alkenyl, alkynyl, aryl, aralkyl and heteroaryl having one or more ring atoms selected from oxygen, sulfur and nitrogen atoms; and wherein any of the foregoing R¹ through R²⁶, Y and A groups having a substitutable position may be substituted by one or more groups independently selected from hydroxy, alkyl, alkenyl, aralkyl, hydroxyalkyl, halo, haloalkyl, oxo, alkoxy, aryloxy, aralkoxy, alkoxyalkyl, alkylcarbonyl, alkoxycarbonyl, carboxyl, cyano, nitro, alkylsulfonyl, haloalkylsulfonyl, aryl, aralkyl, mercaptocarbonyl, alkylthio and

alkylthiocarbonyl, and amino and amido radicals of the formula

wherein D is selected from oxygen atom and sulfur atom, and R³² is selected from hydrido, alkyl, cycloalkyl,

cycloalkylalkyl, aralkyl and aryl; wherein each of R²⁷, R²⁸, R²⁹, R³⁰, R³¹, R³³ and R³⁴ is independently selected from hydrido, alkyl, cycloalkyl, cyano, hydroxyalkyl, haloalkyl, cycloalkylalkyl, alkoxyalkyl, alkanoyl, alkoxycarbonyl, carboxyl, haloalkylsulfinyl, haloalkylsulfonyl, aralkyl and aryl; or a tautomer thereof or a pharmaceutically-acceptable salt thereof.

3. Compound of Claim 2 wherein m is one; wherein each of X¹ and X² is independently selected from oxygen atom and sulfur atom; wherein each of R⁰ and R¹ is independently selected from hydrido, alkyl, hydroxyalkyl, mercaptoalkyl, haloalkyl, cycloalkyl, cycloalkylalkyl, aralkyl, aryl, alkoxyalkyl, alkoxycarbonylalkyl, alkylcarbonyloxyalkyl, alkenyl, cycloalkenyl, alkynyl and cycloalkynyl; wherein R² is selected from alkyl, hydroxyalkyl, halo, haloalkyl, cycloalkyl, cycloalkylalkyl, cycloalkylhaloalkyl, cycloalkylcarbonyl, alkoxy, aralkyl, aralkylhaloalkyl, aryl, aroyl, aryloxy, aryloxyalkyl, aralkoxy, alkoxyalkyl,

alkylcarbonyl, alkoxycarbonyl, alkenyl, cycloalkenyl, alkynyl, cycloalkynyl, cyano, nitro, carboxyl, carboxyalkyl,

alkylcarbonyloxy, mercaptocarbonyl, alkoxycarbonyloxy, alkylcarbonyloxyalkyl, alkoxycarbonylalkyl,

aralkoxycarbonylalkyl, aralkylcarbonyloxyalkyl, alkylthio, cycloalkylthio, cycloalkylalkylthio, arylthio, aralkylthio, aralkylthiocarbonylthio, mercapto, alkylsulfinyl,

alkylsulfonyl, aralkylsulfinyl, aralkylsulfonyl, arylsulfinyl, arylsulfonyl, phthalimido, phthalimidoalkyl, heteroaryl, heteroarylalkyl, cycloheteroalkyl, cycloheteroalkylalkyl and cycloheteroalklylcarbonylalkyl wherein each of said

heteroaryl- and cycloheteroalkyl-containing groups has one or more hetero ring atoms selected from oxygen, sulfur and nitrogen atoms, and wherein R² may be further selected from amino and amido radicals of the formula

wherein X is selected from oxygen atom or sulfur atom; wherein each r is a number independently selected from zero to six, inclusive; wherein each of R¹⁴ through R²⁶ is independently selected from hydrido, alkyl, cycloalkyl, cyano, amino, monoalkylamino, dialkylamino, hydroxyalkyl, cycloalkylalkyl, alkoxyalkyl, aralkyl and aryl; wherein each of R³ through R¹¹ is independently selected from hydrido, hydroxy, alkyl, hydroxyalkyl, halo, haloalkyl, cycloalkyl, alkoxy, aralkyl, aryl, aroyl, aryloxy, aralkoxy, alkoxyalkyl, alkylcarbonyl, alkoxycarbonyl, alkenyl,

cycloalkenyl, alkynyl, cyano, nitro, carboxyl,

alkylcarbonyloxy, mercaptocarbonyl, alkoxycarbonyloxy, alkylthio, arylthio, aralkylthio, mercapto, alkylsulfonyl, aralkylsulfonyl and arylsulfonyl, and amino and amido radicals of the formula

wherein each of R¹⁴, R¹⁵, R¹⁶, R¹⁷, R¹⁸ and R¹⁹ is

independently selected from hydrido, alkyl, cycloalkyl, cyano, amino, monoalkylamino, dialkylamino, hydroxyalkyl,

cycloalkylalkyl, alkoxyalkyl, aralkyl and aryl; and wherein each of R³ through R¹¹ may be further

independently selected from acidic moieties of the formula

wherein each W is independently selected from oxygen atom, sulfur atom and NR³⁹; wherein each of R³⁵, R³⁶, R³⁷, R³⁸ and

R³⁹ is independently selected from hydrido, alkyl, haloalkyl, haloalkylsulfonyl, haloalkylcarbonyl,

cycloalkyl, cycloalkylalkyl, aryl and aralkyl; wherein each of

R³⁵, R³⁶, R³⁷ and R³⁹ may be further independently selected from amino radical of the formula

wherein each of R⁴⁰ and R⁴¹ is independently selected from hydrido, alkyl, cycloalkyl, hydroxyalkyl, haloalkyl,

cycloalkylalkyl, alkoxyalkyl, aralkyl and aryl, and wherein R⁴⁰ and R⁴¹ taken together may form a heterocyclic group having five to seven ring members including the nitrogen atom of said amino radical, which heterocyclic group may further contain one or more hetero atoms as ring members selected from oxygen, nitrogen and sulfur atoms and which heterocyclic group may be saturated or partially unsaturated; wherein R⁴⁰ and R⁴¹ taken together may form an aromatic heterocyclic group having five ring members including the nitrogen atom of said amino radical and which aromatic heterocyclic group may further contain one or more hetero atoms as ring atoms selected from oxygen, nitrogen and sulfur atoms; wherein each of R³⁶ and R³⁷ may be further independently selected from hydroxy, alkoxy, alkylthio, aryloxy, arylthio, aralkylthio and aralkoxy; and the amide, ester and salt derivatives of said, acidic groups; wherein said bioisostere of carboxylic acid may be further selected from heterocyclic acidic groups consisting of heterocyclic rings of four to about nine ring members, which heterocyclic ring contains at least one hetero atom selected from oxygen, sulfur and nitrogen atoms, which heterocyclic ring may be saturated, fully unsaturated or partially

unsaturated, and which heterocyclic ring may be attached at a single position selected from R³ through R¹¹ or may be attached at any two adjacent positions selected from R³ through R¹¹ so as to form a fused-ring system with one of the phenyl rings of Formula II; and the amide, ester and salt derivatives of said heterocyclic acidic groups; wherein Y is a spacer group independently selected from one or more of alkyl, cycloalkyl, cycloalkylalkyl, alkenyl, aryl and aralkyl; and wherein any of the foregoing R¹ through R²⁶ and R³⁵ through R⁴¹, Y and A groups having a substitutable position may be substituted by one or more groups independently

selected from hydroxy, alkyl, alkenyl, aralkyl, hydroxyalkyl, halo, oxo, haloalkyl, alkoxy, aryloxy, aralkoxy, alkoxyalkyl, alkylcarbonyl, alkoxycarbonyl, carboxyl, cyano, nitro,

alkylsulfonyl, haloalkylsulfonyl, aryl, aralkyl,

mercaptocarbonyl, alkylthio and alkylthiocarbonyl, and amino and amido radicals of the formula £

wherein X is selected from oxygen atom and sulfur atom;

wherein R²⁷ is selected from hydrido, alkyl, cycloalkyl, cycloalkylalkyl, aralkyl, aryl and DR³² and

wherein D is selected from oxygen atom and sulfur atom;

wherein R³² is selected from hydrido, alkyl, cycloalkyl, cycloalkylalkyl, aralkyl and aryl; wherein each of R²⁷, R²⁸, R²⁹, R³⁰, R³¹, R³³ and R³⁴ is independently selected from hydrido, alkyl, cycloalkyl, cyano, hydroxyalkyl, haloalkyl, cycloalkylalkyl, alkoxyalkyl, alkanoyl, alkoxycarbonyl, carboxyl, haloalkylsulfinyl, haloalkylsulfonyl, aralkyl and aryl; or a tautomer thereof or a pharmaceutically-acceptable salt thereof.

4. Compound of Claim 3 wherein m is one; wherein each of X¹ and X² is selected from oxygen atom and sulfur atom; wherein each of R⁰ and R¹ is independently selected from hydrido, alkyl, hydroxyalkyl, mercaptoalkyl, haloalkyl, cycloalkyl, cycloalkylalkyl, aralkyl, aryl, alkoxyalkyl, alkoxycarbonylalkyl, alkylcarbonyloxyalkyl, alkenyl,

cycloalkenyl and alkynyl with the proviso that R⁰ and R¹ cannot simultaneously be hydrido; wherein R² is selected from alkyl, hydroxyalkyl, halo, haloalkyl, cycloalkyl, cycloalkylalkyl, cycloalkylhaloalkyl, cycloalkylcarbonyl, alkoxy, aralkyl, aralkylhaloalkyl, aryl, aroyl, aryloxy, aryloxyalkyl, aralkoxy, alkoxyalkyl,

mercaptocarbonyl, mercaptoalkyl, alkoxycarbonyloxy, alkylthio, cycloalkylthio, cycloalkylalkylthio, arylthio, aralkylthio, mercapto, alkylsulfinyl, alkylsulfonyl, aralkylsulfinyl, aralkylsulfonyl, arylsulfinyl, arylsulfonyl, phthalimido, phthalimidoalkyl, heteroaryl, heteroarylalkyl,

cycloheteroalkyl, cycloheteroalkylalkyl and

independently selected from amino and amido radicals of the formula

wherein X is selected from oxygen atom and sulfur atom; wherein each r is a number independently selected from zero to six, inclusive; wherein each of R¹⁴ through R²⁶ is independently selected from hydrido, alkyl, cycloalkyl, cyano, amino, monoalkylamino, dialkylamino, hydroxyalkyl, cycloalkylalkyl, alkoxyalkyl, aralkyl and aryl; wherein each of R³ through R¹¹ is independently selected from hydrido, hydroxy, alkyl, hydroxyalkyl, halo, haloalkyl, cycloalkyl, alkoxy, aralkyl, aryl, aroyl, aryloxy, aralkoxy, alkoxyalkyl, alkylcarbonyl, alkoxycarbonyl, alkenyl,

cycloalkenyl, alkynyl, cyano, nitro, carboxyl, alkylthio, aralkylthio and mercapto; and wherein each of R³ through R¹¹ may be further

independently selected from acidic moieties of the formula

cycloalkylalkyl, alkoxyalkyl, aralkyl and aryl, and wherein R⁴⁰ and R⁴¹ taken together may form a heterocyclic group having five to seven ring members including the nitrogen atom of said amino radical, which heterocyclic group may further contain one or more hetero atoms as ring members selected from oxygen, nitrogen and sulfur atoms, and which heterocyclic group may be saturated or partially unsaturated; wherein R⁴⁰ and R⁴¹ taken together may form an aromatic heterocyclic group having five ring members including the nitrogen atom of said amino radical and which aromatic heterocyclic group may further contain one or more hetero atoms as ring atoms selected from oxygen, nitrogen and sulfur atoms; and the amide, ester and salt derivatives of said acidic groups;

wherein said bioisostere of carboxylic acid may be further selected from heterocyclic acidic groups consisting of heterocyclic rings of four to about nine ring members, which ring contains at least one hetero atom, selected from oxygen, sulfur and nitrogen atoms, which heterocyclic ring may be saturated, fully unsaturated or partially unsaturated, and which heterocyclic ring may be attached at a single position selected from R³ through R¹¹ or may be attached at any two adjacent positions selected from R³ through R¹¹ so as to form a fused-ring system with one of the phenyl rings of Formula II; and the amide, ester and salt derivatives of said

heterocyclic acidic groups; wherein Y is a spacer group independently selected from one or more of alkyl, cycloalkyl, cycloalkylalkyl, alkenyl, aryl and aralkyl; wherein each of R¹ through R²⁶, R³⁵ and R³⁸ through R⁴¹, Y and A independently may be substituted at any substitutable position with one or more groups selected from alkyl, hydroxy, halo, oxo, haloalkyl, alkoxycarbonyl, cyano, nitro,

alkylsulfonyl, haloalkylsulfonyl, aryl, aralkyl, alkoxy, aryloxy and aralkoxy; or a tautomer thereof or a pharmaceutically-acceptable salt thereof.

5. Compound of Claim 4 wherein m is one; wherein each of X¹ and X² is independently selected from oxygen atom and sulfur atom; wherein each of R⁰ and R¹ is independently selected from hydrido, alkyl, hydroxyalkyl, mercaptoalkyl, haloalkyl, cycloalkyl, cycloalkylalkyl, aralkyl, aryl, alkoxyalkyl, alkoxycarbonylalkyl, alkylcarbonyloxyalkyl, alkenyl and alkynyl; wherein R² is selected from alkyl, hydroxyalkyl, halo, haloalkyl, cycloalkyl, cycloalkylalkyl, cycloalkylhaloalkyl, cycloalkylcarbony1, alkoxy, aralkyl, aralkylhaloalkyl, aryl, benzoyl, phenoxy, phenoxyalkyl, phenalkyloxy, phenylthio, phenalkylthio, aralkoxy, alkoxyalkyl, alkylcarbonyl,

alkoxycarbonyl, alkenyl, cycloalkenyl, alkynyl, cyano, nitro, carboxyl, carboxyalkyl, alkylcarbonyloxy,

alkylcarbonyloxyalkyl, alkoxycarbonylalkyl,

aralkoxycarbonylalkyl, aralkylcarbonyloxyalkyl,

mercaptocarbonyl, mercaptoalkyl, alkoxycarbonyloxy, alkylthio, cycloalkylthio, cycloalkylalkylthio, phthalimido,

phthalimidoalkyl, heteroaryl, heteroarylalkyl,

cycloheteroalkyl, cycloheteroalkylalkyl and

independently selected from amino and amido radicals of the formula

wherein X is selected from oxygen atom and sulfur atom; wherein each r is a number independently selected from zero to six, inclusive; wherein each of R¹⁴ through R²⁶ is independently selected from hydrido, alkyl, cycloalkyl, cyano, amino, hydroxyalkyl, alkoxyalkyl, phenalkyl and phenyl; wherein each of R³ through R¹¹ is independently selected from hydrido, hydroxy, alkyl, hydroxyalkyl, halo, haloalkyl, cycloalkyl, alkoxy, phenalkyl, phenyl, benzoyl, phenoxy, phenalkyloxy, alkoxyalkyl, alkylcarbonyl, alkoxycarbonyl, alkenyl, cyano, nitro, carboxyl, alkylthio and mercapto; and wherein each of R³ through R¹¹ may be further

independently selected from acidic moieties of the formula

-Y_nA wherein n is a number selected from zero through two,

inclusive; wherein A is selected from carboxylic acid and bioisosteres of carboxylic acid selected from

wherein each W is independently selected from oxygen atom, sulfur atom and NR³⁹; wherein each of R³⁵, R³⁸ and R³⁹ is independently selected from hydrido, alkyl, haloalkyl, haloalkylsulfonyl, haloalkylcarbonyl, cycloalkyl, phenyl and benzyl; wherein each of R³⁵ and R³⁹ may be further

independently selected from amino radical of the formula

alkoxyalkyl, benzyl and phenyl; and the amide, ester and salt derivatives of said acidic groups; wherein said bioisostere of carboxylic acid may be further selected from heterocyclic acidic groups consisting of heterocyclic rings of four to about nine ring members, which ring contains at least one hetero atom, selected from oxygen, sulfur and nitrogen atoms, which heterocyclic ring may be saturated, fully unsaturated or partially unsaturated, and which heterocyclic ring may be attached at a single position selected from R³ through R¹¹ or may be attached at any two adjacent positions selected from R³ through R¹¹ so as to form a fused-ring system with one of the phenyl rings of Formula II; and the amide, ester and salt derivatives of said heterocyclic acidic groups; wherein Y is a spacer group independently selected from one or more of alkyl, cycloalkyl, cycloalkylalkyl, alkenyl, phenyl, phenalkyl and aralkyl; wherein each of R¹ through R²⁶, R³⁵ and R³⁸ through R⁴¹, Y and A and independently may be substituted at any substitutable position with one or more groups selected from alkyl,

cycloalkyl, cycloalkylalkyl, hydroxy, halo, oxo, haloalkyl, alkoxycarbonyl, cyano, nitro, alkylsulfonyl,

haloalkylsulfonyl, aryl, aralkyl, alkoxy, aryloxy and

aralkoxy; or a tautomer thereof or a pharmaceutically-acceptable salt thereof.

6. Compound of Claim 5 wherein m is one; wherein each of X¹ and X² is independently selected from oxygen atom and sulfur atom; wherein R⁰ and R¹ is independently selected from hydrido, alkyl, hydroxyalkyl, mercaptoalkyl, haloalkyl, cycloalkyl, cycloalkylalkyl, aralkyl, aryl, alkoxyalkyl, alkoxycarbonylalkyl, alkylcarbonyloxyalkyl, alkenyl and alkynyl; where R² is selected from alkyl, aminoalkyl, hydroxyalkyl, halo, haloalkyl, cycloalkyl, cycloalkylalkyl,

alkylcarbonyloxy, mercaptoalkyl, mercaptocarbonyl,

alkoxycarbonyloxy, alkylcarbonyloxyalkyl, alkoxycarbonylalkyl, aralkoxycarbonylalkyl, aralkylcarbonyloxyalkyl, phthalimido, phthalimidoalkyl, imidazoalkyl, tetrazole, tetrazolealkyl. alkylthio, cycloalkylthio, cycloalkylalkylthio, and amino and amido radicals of the formula

wherein X is selected from oxygen atom and sulfur atom; wherein each r is a number independently selected from zero to six, inclusive; wherein each of R¹⁴ through R²⁶ is independently selected from hydrido, alkyl, cycloalkyl, cyano, amino, hydroxyalkyl, alkoxyalkyl, phenalkyl and phenyl; wherein each of R³ through R¹¹ is independently selected from hydrido, hydroxy, alkyl, hydroxyalkyl, halo, haloalkyl, alkoxy, phenyl, benzoyl, phenoxy, alkoxyalkyl, acetyl, alkoxycarbonyl, alkenyl, cyano, nitro, carboxyl, alkylthio and mercapto; and wherein each of R³ through R¹¹ may be further

independently selected from acidic moieties consisting of CO₂H, CO₂CH₃, SH, CH₂SH, C₂H₄SH, PO ₃H_2, NHSO₂CF₃ , NHSO₂C₆F_5, SO₃H, CONHNH₂, CONHNHSO₂CF₃ , CONHOCH₃, CONHOC₂H_{5 ,} CONHCF ₃ , OH, CH₂OH, C₂H₄OH, OPO₃H₂, OSO₃H ,

wherein each of R⁴², R⁴³ and R⁴⁴ is independently selected from H, Cl, CN, NO₂, CF₃, C₂F₅, C₃F₇, CHF₂, CH₂F, CO₂CH₃, CO₂C₂H₅, SO₂CH₃, SO₂CF₃, and SO₂C₆F₅; wherein Z is selected from O, S, NR⁴⁵ and CH_2; wherein R⁴⁵ is selected from hydrido, CH₃ and CH₂C₆H_5; and wherein said acidic moiety may be a heterocyclic acidic group attached at any two adjacent positions of R³ through R¹¹ so as to form a fused ring system with one of the phenyl rings of the biphenyl moiety of Formula II, said biphenyl fused ring system selected from

and the esters, amides and salts of said acidic moieties;

or a tautomer thereof or a pharmaceutically-acceptable salt thereof.

7. Compound of Claim 6 wherein m is one; wherein each of X¹ and X² is independently selected from oxygen atom and sulfur atom; wherein each of R⁰ and R¹ is independently selected from hydrido, methyl, ethyl,

n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl, neopentyl, phenyl, benzyl, phenethyl, cyclohexyl, cyclopropylmethyl, cyclopropylethyl,

cyclohexylmethyl, alkoxycarbonylalkyl, alkylcarbonyloxyalkyl, buten-2-yl, 3-butenyl, butyn-2-yl, butyn-3-yl, haloloweralkyl and hydroxyloweralkyl; wherein R² is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, n-hexyl, isopentyl, neopentyl, phenyl, cyclohexyl, cyclohexylmethyl, CH₃CH=CH-CH₂, SC₃H₇, cyclohex-3 - en-1-yl, SC₄H₉,

CH₂S , CH₃CH=CH, CH₂=CH-CH₂,

CH₃CH₂CH₂CH=CH- , amino, alkoxy, aminomethyl, aminoethyl, aminopropyl, CH₂OCOCH₃, CH₂CI, CH₂OCH₃, CH₂OCH(CH₃) ₂, CH₂CO₂H, CH(CH₃)CO₂H, -CH₂OCOCH₂CH₂ -CH₂CH₂CH₂CO₂H, -CH₂CH₂F, -

CH₂CH₂CH₂F, -CH₂CNO₂, -CH₂SH, -CH₂O- CF₃, CH₂OH,

hydroxyalkyl, halo, 1-oxo-2-phenylethyl, 2-cyclohexylethyl, 3-cyclohexylpropyl, benzyl, 2-phenylethyl, 3-phenylpropyl, cyclohexylmethyl, cyclohexanoyl, 1-butenyl, buten-2-yl,

3-butenyl, butyn-1-yl, butyn-2-yl, butyn-3-yl and

difluoromethyl; wherein each of R³ through R¹¹ is hydrido with the proviso that at least one of R⁵, R⁶, R⁸ and R⁹ is an acidic group selected from CO₂H, SH, PO₃H₂, SO₃H, CONHNH₂, CONHNHSO₂CF₃, OH,

8. Compound of Claim 7 wherein m is one; wherein each of X¹ and X² is independently selected from oxygen atom and sulfur atom; wherein R⁰ and R¹ is independently selected from hydrido, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, 4-methylbutyl, n-pentyl. neopentyl, cyclopropylmethyl, cyclopropylethyl, propenyl, phenyl, benzyl, phenethyl, cyclohexyl, cyclohexylmethyl, methoxycarbonylmethyl, methoxycarbonylethyl, 4-hydroxybutyl, 2-hydroxyethyl and 3-hydroxypropyl; wherein R² is selected from ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, 4-methylbutyl, tert-butyl, n-pentyl, neopentyl, 2-phenylethyl, 2-cyclohexylethyl, benzyl, 2-phenylethyl, 3-phenylpropyl, cyclohexylmethyl, cyclohexyl, propoxy, butoxy, 1-butenyl, buten-2-yl, 3-butenyl, butyn-1-yl, butyn-2-yl, butyn-3-yl, propylthio and butylthio; wherein each of R³ through R¹¹ is hydrido with the proviso that at least one of R⁵, R⁶, R⁸ and R⁹ is an acidic group selected from CO₂H, SH, PO₃H_2, SO₃H, CONHNH_2, CONHNHSO₂CF_3, OH,

9. Compound of Claim 8 wherein m is one; wherein each of X¹ and X² is independently selected from oxygen atom and sulfur atom; wherein each of R⁰ and R¹ is independently selected from hydrido, methyl, ethyl,

n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl,

4-methylbutyl, n-pentyl, neopentyl, cyclopropylmethyl, cyclopropylethyl, propenyl, phenyl, benzyl, phenethyl. cyclohexl, cyclohexylmethyl, methoxycarbonyImethyl,

methoxycarbonylethyl,

4-hydroxybuty, 2-hydroxyethyl and 3-hydroxypropyl; wherein R² is selected from ethyl, n-propyl, isopropyl,

n-butyl, sec-butyl, isobutyl, 4-methylbutyl, tert-butyl, n-pentyl, neopentyl, benzyl, 2-phenylethyl, 3-phenylpropyl, cyclohexylmethyl, cyclohexyl, propoxy, butoxy, 1-butenyl, buten-2-yl, 3-butenyl, butyn-1-yl, butyn-2-yl, butyn-3-yl, propylthio; wherein each of R³, R⁴, R⁶, R⁷, R⁸, R¹⁰ and R¹¹ is hydrido; wherein one of R⁵ and R⁹ is hydrido and the other of R⁵ and R⁹ is an acidic group selected from CO₂H and

or a tautomer thereof or a pharmaceutically-acceptable salt thereof.

10. Compound of Claim 9 wherein m is one; wherein X¹ is an oxygen atom and X² is a sulfur atom; wherein each of R⁰ and R¹ is independently selected from hydrido, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, 4-methylbutyl, n-pentyl, neopentyl,

methoxycarbonyImethyl, methoxycarbonylethyl, 4-hydroxybutyl, 2-hydroxyethyl and 3-hydroxypropyl; wherein R² is selected from ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, 4-methylbutyl, tert-butyl, n-pentyl, neopentyl, benzyl, 2- phenylethyl, 3-phenylpropyl, cyclohexylmethyl, cyclohexyl, propoxy, butoxy, 1-butenyl, buten-2-yl, 3-butenyl, butyn-1-yl, butyn-2-yl, butyn-3-yl, propylthio and butylthio; wherein each of R³, R⁴, R⁶, R⁷, R⁸, R¹⁰ and R¹¹ is hydrido; wherein one of R⁵ and R⁹ is hydrido and the other of R⁵ and R⁹ is an acidic group selected from CO₂H and

or a tautomer thereof or a pharmaceutically-acceptable salt thereof.

11. Compound of Claim 10 wherein m is one; wherein X¹ is an oxygen atom and X² is an oxygen atom; wherein each of R⁰ and R¹ is independently selected from hydrido, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, 4-methylbutyl, n-pentyl, neopentyl,

or a tautomer thereof or a pharmaceutically-acceptable salt thereof.

12. Compound of Claim 6 selected from the group consisting of

8-(buten-2-yl)-3,7-dihydro-1-methyl-3-propyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-bi2henyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-butyl-3,7-dihydro-1-methyl-3-(cyclopropyl-methyl)-7-[[2'-

(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-butyl-3,7-dihydro-1-methyl-3-phenyl-7-[[2'-(1H-tetrazol-5- yl) (1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-butyl-3,7-dihydro-1-propyl-7-[[2'-(1H-tetrazol-5-yl)(1,1'- biphenyl)-4-yl]methyl]-1H-purine-2,6-dione; 8-butyl-3,7-dihydro-1-methyl-7-[[2'-(1H-tetrazol-5-yl)(1,1'- biphenyl)-4-yl]methyl]-6-oxo-2-thioxo-1H-purine;

8-butyl-3,7-dihydro-1-(cyclopropyl-methyl)-3-methyl-7-[[2'-

(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-butyl-3,7-dihydro-1-methyl-3-(cyclopropyl-methyl)-7-[[2'-

(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

1H-purine-2,6-dione; 8-butyl-3,7-dihydro-1-(2-carbomethoxy-ethyl)-3-methyl-7-[[2'- (1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-butyl-3,7-dihydro-1-methyl-3-(prop-2-en-1-yl)-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-butyl-3,7-dihydro-1-propyl-3-methyl-7-[[2'-(1H-tetrazol-5- yl) (1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-thione;

8-butyl-3,7-dihydro-1-(cyclopropyl-methyl)-3-methyl-7-[[2'-

(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- thione;

8-butyl-3,7-dihydro-1-methyl-3-(cyclopropyl-methyl)-7-[[2'- (1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- thione;

8-butyl-3,7-dihydro-1-methyl-3-phenyl-7-[[2'-(1H-tetrazol-5- yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-thione;

8-cyclohexyl-3,7-dihydro-1,3-dimethyl-7-[[2'-(1H-tetrazol-5- yl)(1,1 -biphenyl)-4-yl]methyl]-1H-purine-2, 6-dione;

8-cyclohexyl-3,7-dihydro-1-propyl-3-methyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione; 8-cyclohexyl-3,7-dihydro-1,3-dipropyl-7-[[2'-(1H-tetrazol-5- yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-cyclohexyl-3,7-dihydro-1-(cyclopropyl-methyl)-3-methyl-7- [[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine- 2,6-dione;

8-cyclohexyl-3,7-dihydro-1-methyl-3-(cyclopropyl-methyl)-7- [[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine- 2, 6-dione;

8-cyclohexyl-3,7-dihydro-1-(3-hydroxypropyl)-3-methyl-7-[[2'-

(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-cyclohexyl-3,7-dihydro-1-(2-carbomethoxy-ethyl)-3-methyl-7-

[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-

2, 6-dione;

8-cyclohexyl-3,7-dihydro-1-(2-hydroxyethyl)-1-methyl-7-[[2'- (1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-cyclohexyl-3,7-dihydro-1-methyl-3-(prop-2-en-1-yl)-7-[[2'-

(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione; 8-cyclohexyl-3,7-dihydro-1-propyl-3-methyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- thione;

8-cyclohexyl-3,7-dihydro-1-(cyclopropyl-methyl)-3-methyl-7- [[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-

2,6-thione;

8-cyclohexyl-3,7-dihydro-1-methyl-3-(cyclopropyl-methyl)-7-

[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-

2, 6-thione;

8-cyclohexyl-3,7-dihydro-1-methyl-3-pheny1-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- thione;

8-pentyl-3,7-dihydro-1-methyl-3-propyl-7-[[2'-(1H-tetrazol-5- yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-pentyl-3,7-dihydro-1-propyl-3-methyl-7-[[2'-(1H-tetrazol-5- yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-pentyl-3,7-dihydro-1-methyl-3-isobutyl-7-[[2'-(1H-tetrazol-

5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-pentyl-3,7-dihydro-1-(cyclopropyl-methyl)-3-methyl-7-[[2'-

(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2, - dione; 8-pentyl-3,7-dihydro-1-methyl-3-(cyclopropyl-methyl)-7-[[2'-

(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-pentyl-3,7-dihydro-1-methyl-3-phenyl-7-[[2'-(1H-tetrazol-5- yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-pentyl-3,7-dihydro-3-propyl-7-[[2'-(1H-tetrazol-5-yl)(1,1'- biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-pentyl-3,7-dihydro-1-propyl-7-[[2'-(1H-tetrazol-5-yl)(1,1'- biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-pentyl-3,7-dihydro-1-methyl-7-[[2'-(1H-tetrazol-5-yl)(1,1'- biphenyl)-4-yl]methyl]-6-oxo-2-thioxo-1H-purine;

8-pentyl-3,7-dihydro-1-methyl-7-[[2'-(1H-tetrazol-5-yl)(1,1'- biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-pentyl-3,7-dihydro-1-(3-hydroxypropyl)-3-methyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-pentyl-3,7-dihydro-1-(2-carbomethoxy-ethyl)-3-methyl-7-[[2'-

(1H-tetrazol-5-yl) (1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-pentyl-3,7-dihydro-1-(2-hydroxyethyl)-1-methyl-7-[[2'-(1H- tetrazol-5-yl) (1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-pentyl-3,7-dihydro-1-methyl-3-isobutyl-7-[[2'-(1H-tetrazol-

5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-thione;

8-pentyl-3,7-dihydro-1-(cyclopropyl-methyl)-3-methyl-7-[[2'- (1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- thione; 8-pentyl-3,7-dihydro-1-methyl-3-(cyclopropyl-methyl)-7-[[2'- (1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- thione;

8-pentyl-3,7-dihydro-3-propyl-7-[[2'-(1H-tetrazol-5-yl)(1,1'- biphenyl)-4-yl]methyl]-1H-purine-2,6-thione;

8-pentyl-3,7-dihydro-1-propyl-7-[[2'-(1H-tetrazol-5-yl)(1,1'- biphenyl)-4-yl]methyl]-1H-purine-2,6-thione;

8-(propen-2-yl)-3,7-dihydro-1-methyl-7-[[2'-(1H-tetrazol-5- yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

2,6-dione;

8-(propen-2-yl)-3,7-dihydro-1-(2-carbomethoxy-ethyl)-3-methyl-

7-[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione;

8-(propen-2-yl)-3,7-dihydro-1-(2-hydroxyethyl)-1-methyl-7-

[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-

2,6-dione;

8-(propen-2-yl)-3,7-dihydro-1-methyl-3-(prop-2-en-1-yl)-7-

[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine- 2,6-dione;

8-(propen-2-yl)-3,7-dihydro-1,3-diproρyl-7-[[2'-(1H-tetrazol- 5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-(buten-2-yl)-3,7-dihydro-1-methyl-7-[[2'-(1H-tetrazol-5- yl)(1,1'-biphenyl)-4-yl]methyl]-6-oxo-2-thioxo-1H-purine; 8-(buten-2-yl)-3,7-dihydro-1-methyl-7-[[2'-(1H-tetrazol-5- yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-(buten-2-yl)-3,7-dihydro-1-(3-hydroxypropyl)-3-methyl-7-

[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine- 2,6-dione;

8-(buten-2-yl)-3,7-dihydro-1-(2-carbomethoxy-ethyl)-3-methyl-

7-[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione;

8-(buten-2-yl)-3,7-dihydro-1-(2-hydroxyethyl)-1-methyl-7-[[2'- (1H-tetrazol-5-yl) (1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-(buten-2-yl)-3,7-dihydro-1-methyl-3-(prop-2-en-1-yl)-7-[[2'-

(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-(buten-2-yl)-3,7-dihydro-1-propyl-3-methyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- thione;

8-(buten-2-yl)-3,7-dihydro-1,3-dipropyl-7-[[2'-(1H-tetrazol-5- yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-(buten-2-yl)-3,7-dihydro-1-(3-hydroxypropyl)-3-methyl-7-

[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-

2,6-dione;

8-(buten-2-yl)-3,7-dihydro-1-(2-carbomethoxy-ethyl)-3-methyl-

7-[[2'-(1H-tetrazol-5-yl) (1,1'-biphenyl)-4-yl]methyl]-1H- purdlne-2,6-dione;

8-(buten-2-yl)-3,7-dihydro-1-(2-hydroxyethyl)-1-methyl-7-[[2'- (1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione; 8-(buten-2-yl)-3,7-dihydro-1-methyl-3-(prop-2-en-1-yl)-7-[[2'- (1H-tetrazol-5-yl) (1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-(cyclohex-3-en-1-yl)-3,7-dihydro-1-methyl-3-isobutyl-7-[[2'-

(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- thione;

8-(cyclohex-3-en-1-yl)-3,7-dihydro-1-methyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-6-oxo-2-thioxo-1H- purine;

8-propyl-3,7-dihydro-1-methyl-3-isobutyl-7-[[2'-(1H-tetrazol- 5-yl) (1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-propyl-3,7-dihydro-1-(cyclopropyl-methyl)-3-methyl-7-[[2'-

(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione; 8-propyl-3,7-dihydro-1-methyl-3-(cyclopropyl-methyl)-7-[[2'-

(1H-tetrazol-5-yl) (1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-propyl-3,7-dihydro-1-methyl-3-phenyl-7-[[2'-(1H-tetrazol-5- yl) (1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-propyl-3,7-dihydro-1-propyl-7-[[2'-(1H-tetrazol-5-yl) (1,1'- biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-propyl-3,7-dihydro-1-methyl-7-[[2'-(1H-tetrazol-5-yl) (1,1'- biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-propyl-3,7-dihydro-1-(3-hydroxypropyl)-3-methyl-7-[[2'-(1H- tetrazol-5-yl) (1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-propyl-3,7-dihydro-1-(2-carbomethoxy-ethyl)-3-methyl-7-[[2'-

(1H-tetrazol-5-yl) (1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-propyl-3,7-dihydro-1-methyl-3-(prop-2-en-1-yl)-7-[[2'-(1H- tetrazol-5-yl) (1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-propyl-3,7-dihydro-1-propyl-3-methyl-7-[[2'-(1H-tetrazol-5- yl) (1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-thione;

8-propyl-3,7-dihydro-1,3-dipropyl-7-[[2['(1H-tetrazol-5- yl) (1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-propyl-3,7-dihydro-1-methyl-3-isobutyl-7-[[2'-(1H-tetrazol-

5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-thione;

8-propyl-3,7-dihydro-1-(cyclopropyl-methyl)-3-methyl-7-[[2'- (1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- thione; 8-propyl-3,7-dihydro-1-methyl-3-(cyclopropyl-methyl)-7-[[2'- (1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- thione;

8-propyl-3,7-dihydro-1-methyl-3-phenyl-7-[[2'-(1H-tetrazol-5- yl) (1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-thione;

8-propyl-3,7-dihydro-3-propyl-7-[[2'-(1H-tetrazol-5-yl) (1,1'- biphenyl)-4-yl]methyl]-1H-purine-2,6-thione;

8-propyl-3,7-dihydro-1-propyl-7-[[2'-(1H-tetrazol-5-yl)(1,1'- biphenyl)-4-yl]methyl]-1H-purine-2,6-thione;

8-butyl-3,7-dihydro-1-propyl-3-methyl-7-[[2'-(1H-tetrazol-5- yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-butyl-3,7-dihydro-1-(cyclopropyl-methyl)-3-methyl-7-[[2'-

(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-butyl-3,7-dihydro-1-methyl-3-(cyclopropyl-methyl)-7-[[2'-

(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-propyl-3,7-dihydro-3-propyl-7-[[2'-(1H-tetrazol-5-yl)(1,1'- biphenyl)-4-yl]methyl]-1H-purine-2,6-dione; 8-propyl-3,7-dihydro-1-methyl-3-propyl-7-[[2'-(1H-tetrazol-5- yl) (1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-butyl-3,7-dihydro-1-methyl-7-[[2'-(1H-tetrazol-5-yl) (1,1'- biphenyl)-4-yl]methyl]-6-oxo-2-thioxo-1H-purine; and

8-butyl-3,7-dihydro-1-methyl-7-[[2'-(1H-tetrazol-5-yl) (1,1'- biphenyl)-4-yl]methyl]-1H-purine-2,6-dione.

13. Compound of Claim 12 selected from the group consisting of

8-(2-butenyl)-3,7-dihydro-1-methyl-3-propyl-7-

[[2'-(1H-tetrazol-5-yl) (1,1'-biphenyl)-4- yl]methyl]-1H-purine-2,6-dione;

8-butyl-3,7-dihydro-1,3-dimethyl-7-[[2'-(1H- tetrazol-5-yl) (1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione;

8-butyl-3,7-dihydro-1-methyl-3-proρyl-7-[[2'-

(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]- 1H-purine-2,6-dione;

8-butyl-3,7-dihydro-1-propyl-3-methyl-7-[[2'-

(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-

1H-purine-2,6-dione;

8-butyl-3,7-dihydro-1,3-dipropyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione;

8-butyl-3,7-dihydro-1-methyl-3-isobutyl-7-[[2'-

(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-

1H-purine-2,6-dione;

8-butyl-3,7-dihydro-1-(cyclopropyl-methyl)-3- methyl-7-[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)- 4-yl]methyl]-1H-purine-2,6-dione;

8-butyl-3,7-dihydro-1-methyl-3-(cyclopropylmethyl)-7-[[2'-(1H-tetrazol-5-yl)(1,1'- biphenyl)-4-yl]methyl]-1H-purine-2,6-dione; 8-butyl-3,7-dihydro-1-methyl-3-phenyl-7-[[2'- (1H-tetrazol-5-yl) (1,1'-biphenyl)-4-yl]methyl]- 1H-purine-2,6-dione;

8-butyl-3,7-dihydro-3-propyl-7-[[2'-(1H- tetrazol-5-yl) (1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione;

8-propyl-3,7-dihydro-3-propyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione;

8-propyl-3,7-dihydro-1-methyl-3-propyl-7-[[2'- (1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]- 1H-purine-2,6-dione;

8-butyl-3,7-dihydro-1-proρyl-7-[[2'-(1H- tetrazol-5-yl) (1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione;

8-butyl-3,7-dihydro-1-methyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-6- oxo-2-thioxo-1H-purine; and

8-butyl-3,7-dihydro-1-methyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H- purine-2,6-dione.

14. Compound of Claim 13 which is 8-(2E-butenyl)- 3,7-dihydro-1,3-dimethyl-7-[[2'-(1H-tetrazol-5-yl) [1,1'- biphenyl]-4-yl]methyl]-1H-purine-2,6-dione.

15. Compound of Claim 13 which is 8-butyl-3,7-dihydro-1,3-dimethyl-7-[[2'-(1H-te razol-5-yl) [1,1'- biphenyl]-4-yl]methyl]-1H-purine-2,6-dione.

16. Compound of Claim 13 which is 8-butyl-3,7- dihydro-1-methyl-3-propyl-7-[[2'-(1H-tetrazol-5-yl)[1,1- biphenyl]-4-yl]methyl]-1H-purine-6-one-2-thione.

17. Compound of Claim 13 which is 8-butyl-3,7- dihydro-1-propyl-3-methyl-7-[[2'-(1H-tetrazol-5-yl)[1,1'- biphenyl]-4-yl]methyl-1H-purine-2,6-dione.

18. Compound of Claim 13 which is 8-butyl-3,7- dihydro-1,3-dipropyl-7-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl] 4-yl]methyl-1H-purine-2,6-dione.

19. Compound of Claim 13 which is 8-(2E-butenyl)- 3,7-dihydro-1-methyl-3-isobutyl-7-[[2'-(1H-tetrazol-5- yl)[1,1'-biphenyl]-4-yl]methyl]-1H-purine-2,6-dione.

20. Compound of Claim 13 which is 8-butyl-3,7- dihydro-1-cyclopropyl-3-methyl-7-[[2'-(1H-tetrazol-5-yl)

[1,1'-biphenyl]-4-yl]methyl-1H-purine-2,6-dione.

21. Compound of Claim 13 which is 8-butyl-3,7- dihydro-1-methyl-3-cyclopropyl-7-[[2'-(1H-tetrazol-5-yl)

[1,1'-biphenyl]-4-yl]methyl-1H-purine-2,6-dione.

22. Compound of Claim 13 which is 8-butyl-3,7- dihydro-1-methyl-3-phenyl-7-[[2'-(1H-tetrazol-5-yl)[1,1'- biphenyl]-4-yl]methyl]-1H-purine-2,6-dione.

23. Compound of Claim 13 which is 8-butyl-3,7- dihydro-3-propyl-7-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4- yl]methyl]-1H-purine-2,6-dione.

24. Compound of Claim 13 which is 8-propyl-3,7- dihydro-3-propyl-7-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4- yl]methyl]-1H-purine-2,6-dione.

25. Compound of Claim 13 which is 8-propyl-3,7- dihydro-1-methyl-3-propyl-7-[[2'-(1H-tetrazol-5-yl)[1,1'- biphenyl]-4-yl]methyl]-1H-purine-2,6-dione.

26. A pharmaceutical composition comprising a therapeutically-effective amount of an angiotensin II

antagonist compound and a pharmaceutically-acceptable carrier or diluent, said antagonist compound selected from a family of compounds of Formula I:

alkylthiothiocarbonylalkyl, arylthiocarbonylalkyl,

arylthiothiocarbonylalkyl, aralkylthiocarbonylalkyl,

alkylthiocarbonyl, alkylsulfinyl, alkylsulfonyl,

aralkylsulfinyl, aralkylsulfonyl, arylsulfinyl, arylsulfonyl. heteroaryl having one or more ring atoms selected from oxygen, sulfur and nitrogen atoms, and radicals of the formula

wherein X is oxygen atom or sulfur atom with z being a number selected from one to four, inclusive; wherein each of R¹² and R¹³ is independently selected from hydrido, alkyl, cycloalkyl, cyano, amino, monoalkylamino, dialkylamino, hydroxyalkyl, cycloalkylalkyl, alkoxyalkyl, aralkyl and aryl, and wherein R¹² and R¹³ taken together may form a heterocyclic group having five to seven ring members including the nitrogen atom of said amido radical and which heterocyclic group may further contain one or more hetero atoms as ring members selected from oxygen, nitrogen and sulfur atoms and which heterocyclic group may be saturated or partially unsaturated; wherein each of R² through R¹¹ is independently selected .from hydrido, alkyl, hydroxyalkyl, halo, haloalkyl, cycloalkyl, cycloalkylalkyl, cycloalkylhaloalkyl, cycloalkylcarbonyl, formyl, alkoxy, aralkyl, aralkylhaloalkyl, aryl, aroyl, aryloxy, aryloxyalkyl, aralkoxy, alkoxyalkyl, alkylcarbonyl, alkylcarbonylalkyl, alkoxycarbonyl, alkenyl, cycloalkenyl, alkynyl, cyano, nitro, carboxyl, carboxyalkyl,

aralkylthiocarbonylthio, alkylthiocarbonyl,

aralkylthiocarbonylthio, mercapto, alkylsulfinyl,

alkylsulfonyl, aralkylsulfinyl, aralkylsulfonyl, arylsulfinyl, arylsulfonyl, phthalimido, phthalimidoalkyl, heteroaryl, heteroarylalkyl, cycloheteroalkyl, cycloheteroalkylalkyl and cycloheteroalkylcarbonylalkyl wherein each of said heteroaryl- and cyclohetero-containing groups has one or more ring atoms selected from oxygen, sulfur and nitrogen atoms, and wherein each of R² through R¹¹ may be further independently selected from amino and amido radicals of the formula

p

independently selected from hydroxy and acidic moieties of the formula

alkylthiocarbonyl, alkylsulfinyl, alkylsulfonyl,

haloalkylsulfonyl, aralkylsulfinyl, aralkylsulfonyl,

alkylsulfinyl, alkylsulfonyl, arylsulfinyl, arylsulfonyl, haloalkylsulfinyl, haloalkylsulfonyl, aralkyl and aryl, and wherein each of R²⁷' R²⁸' R²⁹, R³⁰, R³¹, R³³ and R³⁴ is further independently selected from amino and amido radicals of the formula

wherein X is oxygen atom or sulfur atom;

wherein each of R³⁵, R³⁶, R³⁷, R³⁸, R³⁹ and R⁴⁰ is

independently selected from hydrido, alkyl, cycloalkyl, cyano, hydroxyalkyl, cycloalkylalkyl, alkoxyalkyl, haloalkylsulfinyl. haloalkylsulfonyl, aralkyl and aryl, and wherein each of R²⁸ and R²⁹ taken together and each of R³⁰ and R³¹ taken together may form a heterocyclic group having five to seven ring members including the nitrogen atom of said amino or amido radical, which heterocyclic group may further contain one or more hetero atoms as ring members selected from oxygen, nitrogen and sulfur atoms and which heterocyclic group may be saturated or partially unsaturated; with the proviso that R⁰, R¹, and R² cannot all simultaneously be hydrido; or a tautomer thereof or a pharmaceutically-acceptable salt thereof .

27. The composition of Claim 26 wherein said angiotensin II antagonist compound is selected from a family of compounds of Formula II:

hydroxyalkyl, haloalkyl, cycloalkyl, cycloalkylalkyl, aralkyl, aryl, alkoxyalkyl, mercaptoalkyl, alkoxycarbonylalkyl, alkylcarbonyloxyalkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkynyl, alkylsulfonyl, aralkylsulfonyl, arylsulfonyl.

wherein X is oxygen atom or sulfur atom with r being a numbe selected from one or two; wherein each of R¹² and R¹³ is independently selected from hydrido, alkyl, cycloalkyl, cyano, amino, monoalkylamino, dialkylamino, hydroxyalkyl, cycloalkylalkyl, alkoxyalkyl, aralkyl and aryl; with the proviso that R⁰ and R¹ cannot simultaneously be hydrido; wherein R² is selected from hydrido, alkyl, hydroxyalkyl, halo, haloalkyl, cycloalkyl, cycloalkylalkyl,

cycloalkylhaloalkyl, cycloalkylcarbonyl, alkoxy, aralkyl, aralkylhaloalkyl, aryl, aroyl, aryloxy, aryloxyalkyl, aralkoxy, alkoxyalkyl, alkylcarbonyl, alkoxycarbonyl, alkenyl cycloalkenyl, alkynyl, cycloalkynyl, cyano, nitro, carboxyl, carboxyalkyl, alkylcarbonyloxy, alkylcarbonyloxyalkyl, alkoxycarbonylalkyl, aralkoxycarbonylalkyl,

aralkylcarbonyloxyalkyl, mercaptocarbonyl,

aralkylthiocarbonyloxy, aralkylthiocarbonylthio,

aralkylthiocarbonyl, aralkylthiocarbonylthio, mercapto, alkylsulfinyl, alkylsulfonyl, aralkylsulfinyl,

aralkylsulfonyl, arylsulfinyl, arylsulfonyl, phthalimido, phthalimidoalkyl, heteroaryl, heteroarylalkyl,

cycloheteroalkyl, cycloheteroalkylalkyl and

independently selected from amino and amido radicals of the formula

wherein X is selected from oxygen atom or sulfur atom; wherein each r is a number independently selected from zero to six, inclusive; wherein each of R¹⁴ through R²⁶ is independently selected from hydrido, alkyl, cycloalkyl, cyano, amino, monoalkylamino, dialkylamino, hydroxyalkyl, cycloalkylalkyl, alkoxyalkyl, aralkyl and aryl; wherein each of R³ through R¹¹ is independently selected from hydrido, hydroxy, alkyl, hydroxyalkyl, halo, haloalkyl, cycloalkyl, cycloalkylalkyl, alkoxy, aralkyl, aryl, aroyl, aryloxy, aralkoxy, alkoxyalkyl, alkylcarbonyl, alkoxycarbonyl alkenyl, cycloalkenyl, alkynyl, cycloalkynyl, cyano, nitro, carboxyl, alkylcarbonyloxy, mercaptocarbonyl. mercaptothiocarbonyl, alkoxycarbonyloxy, alkylthio,

alkylthiocarbonyl, alkylcarbonylthio, alkylthiocarbonyloxy, alkylthiocarbonylthio, alkylthiothiocarbonyl, arylthio, arylthiocarbonyl, arylcarbonylthio, arylthiocarbonyloxy, arylthiothiocarbonyl, aralkylthio, aralkylthiocarbonyl, aralkylcarbonylthio, aralkylthiocarbonyloxy,

aralkylthiocarbonylthio, aralkylthiocarbonyl,

aralkylthiocarbonylthio, mercapto, alkylsulfonyl,

aralkylsulfonyl and arylsulfonyl, and amino and amido radicals of the formula

wherein X is oxygen atom or sulfur atom;

wherein each of R¹⁴, R¹⁵, R¹⁶, R¹⁷, R¹⁸ and R¹⁹ is

independently selected from acidic moieties of the formula

alkylthiocarbonyl, and amino and amido radicals of the formula

28. The composition of Claim 27 wherein m is one; wherein each of X¹ and X² is independently selected from oxygen atom and sulfur atom; wherein each of R⁰ and R¹ is independently selected from hydrido, alkyl, hydroxyalkyl, mercaptoalkyl, haloalkyl, cycloalkyl, cycloalkylalkyl, aralkyl, aryl, alkoxyalkyl, alkoxycarbonylalkyl,

alkylcarbonyloxyalkyl, alkenyl, cycloalkenyl, alkynyl and cycloalkynyl; wherein R² is selected from alkyl, hydroxyalkyl, halo, haloalkyl, cycloalkyl, cycloalkylalkyl, cycloalkylhaloalkyl, cycloalkylcarbonyl, alkoxy, aralkyl, aralkylhaloalkyl, aryl, aroyl, aryloxy, aryloxyalkyl, aralkoxy, alkoxyalkyl,

cycloalkenyl, alkynyl, cyano, nitro, carboxyl,

wherein each of R¹⁴, R¹⁵, R¹⁶, R¹⁷, R¹⁸ and R¹⁹ is

independently selected from acidic moieties of the formula

cycloalkylalkyl, alkoxyalkyl, aralkyl and aryl, and wherein R⁴⁰ and R⁴¹ taken together may form a heterocyclic group having five to seven ring members including the nitrogen atom of said amino radical, which heterocyclic group may further contain one or more hetero atoms as ring members selected from oxygen, nitrogen and sulfur atoms and which heterocyclic group may be saturated or partially unsaturated; wherein R⁴⁰ and R⁴¹ taken together may form an aromatic heterocyclic group having five ring members including the nitrogen atom of said amino radical and which aromatic heterocyclic group may further contain one or more hetero atoms as ring atoms selected from oxygen, nitrogen and sulfur atoms; wherein each of R³⁶ and R³⁷ may be further independently selected from hydroxy, alkoxy, alkylthio, aryloxy, arylthio, aralkylthio and aralkoxy; and the amide, ester and salt derivatives of said acidic groups; wherein said bioisostere of carboxylic acid may be further selected from heterocyclic acidic groups consisting of heterocyclic rings of four to about nine ring members, which heterocyclic ring contains at least one hetero atom selected from oxygen, sulfur and nitrogen atoms, which heterocyclic ring may be saturated, fully unsaturated or partially

unsaturated, and which heterocyclic ring may be attached at a single position selected from R³ through R¹¹ or may be attached at any two adjacent positions selected from R³ through R¹¹ so as to form a fused-ring system with one of the phenyl rings of Formula II; and the amide, ester and salt derivatives of said heterocyclic acidic groups; wherein Y is a spacer group independently selected from one or more of alkyl, cycloalkyl, cycloalkylalkyl, alkenyl, aryl and aralkyl; and wherein any of the foregoing R¹ through R²⁶ and R³⁵ through R⁴¹, Y and A groups having a substitutable position may be substituted by one or more groups independently selected from hydroxy, alkyl, alkenyl, aralkyl, hydroxyalkyl, halo, oxo, haloalkyl, alkoxy, aryloxy, aralkoxy, alkoxyalkyl, alkylcarbonyl, alkoxycarbonyl, carboxyl, cyano, nitro, alkylsulfonyl, haloalkylsulfonyl, aryl, aralkyl,

mercaptocarbonyl, alkylthio and alkylthiocarbonyl, and amino and amido radicals of the formula

wherein X is selected from oxygen atom and sulfur atom;

wherein D is selected from oxygen atom and sulfur atom;

29. The composition of Claim 28 wherein m is one; wherein each of X¹ and X² is selected from oxygen atom and sulfur atom; wherein each of R⁰ and R¹ is independently selected from hydrido, alkyl, hydroxyalkyl, mercaptoalkyl, haloalkyl, cycloalkyl, cycloalkylalkyl, aralkyl, aryl. alkoxyalkyl, alkoxycarbonylalkyl, alkylcarbonyloxyalkyl, alkenyl, cycloalkenyl and alkynyl with the proviso that R⁰ and R¹ cannot simultaneously be hydrido; wherein R² is selected from alkyl, hydroxyalkyl, halo, haloalkyl, cycloalkyl, cycloalkylalkyl, cycloalkylhaloalkyl, cycloalkylcarbonyl, alkoxy, aralkyl, aralkylhaloalkyl, aryl, aroyl, aryloxy, aryloxyalkyl, aralkoxy, alkoxyalkyl,

cycloheteroalkyl, cycloheteroalkylalkyl and

independently selected from amino and amido radicals of the formula

independently selected from acidic moieties of the formula

cycloalkylalkyl, alkoxyalkyl, aralkyl and aryl, and wherein R⁴⁰ ana R⁴¹ taken together may form a heterocyclic group having five to seven ring members including the nitrogen atom of said amino radical, which heterocyclic group may further contain one or more hetero atoms as ring members selected from oxygen, nitrogen and sulfur atoms, and which heterocyclic group may be saturated or partially unsaturated; wherein R⁴⁰ and R⁴¹ taken together may form an aromatic heterocyclic group having five ring members including the nitrogen atom of said amino radical and which aromatic heterocyclic group may further contain one or more hetero atoms as ring atoms selected from oxygen, nitrogen and sulfur atoms; and the amide, ester and salt derivatives of said acidic groups;

30. The composition of Claim 29 wherein m is one; wherein each of X¹ and X² is independently selected from oxygen atom and sulfur atom; wherein each of R⁰ and R¹ is independently selected from hydrido, alkyl, hydroxyalkyl, mercaptoalkyl, haloalkyl, cycloalkyl, cycloalkylalkyl,

aralkyl, aryl, alkoxyalkyl, alkoxycarbonylalkyl,

alkylcarbonyloxyalkyl, alkenyl and alkynyl; wherein R² is selected from alkyl, hydroxyalkyl, halo,

haloalkyl, cycloalkyl, cycloalkylalkyl, cycloalkylhaloalkyl, cycloalkylcarbonyl, alkoxy, aralkyl, aralkylhaloalkyl, aryl, benzoyl, phenoxy, phenoxyalkyl, phenalkyloxy, phenylthio, phenalkylthio, aralkoxy, alkoxyalkyl, alkylcarbonyl,

alkylcarbonyloxyalkyl, alkoxycarbonylalkyl,

aralkoxycarbonylalkyl, aralkylcarbonyloxyalkyl,

phthalimidoalkyl, heteroaryl, heteroarylalkyl,

cycloheteroalkyl, cycloheteroalkylalkyl and cycloheteroalkylcarbonylalkyl wherein each of said heteroaryl- and cycloheteroalkyl-containing groups has one or more hetero ring atoms selected from oxygen, sulfur and nitrogen atoms, and wherein each of R² through R¹¹ may be further

independently selected from amino and amido radicals of the formula

independently selected from acidic moieties of the formula

independently selected from amino radical of the formula

alkoxyalkyl, benzyl and phenyl; and the amide, ester and salt derivatives of said acidic groups; wherein said bioisostere of carboxylic acid may be further selected from heterocyclic acidic groups consisting of heterocyclic rings of four to about nine ring members, which ring contains at least one hetero atom, selected from oxygen, sulfur and nitrogen atoms, which heterocyclic ring may be saturated, fully unsaturated or partially unsaturated, and which heterocyclic ring may be attached at a single position selected from R³ through R¹¹ or may be attached at any two adjacent positions selected from R³ through R¹¹ so as to form a fused-ring system with one of the phenyl rings of Formula II; and the amide, ester and salt derivatives of said

heterocyclic acidic groups; wherein Y is a spacer group independently selected from one or more of alkyl, cycloalkyl, cycloalkylalkyl, alkenyl, phenyl, phenalkyl and aralkyl; wherein each of R¹ through R²⁶, R³⁵ and R³⁸ through R⁴¹, Y and

A and independently may be substituted at any substitutable position with one or more groups selected from alkyl,

haloalkylsulfonyl, aryl, aralkyl, alkoxy, aryloxy and

aralkoxy; or a tautomer thereof or a pharmaceutically-acceptable salt thereof.

31. The composition of Claim 30 wherein m is one; wherein each of X¹ and X² is independently selected from oxygen atom and sulfur atom; wherein R⁰ and R¹ is

alkylcarbonyloxy, mercaptoalkyl, mercaptocarbonyl,

alkoxycarbonyloxy, alkylcarbonyloxyalkyl, alkoxycarbonylalkyl. aralkoxycarbonylalkyl, aralkylcarbonyloxyalkyl, phthalimido, phthalimidoalkyl, imidazoalkyl, tetrazole, tetrazolealkyl, alkylthio, cycloalkylthio, cycloalkylalkylthio, and amino and amido radicals of the formula

independently selected from acidic moieties consisting of CO₂H, CO₂CH₃, SH, CH₂SH, C₂H₄SH, PO₃H₂, NHSO₂CF₃, NHSO₂C₆F_5,

SO₃H, CONHNH₂, CONHNHSO₂CF₃, CONHOCH₃, CONHOC₂H_5, CONHCF₃, OH, CH₂OH, C₂H₄OH, OPO₃H₂, OSO₃H,

wherein each of R⁴², R⁴³ and R⁴⁴ is independently selected from H, Cl, CN, NO₂, CF_3, C₂F₅, C₃F₇, CHF_2, CH₂F, CO₂CH₃, CO₂C₂H₅, SO₂CH₃ SO₂CF₃ and SO₂C₆F₅; wherein Z is selected from O, S, NR⁴⁵ and CH₂; wherein R⁴⁵ is selected from hydrido, CH₃ and CH₂C₆H_5; and wherein said acidic moiety may be a heterocyclic acidic group attached at any two adjacent positions of R³ through R¹¹ so as to form a fused ring system with one of the phenyl rings of the biphenyl moiety of Formula II, said biphenyl fused ring system selected from

and the esters, amides and salts of said acidic moieties;

or a tautomer thereof or a pharmaceutically-acceptable salt thereof.

32. The composition of Claim 31 wherein m is one; wherein each of X¹ and X² is independently selected from oxygen atom and sulfur atom; wherein each of R⁰ and R¹ is independently selected from hydrido, methyl, ethyl,

cyclohexylmethyl, alkoxycarbonylalkyl, alkylcarbonyloxyalkyl, buten-2-yl, 3-butenyl, butyn-2-yl, butyn-3-yl, haloloweralkyl and hydroxyloweralkyl; wherein R² is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, n-hexyl, isopentyl, neopentyl, phenyl. cyclohexyl, cyclohexylmethyl, CH₃CH=CH-CH₂, SC₃H₇, cyclohex-3 - en-1-yl, SC₄H₉, CH₂S , CH₃CH=CH, CH₂=CH-CH₂,

CH₃CH₂CH₂CH=CH-, amino, alkoxy, aminomethyl, aminoethyl, aminopropyl, CH₂OCOCH₃, CH₂CI, CH₂OCH₃, CH₂OCH(CH₃) ₂, CH₂CO₂H, CH(CH₃)CO₂H, -CH₂OCOCH₂CH₂ -

-CH₂CH₂CH₂CO₂H, -CH₂CH₂F, -

CH₂CH₂CH₂F, -CH₂ONO2, -CH₂SH, -CH₂O CF₃, CH₂OH,

3-butenyl, butyn-1-yl, butyn-2-yl, butyn-3-yl and

y

33. The composition of Claim 32 wherein m is one; wherein each of X¹ and X² is independently selected from oxygen atom and sulfur atom; wherein R⁰ and R¹ is

independently selected from hydrido, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, 4- methylbutyl, n-pentyl, neopentyl, cyclopropylmethyl,

cyclopropylethyl, propenyl, phenyl, benzyl, phenethyl, cyclohexyl, cyclohexylmethyl, methoxycarbonyImethyl,

methoxycarbonylethyl, 4-hydroxybutyl, 2-hydroxyethyl and 3- hydroxypropyl; wherein R² is selected from ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, 4-methylbutyl, tert- butyl, n-pentyl, neopentyl, 2-phenylethyl, 2-cyclohexylethyl, benzyl, 2-phenylethyl, 3-phenylpropyl, cyclohexylmethyl, cyclohexyl, propoxy, butoxy, 1-butenyl, buten-2-yl, 3-butenyl, butyn-1-yl, butyn-2-yl, butyn-3-yl, propylthio and butylthio; wherein each of R³ through R¹¹ is hydrido with the proviso that at least one of R⁵, R⁶, R⁸ and R⁹ is an acidic group selected from CO₂H, SH, PO₃H₂, SO₃H, CONHNH₂, CONHNHSO₂CF₃,

OH,

34. The composition of Claim 33 wherein m is one; wherein each of X¹ and X² is independently selected from oxygen atom and sulfur atom; wherein each of R⁰ and R¹ is independently selected from hydrido, methyl, ethyl,

n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, 4-methylbutyl, n-pentyl, neopentyl, cyclopropylmethyl,

cyclopropylethyl, propenyl, phenyl, benzyl, phenethyl, cyclohexl, cyclohexylmethyl, methoxycarbonyImethyl,

methoxycarbonylethyl, 4-hydroxybuty, 2-hydroxyethyl and 3- hydroxypropyl; wherein R² is selected from ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, 4-methylbutyl, tert- butyl, n-pentyl, neopentyl, benzyl, 2-phenylethyl, 3- phenylpropyl, cyclohexylmethyl, cyclohexyl, propoxy, butoxy, 1-butenyl, buten-2-yl, 3-butenyl, butyn-1-yl, butyn-2-yl, butyn-3-yl, propylthio; wherein each of R³, R⁴, R⁶, R⁷, R⁸, R¹⁰ and R¹¹ is hydrido; wherein one of R⁵ and R⁹ is hydrido and the other of R⁵ and R⁹ is an acidic group selected from CO₂H and

> or a tautomer thereof or a pharmaceutically-acceptable salt thereof.

35. The composition of Claim 34 wherein m is one; wherein X¹ is an oxygen atom and X² is a sulfur atom; wherein each of R⁰ and R¹ is independently selected from hydrido, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, 4-methylbutyl, n-pentyl, neopentyl, cyclopropylmethyl, cyclopropylethyl, propenyl, phenyl, benzyl, phenethyl, cyclohexyl, cyclohexylmethyl,

or a tautomer thereof or a pharmaceutically-acceptable salt thereof.

36. The composition of Claim 35 wherein m is one; wherein X¹ is an oxygen atom and X² is an oxygen atom; wherein each of R⁰ and R¹ is independently selected from hydrido, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, 4-methylbutyl, n-pentyl, neopentyl, cyclopropylmethyl, cyclopropylethyl, propenyl, phenyl, benzyl, phenethyl, cyclohexyl, cyclohexylmethyl,

or a tautomer thereof or a pharmaceutically-acceptable salt thereof.

37. The composition of Claim 36 wherein said angiotensin II antagonist compound is selected from the gorup consisting of

8-(2-butenyl)-3,7-dihydro-1-methyl-3-propyl-7-[[2'-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-butyl-3,7-dihydro-1-(cyclopropyl-methyl)-3-methyl-7-[[2'-

(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-butyl-3,7-dihydro-1-methyl-3-(cyclopropyl-methyl)-7-[[2'-

(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-butyl-3,7-dihydro-1-propyl-7-[[2'-(1H-tetrazol-5-yl)(1,1'- biphenyl)-4-yl]methyl]-1H-purine-2,6-dione; 8-butyl-3,7-dihydro-1-methyl-7-[[2'-(1H-tetrazol-5-yl)(1,1'- biphenyl) -4-yl]methyl] -6-oxo-2-thioxo-1H-purine; and

8-butyl-3,7-dihydro-1-methyl-7-[[2'-(1H-tetrazol-5-yl)(1,1'- biphenyl)-4-yl]methyl]-1H-purine-2,6-dione.

38. The composition of Claim 37 wherein said angiotensin II antagonist compound is 8-(2E-butenyl)-3,7- dihydro-1,3-dimethyl-7-[[2'-(1H-tetrazol-5-yl) [1,1'- biphenyl]-4-yl]methyl]-1H-purine-2,6-dione.

39. The composition of Claim 37 which is 8-butyl- 3,7-dihydro-1,3-dimethyl-7-[[2'-(1H-tetrazol-5-yl) [1,1'- biphenyl]-4-yl]methyl]-1H-purine-2,6-dione.

40. The composition of Claim 37 which is 8-butyl-

3,7-dihydro-1-methyl-3-propyl-7-[[2'-(1H-tetrazol-5-yl)[1,1- biphenyl]-4-yl]methyl]-1H-purine-6-one-2-thione.

41. The composition of Claim 37 which is 8-butyl- 3, 7-dihydro-1-propyl-3-methyl-7-[[2'-(1H-tetrazol-5-yl)[1,1'- biphenyl]-4-yl]methyl-1H-purine-2,6-dione.

42. The composition of Claim 37 which is 8-butyl- 3,7-dihydro-1,3-dipropyl-7-[[2'-(1H-tetrazol-5-yl)[1,1'- biphenyl]-4-yl]methyl-1H-purine-2,6-dione.

43. The composition of Claim 37 which is 8-(2E- butenyl)-3,7-dihydro-1-methyl-3-isobutyl-7-[[2'-(1H-tetrazol- 5-yl)[1,1'-biphenyl]-4-yl]methyl]-1H-purine-2,6-dione.

44. The composition of Claim 37 which is 8-butyl- 3,7-dihydro-1-cyclopropyl-3-methyl-7-[[2'-(1H-tetrazol-5-yl) [1,1'-biphenyl]-4-yl]methyl-1H-purine-2,6-dione.

45. The composition of Claim 37 which is 8-butyl- 3,7-dihydro-1-methyl-3-cyclopropyl-7-[[2'-(1H-tetrazol-5-yl) [1,1'-biphenyl]-4-yl]methyl-1H-purine-2,6-dione.

46. The composition of Claim 37 which is 8-butyl-

3,7-dihydro-1-methyl-3-phenyl-7-[[2'-(1H-tetrazol-5-yl)[1,1'- biphenyl]-4-yl]methyl]-1H-purine-2,6-dione.

47. The composition of Claim 37 which is 8-butyl- 3,7-dihydro-3-propyl-7-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-

4-yl]methyl]-1H-purine-2,6-dione.

48. The composition of Claim 37 which is 8-propyl- 3,7-dihydro-3-propyl-7-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]- 4-yl]methyl]-1H-purine-2,6-dione.

49. The composition of Claim 37 which is 8-propyl- 3,7-dihydro-1-methyl-3-propyl-7-[[2'-(1H-tetrazol-5-yl)[1,1'- biphenyl]-4-yl]methyl]-1H-purine-2,6-dione.

50. A therapeutic method for treating a circulatory disorder, said method comprising administering to a subject susceptible to or afflicted with such disorder a therapeutically-effective amount of a compound of Formula I:

alkylthiothiocarbonylalkyl, arylthiocarbonylalkyl,

arylthiothiocarbonylalkyl, aralkylthiocarbonylalkyl,

alkylthiocarbonyl, alkylsulfinyl, alkylsulfonyl,

aralkylthiocarbonyIthio, alkylthiocarbonyl,

aralkylthiocarbonylthio, mercapto, alkylsulfinyl,

alkylthiocarbonyl, alkylsulfinyl, alkylsulfonyl,

haloalkylsulfonyl, aralkylsulfinyl, aralkylsulfonyl,

wherein X is oxygen atom or sulfur atom;

wherein each of R³⁵, R³⁶, R³⁷, R³⁸, R³⁹ and R⁴⁰ is

independently selected from hydrido, alkyl, cycloalkyl, cyano, hydroxyalkyl, cycloalkylalkyl, alkoxyalkyl, haloalkylsulfinyl, haloalkylsulfonyl, aralkyl and aryl, and wherein each of R²⁸ and R²⁹ taken together and each of R³⁰ and R³¹ taken together may form a heterocyclic group having five to seven ring members including the nitrogen atom of said amino or amido radical, which heterocyclic group may further contain one or more hetero atoms as ring members selected from oxygen, nitrogen and sulfur atoms and which heterocyclic group may be saturated or partially unsaturated; or a tautomer thereof or a pharmaceutically-acceptable salt thereof.

51. The method of Claim 50 wherein said compound is of Formula II:

aralkylcarbonyloxyalkyl, mercaptocarbonyl,

aralkylthiocarbonyloxy, aralkylthiocarbonylthio,

cycloheteroalkyl, cycloheteroalkylalkyl and

independently selected from amino and amido radicals of the formula

mercaptothiocarbonyl, alkoxycarbonyloxy, alkylthio,

aralkylthiocarbonylthio, aralkylthiocarbonyl,

aralkylthiocarbonylthio, mercapto, alkylsulfonyl,

aralkylsulfonyl and arylsulfonyl, and amino and amido radicals of the formula

wherein X is oxygen atom or sulfur atom;

wherein each of R¹⁴, R¹⁵, R¹⁶, R¹⁷, R¹⁸ and R¹⁹ is

independently selected from acidic moieties of the formula

alkylthiocarbonyl, and amino and amido radicals of the formula

wherein D is selected from oxygen atom and sulfur atom, and R³² is selected from hydrido, alkyl, cycloalkyl, cycloalkylalkyl, aralkyl and aryl; wherein each of R²⁷, R²⁸, R²⁹, R³⁰, R³¹, R³³ and R³⁴ is independently selected from hydrido, alkyl, cycloalkyl, cyano, hydroxyalkyl, haloalkyl, cycloalkylalkyl, alkoxyalkyl, alkanoyl, alkoxycarbonyl, carboxyl, haloalkylsulfinyl, haloalkylsulfonyl, aralkyl and aryl; or a tautomer thereof or a pharmaceutically-acceptable salt thereof.

52. The method of Claim 51 wherein m is one; wherein each of X¹ and X² is independently selected from oxygen atom and sulfur atom; wherein each of R⁰ and R¹ is independently selected from hydrido, alkyl, hydroxyalkyl, mercaptoalkyl, haloalkyl, cycloalkyl, cycloalkylalkyl, aralkyl, aryl, alkoxyalkyl, alkoxycarbonylalkyl,

cycloalkenyl, alkynyl, cyano, nitro, carboxyl,

alkylcarbonyloxy, mercaptocarbonyl, alkoxycarbonyloxy, alkylthio, arylthio, aralkylthio, mercapto, alkylsulfonyl, aralkylsulfonyl and arylsulfonyl, and aminό and amido radicals of the formula

wherein each of R¹⁴, R¹⁵, R¹⁶, R¹⁷, R¹⁸ and R¹⁹ is

independently selected from acidic moieties of the formula

cycloalkylalkyl, alkoxyalkyl, aralkyl and aryl, and wherein R⁴⁰ and R⁴¹ taken together may form a heterocyclic group having five to seven ring members including the nitrogen atom of said amino radical, which heterocyclic group may further contain one or more hetero atoms as ring members selected from oxygen, nitrogen and sulfur atoms and which heterocyclic group may be saturated or partially unsaturated; wherein R⁴⁰ and R⁴¹ taken together may form an aromatic heterocyclic group having five ring members including the nitrogen atom of said amino radical and which aromatic heterocyclic group may further contain one or more hetero atoms as ring atoms selected from oxygen, nitrogen and sulfur atoms; wherein each of R³⁶ and R³⁷ may be further independently selected from hydroxy, alkoxy, alkylthio, aryloxy, arylthio, aralkylthio and aralkoxy; and the amide, ester and salt derivatives of said acidic groups; wherein said bioisostere of carboxylic acid may be further selected from heterocyclic acidic groups consisting of

heterocyclic rings of four to about nine ring members, which heterocyclic ring contains at least one hetero atom selected from oxygen, sulfur and nitrogen atoms, which heterocyclic ring may be saturated, fully unsaturated or partially

wherein X is selected from oxygen atom and sulfur atom;

wherein D is selected from oxygen atom and sulfur atom;

53. The method of Claim 52 wherein m is one;

wherein each of X¹ and X² is selected from oxygen atom and sulfur atom; wherein each of R⁰ and R¹ is independently selected from hydrido, alkyl, hydroxyalkyl, mercaptoalkyl, haloalkyl, cycloalkyl, cycloalkylalkyl, aralkyl, aryl, alkoxyalkyl, alkoxycarbonylalkyl, alkylcarbonyloxyalkyl, alkenyl, cycloalkenyl and alkynyl with the proviso that R⁰ and R¹ cannot simultaneously be hydrido; wherein R² is selected from alkyl, hydroxyalkyl, halo, haloalkyl, cycloalkyl, cycloalkylalkyl, cycloalkylhaloalkyl, cycloalkylcarbonyl, alkoxy, aralkyl, aralkylhaloalkyl, aryl, aroyl, aryloxy, aryloxyalkyl, aralkoxy, alkoxyalkyl,

mercaptocarbonyl, mercaptoalkyl, alkoxycarbonyloxy, alkylthio, cycloalkylthio, cycloalkylalkylthio, arylthio, aralkylthio, mercapto, alkylsulfinyl, alkylsulfonyl, aralkylsulfinyl, aralkylsulfonyl, arylsulfinyl, arylsulfonyl, phthalimido, phthalimidoalkyl, heteroaryl, heteroarylalkyl. cycloheteroalkyl, cycloheteroalkylalkyl and

independently selected from amino and amido radicals of the formula

independently selected from acidic moieties of the formula -Y_nA wherein n is a number selected from zero through three, inclusive; wherein A is selected from carboxylic acid and bioisosteres of carboxylic acid selected from

-OH, -SH, -NR³⁵ , -C-WH, -S-WH, and

54. The method of Claim 53 wherein m is one;

wherein each of X¹ and X² is independently selected from oxygen atom and sulfur atom; wherein each of R⁰ and R¹ is independently selected from hydrido, alkyl, hydroxyalkyl, mercaptoalkyl, haloalkyl, cycloalkyl, cycloalkylalkyl, aralkyl, aryl, alkoxyalkyl, alkoxycarbonylalkyl,

alkylcarbonyloxyalkyl, alkenyl and alkynyl; wherein R² is selected from alkyl, hydroxyalkyl, halo, haloalkyl, cycloalkyl, cycloalkylalkyl, cycloalkylhaloalkyl, cycloalkylcarbonyl, alkoxy, aralkyl, aralkylhaloalkyl, aryl, benzoyl, phenoxy, phenoxyalkyl, phenalkyloxy, phenylthio, phenalkylthio, aralkoxy, alkoxyalkyl, alkylcarbonyl,

alkylcarbonyloxyalkyl, alkoxycarbonylalkyl,

aralkoxycarbonylalkyl, aralkylcarbonyloxyalkyl,

phthalimidoalkyl, heteroaryl, heteroarylalkyl,

cycloheteroalkyl, cycloheteroalkylalkyl and

independently selected from amino and amido radicals of the formula

independently selected from acidic moieties of the formula

independently selected from amino radical of the formula

haloalkylsulfonyl, aryl, aralkyl, alkoxy, aryloxy and

aralkoxy; or a tautomer thereof or a pharmaceutically-acceptable salt thereof.

55. The method of Claim 54 wherein m is one;

wherein each of X¹ and X² is independently selected from oxygen atom and sulfur atom; wherein R⁰ and R¹ is

alkylcarbonyloxy, mercaptoalkyl, mercaptocarbonyl,

alkoxycarbonyloxy, alkylcarbonyloxyalkyl, alkoxycarbonylalkyl, aralkoxycarbonylalkyl, aralkylcarbonyloxyalkyl, phthalimido, phthalimidoalkyl, imidazoalkyl, tetrazole, tetrazolealkyl, alkylthio, cycloalkylthio, cycloalkylalkylthio, and amino and amido radicals of the formula

—

independently selected from acidic moieties consisting of CO₂H, CO₂CH₃, SH, CH₂SH, C₂H₄SH, PO ₃H₂, NHSO₂CF₃ , NHSO₂C₆F_5, SO₃H, CONHNH₂, CONHNHSO₂CF₃ , CONHOCH ₃ , CONHOC₂H_{5 ,} CONHCF ₃ , OH, CH₂OH, C₂H₄OH, OPO ₃H₂, OSO ₃H ,

wherein each of R⁴², R⁴³ and R⁴⁴ is independently selected from H, Cl, CN, NO₂, CF_3, C₂F₅, C₃F₇, CHF₂, CH₂F, CO₂CH₃, CO₂C₂H₅, SO₂CH₃ SO₂CF₃ and SO₂C₆F₅; wherein Z is selected from O, S, NR⁴⁵ and CH₂; wherein R⁴⁵ is selected from hydrido, CH₃ and CH₂C₆H_5; and wherein said acidic moiety may be a heterocyclic acidic group attached at any two adjacent positions of R³ through R¹¹ so as to form a fused ring system with one of the phenyl rings of the biphenyl moiety of Formula II, said biphenyl fused ring system selected from

and the esters, amides and salts of said acidic moieties;

or a tautomer thereof or a pharmaceutically-acceptable salt thereof.

56. The method of Claim 55 wherein m is one;

wherein each of X¹ and X² is independently selected from oxygen atom and sulfur atom; wherein each of R⁰ and R¹ is independently selected from hydrido, methyl, ethyl,

CH₂S , CH₃CH=CH, CH₂=CH-CH₂,

CH₃CH₂CH₂CH=CH-, amino, alkoxy, aminomethyl, aminoethyl, aminopropyl, CH₂OCOCH₃, CH₂CI, CH₂OCH₃, CH₂OCH (CH₃) ₂, CH₂CO₂H, CH(CH₃)CO₂H, -CH₂OCOCH₂CH₂ -CH₂CH₂CH₂CO₂H, -CH₂CH₂F, -

CH₂CH₂CH₂F, -CH₂ONO₂, -CH₂SH, -CH₂O , CF₃, CH₂OH,

3-butenyl, butyn-1-yl, butyn-2-yl, butyn-3-yl and

57. The method of Claim 56 wherein m is one;

methoxycarbonylethyl, 4-hydroxybutyl, 2-hydroxyethyl and 3- hydroxypropyl; wherein R² is selected from ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, 4-methylbutyl, tertbutyl, n-pentyl, neopentyl, 2-phenylethyl, 2-cyclohexylethyl, benzyl, 2-phenylethyl, 3-phenylpropyl, cyclohexylmethyl, cyclohexyl, propoxy, butoxy, 1-butenyl, buten-2-yl, 3-butenyl, butyn-1-yl, butyn-2-yl, butyn-3-yl, propylthio and butylthio; wherein each of R³ through R¹¹ is hydrido with the proviso that at least one of R⁵, R⁶, R⁸ and R⁹ is an acidic group selected from CO₂H, SH, PO₃H₂, SO₃H, CONHNH₂, CONHNHSO₂CF₃ ,

OH,

58. The method of Claim 57 wherein m is one;

n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, 4-methylbutyl, n-pentyl, neopentyl, cyclopropylmethyl, cyclopropylethyl, propenyl, phenyl, benzyl, phenethyl. cyclohexl, cyclohexylmethyl, methoxycarbonylmethyl,

methoxycarbonylethyl,

or a tautomer thereof or a pharmaceutically-acceptable salt thereof.

59. The method of Claim 58 wherein m is one;

wherein X¹ is an oxygen atom and X² is a sulfur atom; wherein each of R⁰ and R¹ is independently selected from hydrido, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, 4-methylbutyl, n-pentyl, neopentyl, cyclopropylmethyl, cyclopropylethyl, propenyl, phenyl, benzyl, phenethyl, cyclohexyl, cyclohexylmethyl,

methoxycarbonylmethyl, methoxycarbonylethyl, 4-hydroxybutyl, 2-hydroxyethyl and 3-hydroxypropyl; wherein R² is selected from ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, 4-methylbutyl, tert-butyl, n-pentyl, neopentyl, benzyl, 2- phenylethyl, 3-phenylpropyl, cyclohexylmethyl, cyclohexyl, propoxy, butoxy, 1-butenyl, buten-2-yl, 3-butenyl, butyn-1-yl, butyn-2-yl, butyn-3-yl, propylthio and butylthio; wherein each of R³, R⁴, R⁶, R⁷, R⁸, R¹⁰ and R¹¹ is hydrido; wherein one of R⁵ and R⁹ is hydrido and the other of R⁵ and R⁹ is an acidic group selected from CO₂H and

or a tautomer thereof or a pharmaceutically-acceptable salt thereof.

60. The method of Claim 59 wherein m is one;

wherein X¹ is an oxygen atom and X² is an oxygen atom; wherein each of R⁰ and R¹ is independently selected from hydrido, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, 4-methylbutyl, n-pentyl, neopentyl, cyclopropylmethyl, cyclopropylethyl, propenyl, phenyl, benzyl, phenethyl, cyclohexyl, cyclohexylmethyl,

or a tautomer thereof or a pharmaceutically-acceptable salt thereof.

61. The method of Claim 60 wherein said compound is selected from the group consisting of

8-(2-butenyl)-3,7-dihydro-1-methyl-3-propyl-7-[[2'-(1H- tetrazol-5-yl) (1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6- dione;

8-butyl-3,7-dihydro-1-methyl-3-isobutyl-7-[[2'-(1H-tetrazol-

5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

2, 6-dione;

8-butyl-3,7-dihydro-1-methyl-3-(cyclopropyl-methyl)-7-[[2'-

(1H-tetrazol-5-yl) (1,1'-biphenyl)-4-yl]methyl]-1H-purine-

2,6-dione;

8-butyl-3,7-dihy ro-1-methyl-3-phenyl-7-[[2'-(1H-tetrazol-5- yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-propyl-3,7-dihydro-1-methyl-3-propyl-7-[[2'-(1H-tetrazol-

5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-purine-2,6-dione;

8-butyl-3,7-dihydro-1-propyl-7-[[2'-(1H-tetrazol-5-yl)(1,1'- biphenyl)-4-yl]methyl]-1H-purine-2,6-dionn; 8-butyl-3,7-dihydro-1-methyl-7-[[2'-(1H-tetrazol-5-yl)(1,1'- biphenyl)-4-yl]methyl]-6-oxo-2-thioxo-1H-purine; and

62. The method of Claim 61 which is 8-(2E- butenyl)-3,7-dihydro-1,3-dimethyl-7-[[2'-(1H-tetrazol-5-yl) [1,1'-biphenyl]-4-yl]methyl]-1H-purine-2,6-dione.

63. The method of Claim 61 which is 8-butyl-3,7- dihydro-1,3-dimethyl-7-[[2'-(1H-tetrazol-5-yl) [1,1'- biphenyl]-4-yl]methyl]-1H-purine-2,6-dione.

64. The method of Claim 61 which is 8-butyl-3,7- dihydro-1-methyl-3-propyl-7-[[2'-(1H-tetrazol-5-yl)[1,1- biphenyl]-4-yl]methyl]-1H-purine-6-one-2-thione.

65. The method of Claim 61 which is 8-butyl-3,7- dihydro-1-propyl-3-methyl-7-[[2'-(1H-tetrazol-5-yl)[1,1'- biphenyl]-4-yl]methyl-1H-purine-2,6-dione.

66. The method of Claim 61 which is 8-butyl-3,-7- dihydro-1,3-dipropyl-7-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]- 4-yl]methyl-1H-purine-2,6-dione.

67. The method of Claim 61 which is 8- (2E- butenyl)-3,7-dihydro-1-methyl-3-isobutyl-7-[[2'-(1H-tetrazol- 5-yl)[1,1'-biphenyl]-4-yl]methyl]-1H-purine-2,6-dione.

68. The method of Claim 61 which is 8-butyl-3,7- dihydro-1-cyclopropyl-3-methyl-7-[[2'-(1H-tetrazol-5-yl)

[1,1'-biphenyl]-4-yl]methyl-1H-purine-2,6-dione.

69. The method of Claim 61 which is 8-butyl-3,7- dihydro-1-methyl-3-cyclopropyl-7-[[2'-(1H-tetrazol-5-yl)

[1,1'-biphenyl]-4-yl]methyl-1H-purine-2,6-dione.

70. The method of Claim 61 which is 8-butyl-3,7- dihydro-1-methyl-3-phenyl-7-[[2'-(1H-tetrazol-5-yl)[1,1'- biphenyl]-4-yl]methyl]-1H-purine-2,6-dione.

71. The method of Claim 61 which is 8-butyl-3,7- dihydro-3-propyl-7-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4- yl]methyl]-1H-purine-2,6-dione.

72. The method of Claim 61 which is 8-propyl-3,7' dihydro-3-propyl-7-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4- yl]methyl]-1H-purine-2,6-dione.

73. The method of Claim 61 which is 8-propyl-3,7' dihydro-1-methyl-3-propyl-7-[[2'-(1H-tetrazol-5-yl)[1,1'- biphenyl]-4-yl]methyl]-1H-purine-2,6-dione.

74. The method of Claim 50 wherein said circulatory disorder is a cardiovascular disorder.

75. The method of Claim 50 wherein said cardiovascular disorder is hypertension.

76. The method of Claim 50 wherein said cardiovascular disorder is congestive heart failure.